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I: INTRODUCTION 
 
Antibodies, and more generally protein therapeutics, are one of the most exciting 
breakthroughs of modern medicine [1].  They are treating an ever expanding list of diseases and 
disorders that span the gamut, including but not limited to: cancer, diabetes, cardiovascular 
disease, infertility, asthma, and rheumatoid arthritis.  However, while these medicines have the 
capacity to change medicine today, they face one of the great problems of the 21st century.  Like 
so many of the medical advances of the past 25 years, they offer little to no benefit outside the 
rich world.  Protein therapeutics are cost prohibitive.  Much of this can be owed to the research 
and development costs necessary to bring a drug to market.  In the case of antibodies, much of 
this cost emerges from the front-loaded development costs associated with generating sufficient 
antibody to perform clinical trials [2–4].  The objective of this work is to conduct the 
fundamental research that we believe to be necessary to drive down the sales price to patients.   
The timing of this work is critical.  The era of biosimilars is arriving, with an estimated $33 
billion USD worth of biopharmaceuticals (which are dominated by protein therapeutics) that will 
come off patent by 2016 [5].  Biosimilars are roughly the generic equivalent of chemical based 
drugs, having similar efficacy and pharmacokinetics as the brand name.  Growth factors, perhaps 
the simplest variety of protein therapeutics, have already seen significant cost reduction 
associated with increased competition following patent expiration [6]. Can the same happen with 
antibodies?  As was mentioned prior, much of the development costs are associated with 
generating sufficient product to perform clinical trials.  Given the difficulty that a given company 
has in consistently producing its own patented antibody, it isn’t clear how rapid biosimilars will 
expand into antibodies.  The scientific community is literally at the frontline of this changing 
2 
environment, where the development of a fundamental understanding of what leads to high 
volumetric productivity is paramount.  This is how our work aims to accomplish its objective, 
and the timing is anything but arbitrary.   
Here we investigate the causes of poor volumetric productivity through a metabolic lens.  A 
systems biology approach was applied to this industrial research problem, with the goal of:  
1) Elucidating the metabolic phenotypes associated with high protein productivity  
2) Exploration and evaluation of techniques to encourage productivity 
This can be achieved by increases to specific growth rate, increases to peak viable cell 
densities attained, lengthening cell culture lifespan, and by increasing specific productivity. 
3) Minimizing metabolic pathways known to associate negatively with antibody productivity 
Major emphasis is placed on understanding the causation and minimization of lactate 
production. 
Reducing lactate production has multiple benefits to industrial cell culture.  First, it leads to 
a drop in culture pH.  To compensate, pH can be adjusted by base additions.  While effective, 
base additions increase osmolarity.  When osmolarity reaches a certain threshold, it negatively 
affects final titer [7].  If lactate production can be avoided in the first place, these potential issues 
are avoided.  Furthermore, large scale studies have found lactate production to negatively 
correlate with antibody production [8]. 
In the early 1940’s, antibiotics were a cost-prohibitive novelty.  Penicillin cost $11,000/kg 
in 1944.  However, through much effort and innovation, this cost experienced exponential 
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decline.  Penicillin was changed from a specialty chemical to commodity status, and sold for 
$18/kg in 1977 [9].  Why can’t the same be achieved in protein therapeutics? 
 
The dissertation is divided as follows: 
Chapter II provides background and significance to the research offered in chapters III, IV, V, 
and VI.  Prior work exploring the role of lactate production/consumption upon protein 
therapeutic production is explored.  The mathematical basis for metabolic flux analysis (MFA), a 
powerful technique used to explore the metabolic phenotypes associated with antibody 
production, is provided.  Finally, MFA studies relevant to industrial mammalian cell culture are 
summarized. 
Chapter III examines the metabolic rewiring which occurs over time in an industrial fed-batch 
production process.  A dihydroxyfolate reductase (DHFR) deficient Chinese Hamster Ovary 
(CHO) cell was used, the most widely used cell line for antibody production in industry.  
Increased oxidative pentose phosphate pathway (oxPPP) flux and TCA cycle both correlated 
positively with antibody production.  Alongside the observed correlations, total lactate 
production decreased considerably over the culture lifespan, providing detail of how cell culture 
metabolism changes over time. 
Chapter IV considers the role of engineered apoptotic resistance in CHO metabolism.  Bcl-2Δ 
was expressed, and had considerable impact in reducing lactate production and later increasing 
consumption.  Integrated viable cell density (IVCD) was increased by Bcl-2Δ.  The impact upon 
mitochondrial metabolism was evaluated through both MFA and enzymatic activity analysis. 
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Chapter V explores the role of limiting glutamine availability in cell culture.  As glutamine was 
exhausted from culture, net lactate production reversed.  Furthermore, when the initial glutamine 
concentration was halved, lactate production reduced and growth rate increased. 
Chapter VI embarks on the largest MFA study ever conducted upon antibody producing CHO 
cells.  Here, glutamine synthetase (GS) based antibody expression (popular method, alternative 
to DHFR, used for industrial antibody expression) was examined in multiple clones in an early 
stationary-like phase.  Oxidative metabolism again positively corresponded with specific 
productivity, true for several independently generated clones.  Furthermore, the role that Bcl-2Δ 
played in increasing antibody production was considered. 
Chapter VII provides conclusion by reexamining the significant findings of this work. 
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II: BACKGROUND AND SIGNIFICANCE 
 
Importance to Healthcare 
Protein therapeutics have the capacity to change medicine on a global scale.  They 
comprise a broad class of drugs, and their market composition (based upon US sales) is 
categorized in descending order as follows: antibodies, hormones, growth factors, fusion 
proteins, cytokines, enzymes, blood factors, vaccines, and anti-coagulants [1].  Protein 
therapeutics are protein based drugs, and unlike small molecular weight drugs, they are too 
complex to synthesize chemically.  Therefore, they, and more generally biologics, are produced 
in cell culture.  While the majority of the biologics market is dominated by protein therapeutics, 
some hormones and vaccines are not protein therapeutics.  All protein therapeutics are biologics, 
but not all biologics are protein therapeutics.  This work focuses on protein therapeutics, which 
comprise greater than 90% of biologics [1].   
To produce a protein therapeutic, the cell culture is genetically modified to express a 
biologically active protein that the human body will recognize.  Following generation of a cell 
line, it is cultured in a specially designed media to maximize production, with multiple 
environmental controls (oxygen, pH, temperature, stir rate) optimized to do the same.  Such work 
is often labeled upstream processing.  After a process that typically ranges from several days to a 
few weeks, the protein therapeutic must be purified from the cell culture media, in such a fashion 
that maximal recovery and minimal degradation to the protein is achieved.  Following 
purification, it is packaged in optimal fashion to maximize shelf life.  Purification and packaging 
is often labeled downstream processing.  Considering the multiple levels of optimization 
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required for protein therapeutic production, the engineering challenges are substantial.  This 
work focuses on the engineering challenges of upstream processing. 
Post upstream and downstream processing, the protein therapeutic is finally ready for the 
clinic.  In the clinic the therapeutic is administered and has pharmacokinetic activity, just like a 
small molecular weight drug would (e.g. Aspirin, Claritin, and the majority of drugs that are 
household names).  Unlike a small molecular weight drug, however, protein therapeutics are 
most often administered intravenously.  This is to minimize the acid hydrolysis, naturally taking 
place in the stomach, denaturing the protein therapeutic and damaging efficacy.  Table 2-1 
provides a general overview of the diversity of diseases and disorders that can be treated by 
protein therapeutics, as well as their overall functional class and purpose.   
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Table 2-1.  Overview of protein therapeutics on the market today, broken down into 5 
functional classes.  Table has been adapted from a 2008 review from Leader [2]. 
 
                                                 
1 Attention should be paid to the specificity associated with vaccines relative to the other functional classes.  It is 
possible to list the treatments because recombinant vaccines are quite limited in number. 
2 While not technically a therapeutic, diagnostics are also listed.  This is due to the fact that like the recombinant 
therapeutics, the diagnostics are recombinant proteins produced in similar fashion [21] 
Protein therapeutic functional classes 
Functional Class Purpose Treatment/Target 
Enzymatic or regulatory 
activity 
Replace a deficient or abnormal 
protein 
Hormone deficiencies 
Hemostasis and thrombosis 
Pulmonary disorders 
Gastrointestinal disorders 
Immunodeficiencies 
Metabolic enzyme disorders 
Increase activity of existing 
pathway 
Hematopoiesis 
Fertility 
Immunoregulation 
Hemostasis and Thrombosis 
Endocrine disorders 
Growth regulation 
Provide non-native activity/function 
Enzymatic degradation of 
macromolecules 
Enzymatic degradation of metabolites 
Hemostasis and thrombosis 
Special targeting 
capacity 
Interfere with molecule, deliver 
compound to specific site 
Cancer 
Immunoregulation 
Transplantation 
Pulmonary disorders 
Hemostasis and thrombosis 
Hormone deficiencies 
Vaccines1 
Protection against virus 
Hepatitis B 
Human papillomavirus 
Lyme disease 
Autoimmune protection Hemolytic disease of newborn 
Diagnostics2 Identification 
Infections 
Endocrine disorders 
Cancer 
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Coinciding with the breadth of diseases treatable, as shown by Table 2-1, it is worth 
considering the sheer number of patients being treated.  Currently 9.3% of the American 
population is diabetic [3], and much of the insulin administered to patients today is a synthetic 
product derived from E. coli.  Anyone who has received a hepatitis B vaccination has received a 
protein therapeutic [2], and currently laws exist (in various forms) in all 50 states’ public school 
systems to vaccinate [4].  Therefore, whether the American public is aware of it, a large 
percentage of the US population has already benefitted from this important class of molecules.  
These benefits are often realized because of the fundamental advantages protein therapeutics 
have over small-molecule drugs [2], mostly derived from their incredible specificity and low 
immunogenicity.  Antigen-specific drug targeting within the body is not readily possible with 
small-molecule drugs, but proteins have evolved the native capacity for selective binding to 
specific molecular targets.  Here, the antigen is most often a protein or protein complex. 
Still, most of the protein therapeutics in the marketplace are costly to provide.  In 2006, 
Farid reviewed a number of drugs on the market, and found strikingly high costs per treatment.  
Many of the treatments involving antibodies can cost well over $10,000 per treatment [5].  While 
certainly this cost is shared by the patient and their insurance, it raises concerns over the current 
burden of drug costs on the American economy.  This is especially provoking in light of the 
incoming Patient Protection and Affordable Care Act and the gradual aging of the US population 
[6].   
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Economics 
Economics is the fundamental driver behind research to increase productivity of 
recombinant protein therapeutics.  While the potential for protein therapeutics is remarkably 
high—indeed, they represent the fastest growing class of therapeutic agents [7]—accessibility 
remains low.  If the goal is to reduce the time to market, a better understanding of the overall 
production process is fundamentally necessary.  Achieving this goal is desirable for two reasons.  
First, it is attractive to medicine today because it increases the rate of novel drugs reaching the 
market and decreases product variability.  Second, from an economic perspective, achieving 
faster timelines for bringing a drug to market reduces the front-loaded investment costs for a 
pharmaceutical company, allowing for resource reallocation for the exploration of other novel 
drugs.  Thus, research into recombinant (in this case, meaning DNA derived from humans) 
protein production promotes the drug-development cycle, which is advantageous to the patient 
and industry alike.  So far, industry efforts towards platform-based approaches have been 
beneficial in shortening timelines [8].  Platform approaches are the general recycling of a given 
condition that seems to have been effective in prior processes.  A condition could be in regards to 
environmental culture conditions, cell culture media, or even the way a cell line is generated.  
However, sacrifices to productivity have been made to maximize the speed to market.   
Due to the fact that the majority of protein therapeutics that enter the development 
pipeline do not reach market [9], it is difficult to rationalize substantial time expenditure to 
obtain a high-producing clone in the initial stages of drug development.  This is unfortunate, as 
antibody therapies (the largest class of protein therapeutics [1]) require large amounts of product 
to determine safety and efficacy in clinical trials.  Nonetheless, the industry’s reliance on limiting 
platform processes is clear here, as low productivity and high variability (leading to much of 
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your product being jettisoned) are simply “accepted” [10] as a means to generate enough product 
for phase I and II clinical trials.  This is no doubt stymying drug development and approval rates, 
as a substantial portion of the total drug development cost is attributed to generating a sufficient 
amount of antibody for clinical trials [11,12].  When a drug has passed phase I and II, only then 
is the production process optimized.  Yet even at this stage the ability to make improvements is 
limited by our knowledge of host cell physiology.  In a 2011 FDA-lead drug shortage workshop, 
54% of the actual or potential problems were due to product quality issues and/or manufacturing 
shortages in sterile injectable products (including protein therapeutics) [13].  Therefore, 
fundamental improvements in the production process are necessary to accelerate research and 
improve manufacturability of protein therapeutics, and examination of the molecular and cellular 
mechanisms underlying recombinant protein production is warranted. 
Lastly, to identify the significance of efforts made to improve the scientific community’s 
understanding of protein therapeutics production, consider the nation’s present pharmaceutical 
expenditures.  The United States spent $261 billion in 2012 on pharmaceuticals.  This is 
equivalent to 1.7% of the US GDP, and expenditures are projected to grow at 6.5% annually over 
the next 10 years [14].  $64 billion went to biologics, or roughly 25% of total pharmaceutical 
costs [1].  However, in 2008, only 19% of pharmaceutical costs were related to biologics [15].  
This trend is expected to continue, as in 2012 biologics grew at a rate seven times that of the 
overall pharmaceutical industry [1].  It is generally agreed upon that biologics will continue to 
grow at a rate faster than their small-molecule counterparts.  However, their growth rate has 
varied wildly over the past 10 years (a mark of an immature industry) between 4% and 24% 
[1,15].  Regardless of the exact growth rate in biologics sales, this industry will play a critical 
role in the future US economy.  
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Techniques to increase antibody production 
 Achieving higher titers and volumetric productivities of recombinant proteins have been 
the main goals of the cell culture industry for the past several decades.  There are two primary 
means to accomplish this end.  The first is by achieving higher integrated viable cell densities 
(IVCD), with Equation 2-1 defining the benefit.   
𝑑𝑝
𝑑𝑡
= 𝑞𝑝𝑋 (2-1) 
Where p is product concentration, t time, qp specific productivity and X viable cell density.  With 
a greater number of viable cells maintained over time, greater titers and volumetric productivities 
can be achieved.  The second is to increase the cell-specific productivity.  If either or both can be 
accomplished, without impairing the other, higher titers and volumetric productivities can be 
achieved.  In this dissertation, attention has focused on elucidating metabolic adaptations of host 
cells that lead to enhanced protein productivity or increased IVCD, since both of these factors 
contribute to enhancing cell culture performance.   
Over the past thirty years, final titers have increased over two orders of magnitude from 
about 0.05 g/L to over 10 g/L [16,17].  Most of this increase is attributable to increases in IVCD 
[18].  Peak cell concentrations in a fed-batch process rarely rose above 4 x 106 cells/mL in 1986; 
now they routinely exceed 15 x 106 cells/mL [19].  Additionally, while it was once difficult to 
culture beyond one week, now processes routinely run for three weeks or more.  Increases in 
specific productivity have also been achieved, but has not increased by an order of magnitude 
(like IVCD) [20].   
Regarding cell-specific productivities, in 1991, 50 pg/cell/day of product was achievable 
in a hybridoma cell line [16].  Compared to specific productivities reported today in literature, 
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this would be considered above average [21].  Considering an average CHO cell to be 350 pg, 
and a typical doubling time of 1 day in exponential phase, CHO cells are already capable of 
producing 260 pg of protein a day (host cell protein).  This assumes that roughly 75% of the cell 
mass is attributable to protein [22].  If growth rate were reduced to 20%, and specific 
productivity of total protein (including host cell protein) was assumed to remain constant 
(independent of growth rate), an excess of 200 pg/cell/day of product would be made.  
Furthermore, the sheer diversity of techniques that exist to increase specific productivity suggest 
an empirical approach [23].  The effort to increase specific productivity certainly exists, but the 
direction (or biological understanding) is not clear. 
 
Choice of expression systems  
Cell line.  CHO cell cultures are the predominant system used for production of 
monoclonal antibodies (mAbs) today, a type of protein therapeutic.  CHO cells are used largely 
because of their high productivity, robustness, and safety track record [24].  They are presently 
used to produce 60-70% of recombinant protein therapeutics on the market [25].  Proteins are 
complex in structure and often require post-translational modifications (PTMs), such as 
glycosylation, to have proper activity.  CHO cells are efficient at performing PTMs and can 
generate glycosylation patterns that are similar to humans [26].  Additionally, expression of 
antibody can be achieved with two different vectors.  This is not possible for all mammalian cell 
lines (such as NS0) [27].  Initially, simpler organisms with less challenging growth requirements 
were used, such as E. coli and yeast.  In time, E. coli proved to be quite effective for the 
production of simpler proteins without PTM requirements, such as insulin and the now 
controversial bovine growth hormone (rBGH) [28,29].  Promise has also been shown in using 
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microbes to produce antibody fragments [30].  To this date, considerably more is known about 
yeast and E. coli as they have proven to be more broadly useful to the biotech industry [31].  
However, in the pursuit of more complex protein therapeutics, such as therapeutic antibodies, 
microbes have proven to be largely unsuccessful.  This is due to their general lack of mammalian 
protein processing machinery and/or lack of specific enzymes required for human-like PTMs.  In 
particular, failure to produce therapeutic antibodies with proper glycosylation frequently leads to 
inactivity in the body and rapid clearance rates [32].   
There are multiple mammalian alternatives to CHO.  Initially, most mAb production was 
conducted using hybridoma cell lines.  Mouse hybridoma cell lines, generated from the fusion of 
an antibody-producing B-lymphocyte cell with a myeoloma cell (cancerous plasma B-cell), were 
the first reliable sources of monoclonal antibodies [33].  However, innovations in recombinant 
DNA technology allowed for movement away from hybridoma into what are today more widely 
used mammalian hosts.  The most common host cell lines used today are CHO, murine myeloma 
(NS0), human embryonic kidney (HEK), and baby hamster kidney cells (BHK) [34].   
Expression vectors.  One simple reason for CHO’s predominance could have more to do 
with timing and convenience than logic.  Around the time when the protein therapeutic industry 
was beginning in the early 1980’s, a dihydrofolate reductase deficient (DHFR) CHO line was 
generated by a biologist interested in performing metabolic studies [35].  In this cell line, both 
alleles encoding the dihydrofolate reductase (DHFR) enzyme were either mutated or eliminated. 
This became CHO-DUK-XB11, one of the most widely used CHO cell lines on the market today 
[36].  Just a few years later, an additional DHFR line was generated (by the same biologist) 
where both DHFR alleles were deleted [37].  It was named CHO-DG44, another predominant 
CHO cell line on the market.  Since DHFR is a critical enzyme required for the biosynthesis of 
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purine and pyrimidine nucleotides, cells lacking it cannot grow unless DHFR is expressed 
recombinantly. This was quite useful for protein therapeutics production, as it provided a 
mammalian selection system that did not involve antibiotics, a critical requirement.  Antibiotics 
are generally avoided, as their addition (for host selection) will require subsequent removal in 
downstream purification, requiring increased purification costs.   
DHFR selection involves first cloning the target genes required for protein production 
into a recombinant plasmid that contains the DHFR gene. The plasmid DNA is transfected into 
the host, and the resulting clones are cultured in the presence of methotrexate (MTX) to inhibit 
background DHFR activity [10].  Only the clones that successfully integrated the DHFR-
containing plasmid into their chromosomes will be able to survive in the presence of MTX.  The 
surviving clones not only tolerate the MTX inhibition, but also produce protein therapeutic since 
the target genes were included on the same DNA construct with the DHFR gene.  Gradually, the 
MTX concentration is increased as the cultures grow more tolerant, theoretically leading to better 
producing clones.  Gene copy number has been found to increase to several hundred in the best 
producing clones.  However, there is a drawback to this approach: time.  DHFR selection 
requires several rounds of gene amplification, often taking up to 6 months [27].   
While perhaps obvious, MTX selection is most effective when a DHFR vector is 
transfected into a DHFR host cell.  When this is not the case, antibiotic resistance can be added 
to the plasmid to provide selection [10].  No doubt in part because of the limitations of the 
DHFR system, the glutamine synthetase (GS) system was developed (Figure 2-1).   
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Figure 2-1.  Glutamine Synthetase (GS) plasmid. 
 
GS allows glutamine synthesis from glutamate and ammonia, outlined in Figure 2-2.   
 
 
Figure 2-2.  The role of glutamine synthetase (GS). 
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GS deficiency is a characteristic of most (if not all) CHO cell lines, making it an excellent 
selection system.  GS expression is so low in NS0 lines that it is often designated GS [38].  The 
effectiveness of GS selection, like DHFR selection, is maximized by the addition of a chemical 
inhibitor.  This chemical, methionine sulfoximine (MSX), is an inhibitor of GS.  Following 
transfection, the necessary concentration of MSX is added to limit growth of cells that lack 
expression of the recombinant GS construct.  Gene amplification (through gradual increases in 
MSX concentration) is typically not necessary with GS, even though only 4-10 copies are found 
in each individual clone [10,27].  This allows effective clones to be produced in roughly half the 
time of DHFR selection.  As an additional benefit, GS expression significantly reduces the 
accumulation of ammonia [39], since glutamine does not need to be supplied in the growth 
medium to achieve maximal growth [40]. Ammonia is a major byproduct of glutamine 
metabolism but is inhibitory to cell cultures at sufficient concentrations [41,42]. Eliminating 
glutamine from the medium effectively removes the threat of ammonia accumulation to toxic 
concentrations.  Considering the benefits of the GS system, it has taken a large market share 
away from DHFR, even though it was released on the market roughly ten years following DHFR 
[43].  However, while GS was patented by Lonza, DHFR is not owned by any company.  It 
seems unlikely that patent protection (which recently expired) has limited the adoption of GS, as 
GS licensing from Lonza is trivial compared to the entire R&D cost required to put a drug on the 
market [44].  Regardless, DHFR still manages to be widely used despite its disadvantages 
[36,45]. 
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The role of lactate production in mammalian cell culture 
In spite of the fact that the industry has achieved two orders of magnitude of 
improvement in final titer, many of the same problems from thirty years ago remain today [19].  
Lactate production, and the inefficient use of carbon resources associated with it, is still limiting 
the achievement of higher titers [46].  Lactate production reduces the pH of culture, forcing the 
addition of base.  When base is added, the osmolarity begins to rise.  This effect is most 
pronounced in fed-batch cultures.  Osmotic pressure can be tolerated to reasonably high 
concentrations by CHO cells, but eventually it begins to negatively impact specific growth and 
productivity [47].  In addition to the potential problems posed by osmotic pressure, increased 
lactate production is statistically correlated with decreased productivity [48].  Efforts to reduce 
lactate production, or increase lactate consumption, correlate with increased antibody production.  
While industry has taken advantage of this observation, no one has proven why this correlation is 
observed.   
Cell viability, obviously necessary for antibody production, can be significantly improved 
by reducing lactate production [19].  While the reasons for lactate production in a well-
oxygenated environment are still elusive, its impact upon metabolism is beginning to be better 
understood.  First, it is important to realize just how significant the lactate production flux 
actually is, and how it relates to glucose consumption (Figure 2-3).  
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Figure 2-3.  The metabolic connection between glucose, lactate, and glutamine. 
 
Glucose is typically the largest incoming carbon flux in cell culture, and lactate production can 
account for over half of glucose carbon.  During exponential growth, molar yields of lactate on 
glucose have been reported in the range from 49% to 80% in antibody producing cultures of 
hybridoma, CHO, and BHK cell lines [49], [50], [51].  In our own work examining a CHO cell 
line optimized for industrial production by Amgen, we’ve found that up to 38% of total carbon 
consumption can be tied to lactate production despite achieving antibody titers in excess of 3 g/L 
[52].  This fact underlies the minimal progress that has been made in decreasing lactate 
production.  Yet, this lack of progress is not due to a lack of effort.  Tables 2-2: 2-4 summarize a 
plethora of strategies that have been used to intentionally (and occasionally unintentionally) limit 
lactate accumulation in mammalian culture.   
Environmental manipulations.  Industrial strategies most often focus on 
media/environmental manipulations.  One such strategy is a reduction in temperature, as seen in 
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Table 2-2, from a typical culture condition of 37°C to 30-35°C [11,53,54]. Temperature drops 
are most effective when employed in peak production stage when cell growth is already minimal.  
When correctly timed, reports of doubling in titers are possible [54].     
 
Table 2-2.  Environmental manipulations impacting lactate metabolism.   
Manipulation Metabolic Impact Cell Line Operation Ref. 
Reduce 
temperature 
from 37 to 33°C 
Lactate and glucose flux reduced, but lactate/glucose ratio 
remains unaffected; Titer doubles largely due to doubling 
in specific productivity 
CHO-K1, 
BHK 
Batch [54] 
Increase 
osmolarity from 
290-435mOsM 
Specific productivity increased, titer unaffected; Lactate 
and glucose flux reduced but lactate/glucose ratio 
unaffected; Growth rate reduced by ~ 50% 
Hybridoma Batch [55] 
Increase 
osmolarity from 
290-450mOsM 
Slight increase in specific productivity and final titer; 
Growth rate reduced, but overall IVCD similar; Increase 
in lactate production/glucose consumption 
NS0 Batch [56] 
Increase pCO2 
Effectively increased osmolarity; Decreased growth rate 
and increased specific productivity; No impact upon final 
titer; Increased lactate production/glucose consumption 
CHO Fed-batch [57] 
 
Previous work has found temperature reductions to force the cell into a G0/G1 state where growth 
was arrested and antibody specific productivity frequently increased. When the temperature was 
reduced, it led to an overall reduction in metabolic activity (i.e., less glucose consumed and less 
lactate produced).  However, it had a minimal effect upon the lactate/glucose flux ratio, 
suggesting an insignificant change in the partitioning between glycolytic/mitochondrial carbon 
utilization.   
Another strategy to increase specific productivity involves increasing the osmolarity.  
While there are several ways to accomplish an increase in osmolarity, the rationale for doing so 
is to increase specific productivity by promoting G0/G1 growth arrest.  However, while a 
temperature drop typically reduces overall metabolic activity and reduces nutrient consumption, 
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forcing hypertonic conditions does not always have the same effect.  In two similar studies on 
mammalian culture, specific glucose consumption increased when osmolarity was raised from 
290 to 450 mOsM in NS0 [56], yet glucose consumption decreased when it was raised from 290 
to 435 mOsM in hybridoma [55].  Osmolarity spikes likely have significant cell line 
dependencies [53,58].  While increasing osmolarity generally increases specific productivity, if 
increased too far, it negatively affects the final titer [58].  Additionally, osmotic pressures are 
somewhat difficult to control, as run-to-run there will always be variations in osmolarity (any 
and all metabolic byproducts and substrates impact culture osmolarity).   
Media manipulations.  Several media optimization strategies have been developed and 
implemented to enhance culture performance.  One of the most common techniques is to limit 
the availability of a given nutrient, often glucose or glutamine.  This strategy has been generally 
effective for limiting the production of lactate, and has been implemented for a number of years 
in fed-batch processes.  However, as can be seen in Table 2-3, media manipulation results have 
been varied.   
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Table 2-3. Media manipulations impacting lactate metabolism. 
Manipulation Metabolic Impact Cell Line Operation Ref. 
Media 
Add copper to 
media at 20x 
standard 
concentration 
Induces lactate re-uptake to consume nearly all the 
lactate previously produced; Increased titer by ~60% 
CHO-
DUK-
XB11 
Fed-batch [59] 
Co-limitation of 
glucose and Gln 
Increased biomass yield on glucose; Production of 
NH3, lactate, and Ala virtually eliminated; IVCD and 
final titer slightly increased 
Hybridoma Fed-batch [60] 
Limit glucose 
availability, feed 
based upon OUR 
Fed glucose based upon oxygen uptake rate (OUR),  
lactate/glucose ratio was reduced over time, if only 
mildly; Final titer increased 22% 
Myeloma Fed-batch [61] 
Limit glucose 
availability, feed 
based upon OUR 
As OUR was increased over culture life, 
lactate/glucose ratio decreased; Growth phase 
extended, peak VCD increased by factor of 6, when 
compared to batch; Data from batch culture not shown 
Hybridoma Fed-batch [62] 
Limit glucose 
availability 
Reduced the fraction of  glucose attributable to lactate 
from 81% to 9%; Increased fraction of glucose 
entering TCA cycle from 2% to 48%; Growth rate 
reduced; Final titer increased 100x 
Hybridoma Fed-batch [49] 
Limit glucose 
availability, feed 
glucose based 
upon pH rise 
Reduced lactate production; doubled final titer as a 
result of higher IVCD and specific productivity 
CHO-K1 Fed-batch [63] 
Feed lactate to 
culture as 
alternative to CO2 
Reduced ammonia production following exhaustion of 
lactate from culture; specific productivity, 
glycosylation, and growth rate unaffected 
CHO-
DUK-
XB11 
Fed-batch [64] 
Feed lactate to 
culture at various 
concentrations to 
determine 
inhibitory impact 
Decreased yield of lactate on glucose; Specific 
productivity increased but IVCD decreased; No net 
change in final titer; Slight increase in ammonia 
production rate; Suggests effects of lactate addition 
were the result of osmolarity increases rather than 
lactate per se 
Hybridoma Batch [41] 
Determined 
inhibitory 
concentration of 
ammonia, lactate, 
osmolarity, CO2 
Using principal component analysis, applied optimal 
conditions to increase peak VCD by 17%, final titer by 
40%; Did not report lactate data, just final result 
CHO Fed-batch [65] 
Co-culture 
galactose with 
glucose 
Switched culture from lactate production to lactate 
consumption; Did not impact final titer; Slight 
increase in IVCD and slight decrease in specific 
productivity 
CHO Fed-batch [66,67] 
Limiting Gln 
availability 
When glutamine had been nearly exhausted from 
culture, lactate switched from net production to 
consumption 
CHO-S Batch [68] 
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Substitute Gln for 
pyruvate  
Reduced glucose consumption and reduced lactate 
production, minimal change in lactate/glucose ratio; 
No impact upon growth rate 
CHO, 
BHK, 
MDCK 
Batch 3 [69] 
 
In two separate studies, when glucose was limited the production of lactate was practically 
eliminated, leading to a lactate/glucose ratio of nearly zero [49,60].  However, either the peak 
VCD achieved was diminished or growth rate was reduced, both fundamental problems for 
protein production.  However, in another study, the IVCD achieved was actually increased, in 
addition to reduced specific lactate production, leading to a doubling in the final product titer 
[63].  While this achievement certainly benefited from the increased sensitivity derived from 
using pH measurements to control glucose addition (rather than glucose measurements), it is not 
clear if glucose limitations will be consistently effective.  Another strategy is to substitute 
glucose for another sugar, such as galactose.  Altamirano et al. showed how this could be 
effective in limiting lactate production in two separate studies [66,67].  Unfortunately, these 
efforts did not result in a higher final titer, and generally limited the growth rate, making the 
reduction in lactate production less meaningful.   
One of the more interesting strategies explored was perhaps the most counterintuitive.  Li 
et al. explored the effect of feeding lactate to cell culture, as a substitute for CO2 [64].  
Considering the universal usage of CO2 as a media buffering agent (in tandem with HCO3
-), and 
the universal interest to limit lactate accumulation in media, this study stood in stark contrast to 
other approaches.  In terms of consumption fluxes, lactate was actually the preferred substrate to 
glucose (following addition).  While final titer was not increased, ammonia production was 
                                                 
3 This study induced the production of a vaccine with the inoculation of the flu virus, and media was changed upon 
inoculation, therefore technically making it a fed-batch process, but at least initially having features of a batch 
culture. 
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reduced considerably.  It is possible the excess ammonia was stored as alanine, since significant 
alanine accumulation occurred.  This is significant, as ammonia has been previously shown to 
negatively impact antibody glycosylation quality [25].  Osmolarity and IVCD were also not 
affected. 
Genetic manipulations.  At present, the industry is reluctant to consider genetic 
manipulations to their host cell lines.  This is likely due to a combination of factors.  The first 
issue deals with time.  Media can be altered and its effects tested immediately in culture.  
Improvements to media formulation can also be more easily implemented with other processes 
(using different cell lines).  Companies are unsure how the FDA will regulate genetic 
modifications to their cell lines, as outside of the DHFR and GS expression systems, there are 
not many precedents for using genetically engineered host cells.  Perhaps only when genetic 
modification(s) enable considerable economic advantage will the industry reconsider this 
approach.  Of all the genetic manipulations listed, the only one that has gained significant 
acceptance in the industry is GS [38,70].  Regardless, this has not stifled the academic interest or 
pursuit of uncovering meaningful and useful genetic alterations (Table 2-4).   
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Table 2-4. Genetic manipulations impacting lactate metabolism. 
Manipulation Metabolic Impact Cell Line Operation Ref. 
Genetic 
Downregulate 
LDH with RNAi 
Reduced lactate production, glucose consumption; 
Negligible change in glucose/lactate ratio, IVCD; 
Increased titer more than 2x compared to control 
CHO Batch [71] 
Overexpress 
GAPDH and 
Anti-Sense LDH 
Anti-LDH: Reduced lactate production; Increased IVCD, 
No impact upon final titer.  Anti-LDH + GAPDH: Limited 
lactate production; Increased IVCD, titer doubled 
CHO 
(DHFR-) 
Batch [72] 
Partial knockout 
of LDH 
Increased IVCD, doubled final titer; Reduced lactate 
production by ~50%, glucose consumption by ~25% 
Hybridoma Batch [73] 
Knockdown of 
LDH and PDHK 
Transfected cell to express siRNA for PDHK and LDH; 
Reduced lactate production by 90%; Increased specific 
productivity by 75%; IVCD not significantly effected 
CHO-
DUK-
XB11 
Fed-batch [74] 
Overexpress 
anti-apoptotic 
genes E1B19K, 
Aven, XIAP 
Increased IVCD, prolonged culture life; Increased capacity 
to consume lactate, decreased ammonia accumulation; 
Nearly doubled final titer 
CHO-K1-
SV 
Batch [75] 
Express 
cytosolic PC  
Doubled final titer; Increased cellular ATP content; 
Lactate/glucose ratio reduced; Increased viability in later 
stages of culture 
BHK 
Batch, 
Continuous 
[76,
77] 
Express 
cytosolic PC  
Reduced lactate and ammonia accumulation; Slight 
increase in peak VCD; Final titer not affected 
HEK 293 Fed-batch [78] 
Express 
cytosolic PC  
Reduced lactate and ammonia production; Increased IVCD 
by ~1/3; Increased titer by ~1/3 
HEK 293 Batch [79] 
Express 
cytosolic PC  
Increased IVCD; Doubled final titer; Reduced lactate 
production; Increased specific productivity as much as 
80% 
CHO-K1, 
BHK-21 
Batch [54] 
Express Glut5 
fructose 
transporter 
Decreased lactate production and fructose consumption; 
Unfortunately decreased IVCD, too 
CHO-
DUK-
XB11 
Batch [80] 
Reduce Glut1 
activity 
Knocked down Glut1 activity through anti-sense 
expression, reduced glucose consumption; Widely varying 
growth rates among clones generated, expression of Glut1 
anti-sense unstable over time 
Hybridoma Batch [81] 
Overexpress 
Asp/Glu 
Transporter and 
Timm8a1 
Neither Timm8A1 or Aralar1 significantly affected 
glucose consumption; Reversed lactate production; 
Decreased lactate accumulation; Titer not reported 
CHO Batch [82] 
Overexpress 
Asp/Glu 
Transporter  
Increased mitochondrial ATP production using 2 separate 
isoforms of Asp/Glu transporter; Did not measure glucose 
uptake or lactate production 
CHO Batch [83] 
Overexpress 
ALT 
Increased volumetric productivity by ~60%; Reduced 
ammonia and lactate accumulation; Increased IVCD 
CHO-
DUK-
XB11 
Fed-batch [84] 
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 The strategy to overexpress pyruvate carboxylase (PC) deserves special attention, as five 
separate studies were conducted upon it.  Specifically, the cytosolic variety of pyruvate 
carboxylase was expressed, which does not endogenously exist in the CHO genome [85] and was 
cloned from yeast.  This enzyme is responsible for the carbon fixing reaction that uses pyruvate 
as a substrate and generates the four-carbon molecule oxaloacetate.  Oxaloacetate is then 
converted into malate, via cytosolic malate dehydrogenase, and subsequently transported into the 
mitochondria (Figure 2-4).   
 
 
Figure 2-4. The impact of yeast-based cytosolic pyruvate carboxylase (PC) expression. 
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This provided an additional path, in addition to pyruvate dehydrogenase, for carbon to be 
transported to the mitochondria.  Since this process oxidizes NADH into NAD+, it has the added 
advantage of generating a redox cofactor likely in short supply in the cytosol.  Not surprisingly, 
when cytosolic PC was expressed, lactate production was reduced.  Moreover, all five studies 
reported practical benefits as a result of PC expression, where higher IVCD [54,79] was often 
achieved in addition to higher specific productivity [54] and final titer [54,77,79].   
Another effective strategy to limit lactate accumulation was examined by Dorai where 
multiple anti-apoptotic genes were overexpressed [75].  Here, perhaps as a consequence of 
limiting the progression of apoptosis, IVCD was increased by 80%.  This led to the final titer 
being increased by 78%, an achievement owed largely to an increase in IVCD.  However, the 
expression of the anti-apoptotic genes had an additional effect, where accumulation of lactate 
was significantly reduced.  This largely was an effect of augmented lactate consumption, which 
perhaps was facilitated by the measured enhancement in mitochondrial potential. 
A general theme emerges upon examination of the environmental, media, and genetic 
developments that have been made.  First is the realization that both the industry and academics 
have went to great lengths to reduce the production of a natural metabolic byproduct, lactate.  
Furthermore, of all the environmental, media, and genetic strategies, there are two common 
themes.  One is the reduction in the total amount of nutrients, namely glucose, being consumed 
[55,63,69,71,80,81].  The other is the redistribution of the nutrients that have been consumed, 
commonly represented in the glucose/lactate flux ratio [62,64,72,74,78,79,84].  Often, both of 
these themes can be simultaneously achieved [49,54,60–62,68,73,76,77,82].  A redistribution of 
the nutrients consumed (change in glucose/lactate flux ratio) is often more desirable, as this 
doesn’t deplete the availability of incoming substrates to allocate towards the production of 
28 
biomass or product protein.  Among the six studies that resulted solely in a reduction of 
incoming nutrients, only 1 out of 6 clearly had a positive outcome [71].  In this case, a positive 
impact is defined as an increase in growth rate or IVCD (biomass) or an increase in specific 
productivity or final titer (product). Comparatively, 5 out of 7 studies associated with nutrient 
redistributions clearly had positive impacts, with the remaining 2 reducing ammonia 
accumulation. Lastly, among the ten studies where total nutrient uptake was decreased and 
redistributed, 8 out of 10 studies had positive impacts, with the remaining 2 lacking the reported 
data to judge.  Considering all 23 studies considered here, the data clearly suggest that reducing 
lactate production, without having any nutrient consumption redistribution, is insufficient to have 
a positive outcome on production.  Therefore, glucose/lactate ratio serves as a much more 
reliable indicator of cell culture performance.   
It should be noted that while the glucose/lactate ratio is meaningful, it has limitations.  
Simply quantifying glucose and lactate flux does not provide any information as to what is the 
source of the lactate.  It also doesn’t consider the other metabolic byproducts that are typically 
produced during a production process.  However, lactate is the largest carbon output besides 
biomass production during exponential growth [52], so this ratio provides insight into the cellular 
carbon budget.  With less glucose converted to lactate, more can be shuttled into the 
mitochondria to engage in oxidative metabolism.  This in turn can fuel improved protein 
productivity, as evidenced by a positive correlation between oxygen uptake rate (OUR) and 
volumetric productivity [17]. 
 As can be clearly identified from Tables 2-4, strategies to limit/eliminate lactate 
production over the past twenty years have been varied in approach and success.  Nonetheless, 
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previous work provides insight on how to improve the process as the industry moves more from 
an empirical to a systems-based approach [18]. 
Cellular physiology of lactate production.  Figure 2-5 illustrates how lactate production 
and consumption affects cytosolic reduction/oxidation (redox). 
 
 
Figure 2-5.  Cellular redox and energetics surrounding lactate production. 
 
Figure 2-5 also highlights the significance of the lactate/glucose ratio.  When glucose is 
catabolized to pyruvate, NAD+ is reduced to NADH.  For glycolysis to continue, NAD+ must be 
regenerated.  This is a major function of lactate production, to generate NAD+ by oxidizing 
NADH.  NADH reducing equivalents can also be transported into the cytosol using the malate-
aspartate (Mal/Asp) shuttle.  Nucleotides such as NADH cannot pass across the mitochondrial 
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membrane. Therefore, NADH is used to reduce oxaloacetate to malate, which can be transported 
into the mitochondrial matrix and oxidized as a way to transfer NADH reducing equivalents 
from the cytosol to the mitochondria, as shown in Figure 2-6. 
 
 
Figure 2-6. The malate/aspartate shuttle.  The critical role of glycolysis and respiration in both 
mitochondrial and cytosolic redox states has been highlighted. 
 
The Mal/Asp shuttle is typically not sufficient to satisfy the glycolytic demand for NAD+ 
when the glucose consumption rate is high.  In this instance, conversion of pyruvate to lactate 
can be used as a rapid source of cytosolic NAD+.  This underlies the significance of the 
lactate/glucose ratio.  If the ratio falls, it is probable that the mitochondria are playing a greater 
role in redox provision.  If it remains constant despite a fall in lactate production, it indicates a 
proportionate decrease in both glycolytic and mitochondrial metabolism.  It is for this reason that 
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we and others have suggested the importance of the mitochondrial/glycolytic ratio [86].  The 
mitochondrial/glycolytic ratio considers the ratio of carbon directed to the mitochondria, 
compared to carbon directed to lactate, at the pyruvate node.  This differs from the glucose to 
lactate ratio in that it takes into account the carbon flux lost to CO2, when traveling through the 
pentose phosphate pathway. 
 
The role of upstream mRNA and protein expression 
While this work primarily focuses on metabolism studies, useful insight can be collected 
from upstream genomic/transcriptomic/proteomic studies.  Since it is reasonable to question 
whether central metabolism, or energy related pathways, are the limiting factor for antibody 
production, we explore it here.   
A transcriptomic study considered mRNA expression associated with an antibody 
producing line, and a wild-type non-expressing cell line [87].  Specifically, the mRNA related to 
protein synthesis and ribosomes was considered.  Interestingly, the wild-type line had 
considerably more mRNA expression than the antibody secreting line.  Therefore, it was argued 
that antibody expression plays a rather small role in the total protein being synthesized.  This 
indicated the potential for considerable ground to be gained in specific productivity.  Other work 
has considered the relative abundance of light and heavy chain mRNA.  Under exponential 
growth, there is a correlation between specific productivity and expression level of antibody 
mRNA.  However, as the culture moves into stationary phase, where the majority of antibody is 
generated, this correlation was lost [53].  Another study asked the question if sufficient 
machinery existed to generate/secrete protein, and used proteomics to quantify the relative 
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unfolded protein response (UPR) as indication of bottlenecks [88].  Again, the authors found no 
evidence to suggest UPR in antibody producing cell lines.  Lastly, karytopic studies have been 
done on CHO cells in an effort to determine if genetic stability has a correlation with specific 
productivity [89].  One author’s findings indicated that while significant aneuploidy existed in 
CHO cells (the Chinese Hamster is naturally diploid), and revealed that chromosomal aberations 
in general do occur in the presence of any transfection, there was no correlation between genetic 
stability and specific productivity.  Taken collectively, these findings suggest that the rate 
limiting step to increasing specific productivity may not present itself in upstream limitations, it 
may be associated with central metabolism. 
 
13C metabolic flux analysis (MFA) 
 Fundamentally, metabolic flux analysis (MFA) aims to quantify the intracellular rates of 
metabolism.  It is most useful when a given hypothesis cannot be tested without quantitative 
knowledge of intracellular rates of reactions.  Many types of metabolic measurements (e.g., 
glucose/lactate ratio) can provide partial information about central metabolism without applying 
metabolic flux analysis.  However, the interpretation of these measurements has limitations and 
is subject to various approximations.  On the other hand, MFA allows researchers to 
quantitatively map the flow of carbon through intracellular metabolic pathways, providing rich 
information about the relative importance of carbon sources and sinks within the metabolic 
network and the partitioning of carbon among these various pathways (Figure 2-7).   
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Figure 2-7. 13C metabolic flux analysis can be used to supplement the information provided 
by metabolic studies.  Without MFA, the cell is often viewed as a black box.  All of the inputs 
and outputs can be quantified, but due to metabolic complexities, it is impossible to define the 
intracellular fluxes without additional information.  Such additional information can be provided 
by the application of 13C tracers.  Vi represents an individual flux, and A-G are generic 
intracellular metabolites.  
 
13C metabolic flux analysis simply refers to the usage of 13C tracers.  This could be glucose, as 
shown in Figure 2-7, or most any other nutrient consumed by the cell (provided it is available for 
purchase).   
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 13C MFA provides additional constraints to a metabolic network, proportional to the 
number of metabolites measured.  Metabolite labeling is measured through mass spectral 
analysis.  When the selected source (13C tracer) is consumed, the labeled carbon is turned over 
into other metabolites.  The resultant mass spectral metabolite detail provides further constraints 
to a metabolic model, allowing cyclic pathways (such as the pentose phosphate pathway or 
tricarboxylic acid (TCA) cycle), which are typically undeterminable, to be quantified.  This is 
achieved through a mathematical model that integrates mass spectral data and extracellular 
fluxes to calculate the intracellular fluxes of a metabolic model. 
 
Model inputs 
 There are two types of measured inputs used to calculate fluxes with 13C MFA.  The first 
deals with extracellular fluxes, encompassing all the production and consumption fluxes of the 
cell.  As can be seen in Figure 2-7, a product can be a simple metabolite, such as lactate, or a 
complex macromolecule, such as biomass or antibody.  These inputs effectively contribute mass 
balance constraints to the model.  The other input involves the information acquired from using a 
13C tracer.  As a tracer incorporates itself into downstream metabolites, information is provided 
as to not only the source but the path that the tracer took to get there. This is because different 
pathways produce different carbon rearrangements, which results in unique labeling patterns in 
the downstream products. As an example, consider the pentose phosphate pathway (PPP) shown 
schematically in Figure 2-5.  If [1,2-13C2]glucose is fed to the culture, either doubly or singly 
labeled pyruvate will emerge depending on the relative contributions of glycolysis versus PPP, 
respectively (Figure 2-8). 
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Figure 2-8.  Discerning between the split of glycolysis and the pentose phosphate pathway.  
The mass isotopomer distribution of pyruvate, if generated purely through PPP or glycolysis, is 
shown.  Any linear combination of the two can also exist, as the cell will often utilize both 
pathways simultaneously. Linear regression can be used to determine the actual glycolysis/PPP 
split ratio by fitting the experimental measurements to a mathematical model that accounts for 
the stoichiometry and atom rearrangements of the metabolic network. 
 
Mass isotopomers are molecules that have the same chemical composition but different 
masses, due to differing incorporation of 13C.  Gas chromatography-mass spectroscopy (GC-MS) 
can accurately separate and determine the relative abundances of different mass isotopomers 
from the same metabolite.  As stated previously, the relative abundances of these mass 
isotopomers are dictated by the selected tracer and the path that the tracer took as it moved 
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through the network.  Therefore, while only mass balances can be formed from extracellular 
fluxes input to the model, addition of mass spectral (MS) data allows the model to be extended to 
include isotopomer balances. This typically results in an overdetermined system of equations that 
can be solved by least-squares regression to estimate the fluxes of interest.  In the example 
provided in Figure 2-8, the ratio of the PPP flux compared to glycolysis is determined by the MS 
data acquired. 
One key limitation of conducting 13C MFA based on MS measurements has to do with 
the inability of MS to determine position-specific labeling.  As can be seen in Figure 2-8, there is 
no way to distinguish between the M2 signal generated from the PPP and glycolysis.  Nuclear 
magnetic resonance (NMR) can determine this positional information, and this provides an 
alternative technique to acquire labeling data for 13C MFA studies. However, NMR requires 
considerably more sample volume and is much more costly to operate than MS [90,91]. Both are 
viable platforms and have experienced significant methodological development for MFA 
application in the past twenty years [92].  In this dissertation, mass spectral analysis is used 
exclusively. 
All of the MFA studies presented in this dissertation depend upon two assumptions.  The 
first is metabolic steady-state, which implies that the metabolic fluxes are constant over time. 
This is assessed by monitoring the changing concentration of nutrients/products/byproducts in 
the media to identify phases when the cell-specific rates of change are constant.  Typically, 
measurements of viable cell density (VCD) and nutrient concentrations are made over a 
minimum of 2 days to determine these extracellular fluxes.  Secondly, the models assume 
isotopic steady-state.  This requires sufficient time for the tracer to equilibrate with the system, 
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with 2 days post-administration generally found to be sufficient for most intracellular metabolites  
in CHO cells [93]. 
 
Mathematics of MFA  
MFA attempts to represent the entire experimental data set as accurately as possible by 
adjusting the flux parameters to minimize the differences between model-simulated and 
experimentally determined values.  The MFA objective function is constructed to minimize the 
sum-of-squared residuals. Therefore, some experimental measurements may be fit by the model 
better than others.  This could be a result of an inaccurate experimental measurement or by an 
error or omission in the model.  Once the overall fit has been optimized, the goodness-of-fit is 
determined through a chi-squared test and by assessing the distribution of the residuals [94].  It is 
through this simulation and comparison process that the model is adjusted to best estimate each 
individual flux, indicated by Vi in Figure 2-9. 
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Figure 2-9.  13C metabolic flux analysis.  The network diagram has been borrowed from Figure 
2-7.  These two varieties of measurements, extracellular fluxes and mass isotopomer abundances, 
are used in tandem to estimate the intracellular fluxes.  Fluxes Vi are adjusted to optimize the fit 
between simulated and experimental values. 
 
After constructing the appropriate reaction network to represent the system of interest, 
this information can be used to construct a stoichiometric matrix S and unknown flux vector v.  
The steady-state metabolite mass balances can be written in matrix form using the following 
equation 
𝑆 ∙ 𝑣 = 0  
The stoichiometric matrix S is m x n, where m is the number of balanced metabolites and n is the 
number of fluxes.  However, only (nr) fluxes can be freely adjusted, where r is the rank of S, 
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and the remaining r fluxes are dependent on these “free” fluxes as a result of mass conservation  
[94].  The full flux vector can be determined from the free fluxes through a linear transformation  
𝑣 = 𝐾 ∙ 𝑢 
where K is the nullspace matrix of S and u is the vector of free fluxes.  The nullspace matrix is 
not unique, but can be constructed from any collection of vectors that form a basis for the 
nullspace of S.  The size of the nullspace matrix is n x (nr).  
 Typically, there are not enough extracellular measurements available to determine all 
(nr) free fluxes, and the system is underdetermined. Flux balance analysis (FBA) is an approach 
closely related to MFA that aims to explore the set of possible solutions to this underdetermined 
set of equations [95].  However, FBA doesn’t utilize the added information provided by 13C 
tracers.  Consequently, assumptions must be made to determine the system, and statistical 
analysis of any kind is limited [95].  On the other hand, inclusion of mass spectral measurements 
and isotopomer balances into the model results in an overdetermined system, which can be 
solved for a unique flux solution using least-squares regression. Furthermore, the flux solution 
can be subjected to statistical goodness-of-fit and uncertainty analyses that enable, for example, 
95% confidence intervals to be determined for each flux. 
 The objective function of the 13C MFA procedure can be expressed mathematically as 
min 𝛷 = (𝑥(𝑢) − 𝑥𝑜𝑏𝑠)𝑇 ∙  Σ𝑥
−1 ∙ (𝑥(𝑢) − 𝑥𝑜𝑏𝑠) 
subject to K∙u ≥ 0 
where Φ is the sum-of-squares objective function, x(u) is the simulated measurements vector, 
and xobs is the experimental measurements vector.  Σx is the covariance matrix of the 
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experimental measurements.  It includes the individual measurement variance on the diagonal of 
the matrix.  Σx serves to make the objective function covariance-weighted.  Solution of the above 
optimization is accomplished by application of the Levenberg-Marquardt gradient-based 
algorithm [96], or any other suitable minimization technique. 
 In order to perform the optimization, the isotopomer balances must be solved at each 
iteration to simulate the MS measurements contained in the vector x for a given guess of the free 
flux vector u. The most efficient approach for solving these balance equations  involves 
decomposing the metabolites into a collection of elementary metabolite units (EMUs), which are 
unique subsets of the atoms that comprise each metabolite [97].  For each molecule of atom size 
N, there are a maximum of 2N-1 EMUs.  However, not all EMUs are required to simulate the 
limited MS measurements that are available. Therefore, the EMU approach is computationally 
efficient because it only solves for the isotopomer distributions of EMUs that contribute to an 
actual experimental measurement [98].  Prior to the inception of the EMU approach, all 
isotopomers were balanced and solved simultaneously, leading to vastly larger systems of 
equations that required significantly more computational time.  The first systematic approach to 
enumerate and solve all isotopomer balances was introduced by Schmidt et al. [99], which paved 
the way for modern approaches based on cumomer or EMU balances [91]. 
 Using the EMU approach, EMUs can be grouped based upon their size (i.e., the number 
of atoms they contain).  Like a mass balance constructed around a metabolite, balance equations 
can be formed around EMUs in order to simulate the experimental labeling.  EMU balances can 
be arranged as a cascaded system of linear equations and expressed in matrix form as 
𝐴1 ∙ 𝑋1 = 𝐵1 ∙ 𝑌1(𝑦1
𝑖𝑛) 
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𝐴2 ∙ 𝑋2 = 𝐵2 ∙ 𝑌2(𝑦2
𝑖𝑛, 𝑋1) 
⋯ 
𝐴𝑛 ∙ 𝑋𝑛 = 𝐵𝑛 ∙ 𝑌𝑛(𝑦𝑛
𝑖𝑛, 𝑋𝑛−1, 𝑋𝑛−2, … , 𝑋1) 
Where Ai and Bi are matrices that depend on the free flux values, Xi is an unknown matrix that 
contains the mass isotopomer distributions (MIDs) of all balanced EMUs of size i, and Yi is a 
matrix of known source MIDs (yi
in) or previously calculated MIDs (X1, X2, …).  The source 
metabolites could be the isotopic tracer applied, or an unlabeled metabolite.  At the ith step, the 
system is solved for Xi.  The EMU balances are solved in ascending size order, e.g., the EMUs of 
size i=1 must be solved before the EMUs of size i=2, as Y2 depends upon X1.  It is through these 
EMU balances and the sum-of-squares minimization that the experimentally measured 
extracellular fluxes and mass spectral data (MIDs) are merged together to estimate the unknown 
free fluxes of the system. 
 
Alternatives to 13C MFA 
In the absence of MFA, the cell can be modeled as a black box.  This allows for all of the 
metabolic inputs and outputs to be accounted for using a stoichiometric analysis [49].  
Stoichiometric analysis involves quantifying the rates of all major incoming and outgoing 
metabolic fluxes, so that carbon and redox balance can be assessed.  Biomass and antibody 
generation are accounted for, and the metabolic demands for their synthesis are defined. 
A natural next step to a stoichiometric analysis is the application of all the associated 
measurements to a metabolic model.  This can involve the application of FBA to estimate 
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unknown intracellular fluxes based on mass balancing.  However, central metabolism involves 
cycles, split pathways, and reversible reactions, all of which are not possible to fully resolve 
based solely on the extracellular measurements [100].  Therefore, additional assumptions and 
constraints are imposed upon the model.  Constraints typically involve using cofactor balances, 
i.e. ATP, NADH, and NADPH.  Unfortunately, applying cofactor balances is rather difficult and 
can lead to metabolic models that poorly represent metabolism.  First, it is challenging to 
determine the efficiency in conversion of NADH to ATP [101].  Second, determining cell 
maintenance requirements for cofactors is equally difficult [90].  Simply put, it is impossible to 
accurately know all the energy producing/consuming reactions in the cell, and therefore difficult 
to appropriately apply cofactor balances [100].  Furthermore, imposing cofactor balances 
generally fall short of determining a metabolic network [102].   
If a single solution is to be determined, additional assumptions can be made.  This 
involves the application of linear programming to optimize a cellular objective [103], i.e., to 
maximize or minimize a given product.  To provide an example, the objective could be to 
maximize/minimize ATP or NAD(P)H.  A freely available software (named COBRA) can be 
used to calculate FBA solutions for any user-specified objective function [104].  However, these 
solutions are, by definition, found at the extreme edge of a bounded multidimensional solution 
space [90].  This may or may not be a biologically relevant representation of the metabolism 
exhibited.  Only through comparison to a flux map derived from 13C MFA can this solution be 
properly validated.  
While these shortcomings clearly point towards the advantages of 13C MFA, there are a 
few key advantages to FBA.  Unlike 13C MFA, it doesn’t require the purchase of isotope tracers.  
Generally, this does limit 13C MFA experiments to bench-top scale [92].  Additionally, FBA is 
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simpler and considerably less laborious than 13C MFA [102].  The relative importance of 
accuracy vs monetary/time cost must be balanced, in order to assess the usefulness of FBA 
versus 13C MFA. 
MFA is a powerful tool to generate representative flux maps that characterize an 
experimental system.  For predictive models, often kinetics-based approaches are more useful 
[105,106].  As an added benefit, they do not require metabolic steady-state assumptions (a 
requirement of both MFA and FBA).  However, as is the case with all kinetic models, they 
require identification of suitable rate expressions and kinetic constants before reliable predictions 
can be obtained, which is often difficult to achieve in biologically relevant networks. 
 
Past applications of MFA to investigate mammalian hosts capable of protein production 
 MFA has been applied to several past mammalian cell culture studies that explored the 
effects of media alterations, environmental changes, and the changes to cell metabolism occuring 
over a culture’s operational lifetime. Industrially relevant fed-batch and perfusion processes have 
both been investigated.  Some of the significant findings, to advance MFA technique and 
enhance industrial cell culture understanding, are discussed here. 
 
 Continuous culture.  It is important to realize that metabolic steady-state can be more 
readily achieved in a continuous or perfusion setup, as compared to fed-batch.  Continuous 
cultures hold a relatively constant media condition and cell density.  Many of the earlier MFA 
studies took advantage of this detail.  Sharfstein et al. took this a step further in 1994, when she 
conducted 13C MFA using in-vivo NMR [107] with a hybridoma cell line.  In this case, the entire 
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reactor was placed directly in the magnetic field (of NMR) over the course of the experiment.  
This design allows metabolites to be quantified in real-time, whereas the majority of 13C MFA 
must conduct offline analysis.  Due to a lack of signal sensitivity, however, high cell densities 
are required by this in-vivo approach.  For this reason, Sharfstein et al. utilized a hollow fiber 
reactor, known for being capable of especially high cell densities [108].  This allowed for 
increased signal to be generated for a given metabolite.  Labeling patterns of glycolytic 
intermediates, amino acids, and lipids were all determined.  Independent experiments were 
conducted using either [1-13C1]glucose or [3-
13C1]glutamine as the labeled source.  The 
experiment tested the impact of decreasing glutamine concentration upon antibody production.  
Two conditions were considered, including glutamine at 1.7 and 4 mM concentration.  Changing 
glutamine concentration did not substantially impact the PPP or glycolysis.  When glutamine 
concentration was reduced however, amino acids (mostly glutamine) entering the TCA cycle via 
α-ketoglutarate were roughly halved.  Additionally, when the concentration was reduced, relative 
specific antibody production significantly increased.  Based upon these findings, Sharfstein et al. 
reported antibody production might not be limited by energy production.  Final titer was roughly 
25 mg/L, at least 2 orders of magnitude less than typical titers achieved at present.  The 
miniscule antibody production of this study may explain the lack of correlation with energy 
production.  Finally, this work determined that significant exchange fluxes were occurring 
between TCA intermediates and extracellular amino acids, a point still relevant to 13C MFA 
studies today. 
As a follow up study to this, using the same reactor setup, Mancuso et al. further 
examined the effect of limiting glutamine upon hybridoma [109].  In this study only [1-
13C1]glucose was used, and metabolite labeling determined by NMR.  Glycolytic intermediates, 
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lipids, and amino acids were measured.  When glutamine was abruptly eliminated from culture, 
specific productivity was significantly increased (more than doubled).  With it, glycolytic flux 
was not significantly affected, but overall ATP production reduced by 20% (based upon 
reduction in oxygen uptake rate).  Lipid synthesis (growth) was unaffected.  Mancuso et al. 
concluded that antibody production was not limited by energy, as was the case in Sharfstein’s 
study.  However, it is important to note that maximal specific productivity here was 
approximately 1 pg/cell/day.  This is considerably less than the excess of 50 pg/cell/day achieved 
more recently [52].   
Metabolic steady-state is essential to MFA, but it doesn’t mean that multiple metabolic 
steady-states cannot exist.  Two separate hybridoma FBA studies proved just this.  In the first 
study, Follstad et al. used a chemostat and experimentally set out to experimentally determine the 
effect of various dilution rates upon metabolism [110].  Here, as the initial (control) residence 
time of approximately 5.2 days was stepped down to lesser dilution rates (eventually ¼ the 
control condition), an increased fraction of pyruvate was transported into the mitochondria to 
participate in the TCA cycle.  Dilution rates were held constant for a minimum of 5 residence 
times (in most cases more), and after 68 days of culture, dilution rates were increased back to the 
control.  Even though the dilution rate was the same, viable cell density at steady-state was 
approximately doubled and lactate production reduced by 18%. 
In the second study exploring multiple metabolic steady-states, Europa et al. conducted 
another FBA study upon hybridoma.  Initially cultured in fed batch, the experimental condition 
was fed at low glucose concentrations (approximately 1/20th the control), and the control at 
relatively high glucose concentrations (approximately 19mM).  After culturing for 12 hours, both 
cultures were moved into a chemostat.  Upon moving into chemostat with a residence time of 
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approximately 6 days, two different metabolic steady-states were observed, even though glucose 
concentration was now equal and constant for both conditions.  In the control, the lactate/glucose 
flux ratio was 1.4.  In the experimental condition, glucose flux was reduced to ¼ the control, and 
lactate/glucose ratio <0.1.  Impressively, antibody specific production was not affected in spite of 
this, and maintained at 0.45 pg/cell/day.  While metabolic fluxes were generally reduced across 
the board, TCA cycle fluxes were reduced by 90% in the experimental condition.  Alongside, 
glucose and glutamine fluxes were only reduced by 75% in the experimental condition.  Again, it 
did not appear that energetics were limiting to antibody production at the given rate.  Multiple 
metabolic steady-states in NS0 and HeLa have also been confirmed in more recent kinetic 
studies from Mulukutla et al. [111,112].  Mulukutla’s work models a continuous solution space, 
based upon experimental results, of a given metabolic steady-state.  As a consequence, his 
computational model provides insight to conditions not explicitly tested, a useful result for 
industry. 
In a semi-continuous reactor design, Sheikholeslami et al. performed 13C MFA upon an 
inducible antibody producing CHO cell [113] cultured in shake flasks.  [1-13C1], [6-
13C1], and 
[U-13C6]glucose served as tracers, along with [U-
13C5]glutamine, in four separate parallel studies.  
LC-MS was used to determine the labeling of extracellular lactate, glutamate, aspartate, and 
alanine.  Here, 30% of the culture volume was abruptly replaced on a daily interval, making this 
a semi-continous design, by centrifuging the culture and partially replacing the supernatant 
accordingly.  Cultures appeared to exhibit exponential growth during the labeled experiment, and 
maintained a specific productivity of 13.7 pg/cell/day.  When antibody production was induced, 
the oxPPP flux was nearly halved.  TCA cycle fluxes reportedly increased by an average of 17%.  
Application of the results from this study should be carefully considered alongside the fact that 
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the culture conditions were not really continuous or fed-batch.  However, the fact that oxPPP 
flux reduced when antibody production was induced is a surprising result.  To date, it is the only 
MFA study which offers comparison of the oxPPP flux of an antibody producing and control line 
during exponential growth.   
 
Fed batch culture.  MFA has also been applied to fed-batch bioreactors.  Sengupta et al. 
used 13C MFA to evaluate the impact of differing environmental conditions (partial pressure 
CO2, dissolved oxygen (DO), temperature) and feed volumes upon stationary phase metabolism 
[114].  Specifically, the labeled experiment was conducted between day 17 and 20 of culture.  
GS-CHO was cultured in the presence of both [U-13C6] and [1-
13C1]glucose.  LC-MS was used to 
determine metabolite labeling of various glycolytic intermediates.  While MS data was collected 
for TCA intermediates and amino acids, it was not used as a constraint in the model.  The authors 
omitted the data because isotopic steady-state had not been reached in 4 hours’ time for amino 
acids or TCA intermediates in the preliminary labeling experiment.  Seemingly contrasting with 
the findings of Sheikholeslami et al., Sengupta et al. reported that nearly all glycolytic flux was 
directed to the oxPPP, regardless of the environmental conditions tested.  In some cases, there 
was even evidence of a glycolytic recycle, allowing the oxPPP flux to be in excess of the glucose 
flux.  However, it is important to remember that here the stationary phase is being considered, 
not the exponential phase.  Furthermore, there is no comparison to a control cell line not 
secreting antibody.  The conditions most associated with high (more specifically, recycle) oxPPP 
flux were associated with low dissolved CO2 (low partial pressure).  Notably, pH was held 
constant for all conditions.  The condition with the highest pyruvate flux directed to the 
mitochondria was associated with the highest antibody productivity.  The two conditions with the 
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reduced oxPPP activity were associated with increased antibody productivity, drawing 
comparison to the findings of Sheikholeslami et al. 
 Ahn et al. used a similar approach to Sengupta et al. in that they too performed 13C 
stationary MFA only upon glycolytic intermediates measurements [115].  Here, Ahn et al. used 
[1,2-13C2]glucose as the labeled source, and cultured adherent CHO-K1 in T-25 flasks.  
Metabolite labeling results were assessed using a GC-MS.  After performing stationary MFA to 
determine glycolytic and PPP fluxes, isotopic non-stationary (INST) MFA was applied to the MS 
results of TCA intermediates, amino acids, and fatty acids.  This calculated all remaining fluxes, 
including those associated with the TCA cycle.  INST-MFA was used because isotopic steady-
state was not achieved in the TCA intermediates.  This work analyzed the changes to metabolism 
which occur during the exponential growth phase and stationary phase.  The growth phase 
correlated with high glycolytic flux, high lactate production, and high cycling anaplerotic fluxes 
(PC and malic enzyme (ME)).  As the culture shifted to stationary phase, a similar profile to 
Sengupta’s work was observed, with increased oxPPP and TCA cycling.  Lactate production 
actually reversed during the stationary phase, in agreement with other work exploring the 
exponential and stationary phase in CHO [116]. 
 As a follow up study to this, Ahn et al. explored a means to shorten the required length of 
time to perform steady-state 13C MFA [117].  In two parallel studies, [U-13C5]glutamine and 
[1,2-13C2]glucose were used.  Still using CHO-K1 in T-25 flasks, he largely replicated the results 
of his prior study.  However, he found through GC-MS that isotopic steady-state could be 
achieved in TCA intermediates in just 3 hours, and glycolytic intermediates in only 1.5 hours.  
This experimental design development would potentially be useful where metabolic steady-state 
of the period of interest was known/hypothesized to be limited in time.  The INST-MFA 
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technique previously mentioned addtionally serves as a situational option.  INST-MFA does not 
require assumptions about isotopic steady-state, but does require additional measurements, and 
involves additional computational complexity [118]. 
 Metabolism is dynamic.  To this end, much effort has been placed in developing dynamic 
MFA approaches [119,120].  Whilst 13C dynamic MFA has yet to be accomplished, it is being 
developed.  Fortunately, even fed-batch processes exhibit quasi- steady-state metabolism for a 
sufficient period of time to perform MFA in the midst of changing nutrient availability.  
Regardless, the steady-state assumption can be a challenge to consistently satisfy without a priori 
knowledge of a given system.   
In summary, all the MFA approaches listed here are useful when used in the appropriate 
situation.  Time, cost, scale, and predictive/representative capacity of metabolic steady-state are 
the major factors to consider when determining which type of metabolic model to use. 
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METABOLISM IN AN INDUSTRIAL FED-BATCH CHO CELL CULTURE 
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Abstract 
Cell metabolism can vary considerably over the course of a typical fed-batch antibody 
production process. However, the intracellular pathway alterations associated with various 
phases of growth and antibody production have yet to be fully elucidated using industrially 
relevant production hosts. Therefore, we performed 13C labeling experiments and metabolic flux 
analysis (MFA) to characterize CHO cell metabolism during four separate phases of an industrial 
fed-batch culture.  First, we found that peak specific growth rate was associated with high lactate 
production and minimal TCA cycling.  Conversely, we found that lactate metabolism switched 
from net production to net consumption as the culture transitioned from peak growth to peak 
antibody production.  During the peak antibody production phase, energy was primarily 
generated through oxidative phosphorylation, which was also associated with elevated oxidative 
pentose phosphate pathway (oxPPP) activity.  Interestingly, as TCA cycling and antibody 
production reached their peaks, specific growth rate continued to diminish as the culture entered 
stationary phase.  However, TCA cycling and oxPPP activity remained high even as viable cell 
density began to decline.  Overall, we found that a highly oxidative state of metabolism 
corresponded with peak antibody production, whereas peak cell growth was characterized by a 
highly glycolytic metabolic state.   
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Introduction 
Chinese hamster ovary (CHO) cells are currently the preferred host for recombinant 
antibody production, supplying 60-70% of the nearly $100 billion global biotherapeutics market 
[2].  Production of recombinant antibodies is energetically costly to the host cell, requiring 
roughly three molecules of ATP to synthesize just one peptide bond [3].  A highly producing cell 
line can potentially generate 40 pg of antibody each day [3], representing up to 20% of the cell’s 
total intracellular protein [4]. Despite these energy and material demands, mammalian cell lines 
often exhibit an inefficient glycolytic state of metabolism involving rapid conversion of glucose 
to lactate even in the presence of abundant oxygen [2].  Furthermore, increased consumption of 
glutamine is also exhibited by many continuous cell lines, but much of the nitrogen provided by 
this substrate is subsequently lost to the production of ammonia and alanine [5]. While 
minimizing wasteful byproduct accumulation has been a goal of the mammalian biotech industry 
for over twenty-five years, it still remains an unresolved issue.  Furthermore, many production 
cultures will shift from net production to net consumption of these byproducts during the 
bioprocess run [6], however, the regulatory mechanisms that control this switch are still poorly 
understood.   
Fed-batch bioreactors are the most common system of monoclonal antibody production 
used today [7].  Fed-batch reactors have a key advantage over other systems, such as perfusion 
culture, because a higher final product titer can be achieved.  This limits the cost associated with 
downstream processing and purification [8].  One challenge of fed-batch designs is that culture 
metabolism changes substantially over the course of the production run.  This can be attributed to 
changing nutrient availability and cell density that give rise to transitions between distinct 
growth phases (i.e., exponential, stationary, and decline).  Furthermore, concentrations of lactate, 
63 
ammonia, and other waste products can accumulate during early growth phases to concentrations 
that inhibit cell growth and antibody productivity and impact protein glycosylation during later 
phases [9]. Byproduct accumulation can also lead to excessive increases to osmolarity, especially 
when online base addition is used to control pH [10]. To mitigate these effects, much prior work 
has examined the impacts of process parameters such as pH, temperature, CO2, and osmolarity 
on process performance [7]. Information from these studies has been used to design optimal 
media formulations and feeding strategies that reduce byproduct accumulation by limiting the 
supply of glucose, glutamine, or other nutrients to the culture [8], [11].  Further work has 
examined metabolic engineering of CHO cells to enhance pyruvate entry into mitochondria by 
overexpressing the pyruvate carboxylase (PC) enzyme [12] or to resist cell toxicity by 
overexpressing various anti-apoptotic proteins [13].  
While previous studies have led to substantial improvements in bioprocess rates and 
titers, the ability to precisely quantify cell metabolism throughout multiple growth phases is 
essential to further understand and optimize the industrial fed-batch production process. 
Metabolic flux analysis (MFA) provides a powerful approach to map intracellular carbon flows 
of cultured cells and thereby elucidate the functional behavior of entire biochemical networks, as 
opposed to studying individual reactions or nodes in isolation. MFA has been applied to a variety 
of bioprocess applications, including optimization of medium composition and feeding strategies 
[14], data reconciliation and error analysis of measured rates [15], and to draw comparisons 
between the metabolism of CHO cells and other continuous cell lines [16].  Most prior MFA 
studies on CHO cells have relied on classical metabolite balancing to estimate fluxes without the 
use of 13C tracers [2]. This necessitates the use of simplified network models and ad hoc 
assumptions to determine fluxes based on measured nutrient uptake and product secretion rates. 
64 
Alternative approaches have also been developed to calculate upper and lower flux bounds using 
large-scale stoichiometric models without attempting to solve explicitly for the unidentifiable 
fluxes [16]. To our knowledge, only three prior MFA studies have applied 13C tracing of CHO 
cell cultures to fully resolve fluxes through parallel and cyclic reaction pathways (e.g., oxPPP, 
PC, etc.) [17]–[19]. However, only Sengupta et al. [19] applied 13C-MFA to examine fed-batch 
culture of an antibody-secreting CHO cell line, and their work was limited to the late stationary 
growth phase. On the other hand, Ahn and Antoniewicz [17] applied 13C-MFA to compare flux 
maps between exponential and stationary growth phases of a fed-batch CHO culture, but their 
work examined an adherent CHO-K1 line that did not express recombinant antibody. Therefore, 
comprehensive understanding of CHO cell physiology based on 13C-MFA is still lacking, 
especially in regards to how CHO metabolism adapts to changing growth and antibody secretion 
rates over the course of an industrially relevant fed-batch bioprocess. 
In this study, we have performed 13C labeling experiments and MFA to characterize cell 
metabolism throughout four separate phases of an industrial fed-batch process.  A small-scale 
culture system with a highly productive (HP) recombinant antibody-producing CHO cell line 
was used to represent a typical manufacturing-scale serum-free process.  Using MFA, we 
initially observed that the demands of peak growth were met by a highly glycolytic state of 
metabolism, but as time progressed the culture shifted to an increasingly oxidative state that 
coincided with peak antibody production.  All major pathways of central metabolism were 
considered in our analysis, including glycolysis, pentose phosphate pathway, TCA cycle, and 
various cataplerotic and anaplerotic pathways.  In a complementary study, both the expression 
and activity of several relevant enzy1mes within these pathways were verified [20].  To our 
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knowledge, this is the first time that MFA has been applied to characterize multiple phases of an 
industrial antibody-producing fed-batch CHO cell bioprocess. 
 
Materials and Methods 
Cell culture 
A highly-productive (HP) CHO cell line was generated by transfecting plasmid DNA 
containing mAb light chain and heavy chain into a dihydrofolate reductase-deficient CHO cell 
line adapted to suspension and serum-free growth media.  Prior to the experiment, these cell lines 
were passaged every three or four days at a density of 3x105cells/mL in peptone- and 
methotrexate-containing growth media in a humidified incubator maintained at 36°C and 5% 
CO2 with shaking at 150 RPM.  For further information about culture conditions, refer to Dean 
and Reddy [20]. 
To initiate the fed-batch experiment, the culture was inoculated into a chemically defined 
production media at a viable cell density of approximately 5x105 cells/mL.  Fed-batch cultures 
were grown using 25 mL of culture volume in 125mL shake flasks or 3.6 mL in 24 deep-well 
plates in humidified incubators maintained at 36oC and 5% CO2 with shaking at either 150 RPM 
(125mL shake flask) or 220 RPM (24 deep-well plate).  The production was carried out for ten 
days by feeding 5%, 5%, and 9% of the initial culture volume of a chemically defined 
concentrated amino acid feed on days three, six, and eight.  On days three, six, and eight, glucose 
concentrations were adjusted to 55.6 mM (10 g/L). 
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Determination of nutrient uptake and product excretion rates 
Extracellular media samples were taken at multiple times throughout the experiment.  
Glucose and lactate concentrations were determined by enzymatic assay using an automated 
Poly-chem instrument (Polymedco, Cortlandt Manor, NY).  Viable cell density (VCD) was 
determined by using a ViCell (Beckman Coulter, Fullerton, CA).  Antibody titer was determined 
by high performance liquid chromatography (HPLC) using a Protein-A column.  Amino acid 
concentration was determined by HPLC using a 6-aminoquinolyl-N-hydroxysuccinimidyl 
carbamate derivatization method. Extracellular pyruvate concentrations were determined using 
an organic acid Aminex HPX-87H column (Biorad, Hercules, CA) as previously described [21]. 
The specific growth rate and cell specific rates of nutrient uptake and product excretion 
were determined using the following equations: 
𝑑𝑋
𝑑𝑡
= 𝜇𝑋  (3-1) 
𝑑𝐶𝑖
𝑑𝑡
= −𝑘𝑖𝐶𝑖 + 𝑞𝑖𝑋  (3-2) 
where X represents viable cell density, µ represents specific growth rate, and t represents time.  
In the second equation, Ci represents concentration, qi represents cell specific production rate (or 
consumption rate if negative), and ki represents the first-order degradation rate of the i
th 
biochemical component in the extracellular medium.  Degradation rate for most metabolites was 
negligible, with the lone exception of glutamine.  The spontaneous rate of glutamine degradation, 
calculated in the absence of cells at incubation conditions, was found to be 0.087 day-1.  This rate 
of degradation was significant (relative to cell specific uptake), as has been reported previously 
in literature [22].  All specific rates were calculated using the method of Glacken et al. [23], 
where regression analysis was applied to the extracellular time course measurements. 
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Steady state labeling experiment 
Steady-state labeling was achieved in free intracellular metabolites by feeding labeled 
substrate for a minimum of 48 hours prior to sampling, which has been previously shown to be 
sufficient to achieve isotopic equilibrium in CHO cell cultures [24]. Because the metabolism of 
the culture was changing gradually over time, the measured labeling represents a quasi-steady 
state condition based on the assumption that the dynamics of isotope labeling occur more rapidly 
than the metabolic transients.  Some bias may be introduced into the MFA results to the extent 
that this assumption is not strictly satisfied; however, we expect that our key conclusions are 
robust to minor violations of this assumption. 
Multiple parallel 13C labeling experiments were performed to enable flux analysis of each 
growth phase (Table 3-1).  
 
Table 3-1.  Fed batch schedule for isotope labeling experiments.  Parallel 13C-labeling 
experiments were carried out to enable ﬂux analysis of each growth phase. The lightly shaded 
section indicates when the culture was exposed to 13C labeled substrates. The culture was 
regularly fed an optimized nutrient-rich complex on the days indicated by ‘‘Feed.’’ Fields 
labeled as ‘‘Quench’’ indicate the times when the culture was harvested for intracellular 
metabolite analysis. The darkly shaded section of the chart represents the post- experiment 
period. The culture had already been quenched and terminated prior to that time. 
 
Day 0 1 2 3 4 5 6 7 8 9 10 
Day 0-3 Seed   Quench        
Day 3-5 Seed   Feed  Quench      
Day 6-8 Seed   Feed   Feed  Quench   
Day 8-10 Seed   Feed   Feed  Feed  Quench 
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In the case of the Day 0-3 experiment, 72 hours were allowed to achieve isotopic steady state.  
Two separate tracer experiments were conducted in parallel for the Day 0-3 time interval.  In the 
first experiment, a cocktail of glucose tracers was administered, composed of 50% [1, 2-13C2] 
glucose, 30% [U-13C6] glucose, and 20% [1-
13C] glucose.  [U-13C6] glucose has been previously 
shown to be an effective tracer for estimating TCA cycle fluxes, while [1, 2-13C2] glucose and [1-
13C] glucose provide information on the branch ratio between glycolysis and oxPPP [25]. The 
tracer mixture was optimized using the approach of Möllney et al. [26].  In the second 
experiment, [U-15N2, U-
13C5] glutamine was used to achieve increased labeling of TCA cycle 
intermediates, since a large fraction of the glucose substrate was diverted to lactate during the 
initial Day 0-3 time interval. The labeling data from both experiments were simultaneously fitted 
to the same isotopomer model in order to estimate metabolic fluxes. The three other fed-batch 
phases of interest for this study (Day 3-5, Day 6-8, and Day 8-10) used 100% [U-13C] glucose as 
the labeled substrate. This tracer was chosen in order to maximize identifiability of TCA cycle 
and amphibolic mitochondrial pathway fluxes. In these latter experiments, labeling was allowed 
48 hours to equilibrate.  
 
Metabolite quenching and extraction 
Due to the fact that some intracellular metabolites are turned over on a seconds time 
scale, rapid quenching is necessary to capture an accurate snapshot of intracellular metabolism 
[27].  With this in mind, an ammonium bicarbonate (AMBIC) quench was performed [28].  
Here, AMBIC makes up 0.85% w/v of the aqueous portion of the quench solution, which is a 
60/40 mixture of methanol/AMBIC pre-cooled to -40°C. At each sample time point, an aliquot 
of culture medium containing approximately 10 million viable cells was drawn into a syringe and 
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rapidly ejected into the quench solution.  Following the quench, metabolite extraction was 
performed using the Folch method [29].   
 
Derivatization and gas chromatography mass spectrometry (GC-MS) analysis 
Derivatization for GC-MS was initiated by dissolving evaporated metabolite extracts in 
50 µL of methoxyamine reagent (MOX; Pierce, Rockford, IL).  Following 30 minutes of 
sonication at room temperature, the sample was incubated for 90 minutes at 40°C.  Then, 70µL 
of MTBSTFA + 1% TBDMCS (Pierce, Rockford, IL) in pyridine was added, and the solution 
was incubated for 30 minutes at 70°C.  Lastly, the samples were centrifuged at 14,000 RPM to 
remove any solid precipitates.   
Derivatized extracts were analyzed with a HP5-MS capillary column (30 m × 0.25 mm 
i.d. × 0.25 µm; Agilent J&W Scientific) installed in an Agilent 7890A gas chromatograph (GC).  
The injection volume was 1 µL and all samples were run in split mode (50:1) with an inlet 
temperature of 270°C.  Helium flowrate was set to 1 mL/min.  The GC oven temperature was 
held at 80°C for 5 minutes, ramped at 20°C/min to 140°C and held for 0 minutes, and ramped 
once more at 4°C/min to 280°C and held for 5 minutes.  Mass spectra were obtained using scan 
mode over the range of 100 to 500 m/z.  Raw ion chromatograms were integrated using a custom 
MATLAB program that applied consistent integration bounds and baseline correction to each 
fragment ion [30]. 
 
Isotopomer network model 
A reaction network was generated to accurately represent the central metabolism of CHO 
cells.  This network consisted of glycolysis, TCA cycle, pentose phosphate pathway, multiple 
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cataplerotic and anaplerotic reactions, and both catabolism and anabolism of amino acids.  ATP 
and NAD(P)H were not included in the stoichiometric balances, as they have been shown to 
produce inconsistent results in mammalian cell cultures [31].  In total, there were 71 reactions 
that made up this network with 23 extracellular metabolites and two macromolecular products, 
antibody and biomass.  Further details of the reaction network are provided in the Supplementary 
Materials. 
 
Biomass and antibody demands 
In order to develop an accurate biomass equation, the dry weight of the HP cell line was 
determined to be approximately 329 pg on average.  This was calculated after drying and 
weighing a known amount of cells in a plastic petri dish in a non-humidified 37oC incubator. The 
composition of the cell mass was based upon previous work available in literature for hybridoma 
cells [32].  The included contents of the dry cell mass for the biomass equation were protein, 
glycogen, lipids, and nucleotides.  Each macromolecule was stoichiometrically decomposed into 
its independent precursor building blocks.  Protein composition was based upon the relative 
amount of each amino acid.  Each glycogen monomer was assumed to be composed of one G6P.  
Lipids were broken down into cholesterol, phosphatidylcholine, phosphatidylethanolamine, 
phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerol, and 
sphingomyelin. Biosynthesis of nucleotides was also considered, based on the demands of both 
DNA and RNA.  The biosynthetic demands for recombinant antibody production were based 
solely upon its amino acid composition. For further information about both the antibody and 
biomass equations, refer to the Supplementary Materials. 
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Flux determination and statistical analysis 
Isotopic steady-state MFA was applied based on both the measured cell specific uptake 
and excretion rates and the measured intracellular isotopomer abundances [30].  This approach 
involved solving an inverse problem where metabolic fluxes were determined by least-squares 
regression of experimental measurements using the isotopomer network model.  Flux estimations 
were repeated a minimum of 100 times from a randomized initial guess to ensure the global 
solution was obtained.  A chi-square statistical test was used to assess goodness-of-fit and a 
sensitivity analysis was performed to determine 95% confidence intervals associated with the 
reported flux values [33]. 
 
Results and Discussion 
Stoichiometric analysis 
A stoichiometric analysis was performed upon four separate growth phases of a 10-day 
fed-batch culture (Table 3-2), accounting for all major incoming and outgoing carbon fluxes 
except carbon dioxide.   
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Table 3-2.  Key characteristics of each fed-batch phase.  Standard error of the mean is 
reported for gross speciﬁc growth rates (μgross) and speciﬁc death rates (kd). The difference 
between these two rates gives the net speciﬁc growth rate. 
 
Time 
(Day) 
Growth Rate (Day -1) Phase Key Characteristic(s) 
0-3 0.66±0.01 Early Exponential Peak growth rate and glycolytic flux 
3-5 0.52±0.04 Late Exponential Peak oxPPP flux 
6-8 0.17±0.02 Stationary Peak antibody production and TCA cycling 
8-10 -0.02±0.05 Decline Viability drops/oxPPP and TCA maintained 
 
Glucose and amino acids supplied essentially all of the incoming carbon flux to the culture, with 
pyruvate serving as an additional source during the initial growth phase. While glutamine was 
the most important amino acid during Early Exponential phase, other amino acids became 
important in later growth phases once glutamine had been depleted from the medium. During 
Early and Late Exponential phases, most of the carbon consumed was used for biomass 
production (Figure 3-1), with the balance largely converted to lactate (Figure 3-2). 
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Figure 3-1. Major nutrient uptake and product formation rates.  A: Key biosynthetic and 
nutrient uptake rates expressed on a carbon basis. Error bars indicate the standard error of the 
regressed rate parameters. B: Speciﬁc lactate and antibody ﬂuxes during each phase. 
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Figure 3-2. Stoichiometric analyses of measured nutrient uptake and product formation 
rates. Fractional contributions are expressed on a carbon basis and were calculated from direct 
measurements of extracellular medium composition over time, with the exception of carbon 
dioxide. The CO2 contribution was estimated from the difference between measured incoming 
and outgoing carbon ﬂuxes, as needed to complete the mass balance. The estimated CO2 
production rates were within the expected range based on experimentally determined rates of 
oxygen consumption and respiratory quotient obtained from independent bioreactor studies [33]. 
‘‘Other’’ indicates the sum of several amino acids that make minor contributions to overall 
carbon ﬂux. 
 
At later phases, biomass synthesis was diminished and antibody production became a 
major component of the biosynthetic demand. Furthermore, lactate metabolism switched from 
net production to net consumption as the culture entered Stationary phase.  The overall rate of 
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carbon consumption fell gradually at each fed batch stage (Figure 3-3), which can be largely 
attributed to the falling specific growth rate (Figure 3-1). 
 
 
Figure 3-3. Total incoming carbon ﬂux during each fed-batch phase. The contributions of all 
measured incoming carbon sources have been summed. Error bars indicate the propagated 
standard error. 
 
Nutrient consumption. When glutamine and glucose carbon fluxes are summed, they 
compose approximately 65% of the total incoming extracellular flux during Early Exponential 
phase. Glutaminolysis was substantially reduced following this phase, but glucose consumption 
remained relatively high throughout all growth phases and never dropped below 50% of its initial 
rate.  The rate of glutamine uptake during Early Exponential phase greatly exceeded the 
biosynthetic demand for biomass or antibody production.  The excess glutamine consumed was 
catabolized to provide energy, as has been observed before [34].  Experiments using [U-13C6] 
and [U-15N2] glutamine showed that glutamine was largely converted to alanine and lactate [20].  
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The total amino acid contribution to incoming carbon flux was considerable over the entire fed-
batch process (between 30% to 50% of total carbon), with the uptake of other amino acids 
increasing after glutamine was depleted. In particular, asparagine represented 5% of the 
incoming carbon flux during Early Exponential and 8% during Stationary phase. 
 
Product formation. Antibody production was at its minimum during Early Exponential 
phase (only 3% of output carbon flux), but production rate more than doubled during Stationary 
phase (34% of output carbon flux) (Figure 3-2).  Conversely, biomass production went from 
being the largest single flux (incoming or outgoing) at Early Exponential phase to being non-
existent during Decline.  In spite of this, we observed that antibody demand for incoming carbon 
flux was less than biomass demand in most phases, with the only exception being Decline phase 
when no biomass was generated. Following a similar pattern as biomass production, lactate 
production represented over 30% of the total outgoing carbon flux during Early Exponential 
phase.  It was substantially reduced during Late Exponential, and it reversed direction during 
Stationary phase.  The production of several amino acids such as glutamate, alanine, and 
aspartate was also observed, where glutamate excretion was associated with increased glutamine 
uptake and aspartate excretion was associated with increased asparagine uptake. 
 
Metabolic flux analysis 
To further investigate the intracellular pathway alterations associated with the various 
growth phases of this fed-batch process, 13C labeling experiments were performed to enable 
comprehensive metabolic flux analysis.  The MFA results for each growth phase are summarized 
in the flux maps shown in Figure 3-4.  
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Figure 3-4. Metabolic ﬂux maps for all growth phases. Reported ﬂuxes (mmol/106 cells day) 
are the median of the 95% conﬁdence interval, with associated standard errors shown. Arrow 
thickness is scaled proportional to the ﬂux value. Dotted lines indicate transfer of identical 
metabolites involved in separate pathways, and are not actual ﬂuxes included in the model. The 
ﬂux maps were generated using Cytoscape, a freely available software [35].  A: Early 
Exponential; B: Late Exponential; C: Stationary; and D: Decline. 
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In the following, we discuss the key features of each major pathway and how the functional state 
of the network varies over time.  Here, it is important to consider the total incoming carbon flux 
(Figure 3-3) in addition to the reported intracellular fluxes. 
 
Glycolysis. Growth was at its maximum during Early Exponential phase, yet most of the 
incoming carbon from glucose was converted to lactate and alanine.  Minimal flux was diverted 
into the oxidative pentose phosphate pathway (oxPPP), as over 90% of the incoming glucose was 
metabolized directly into glycolysis.  High glycolytic activity, and specifically lactate 
production, has been previously associated with increased growth of mammalian cells.  As stated 
in previous work [36], one hypothesis is that lactate production is an adaptation to increase the 
availability of biosynthetic precursors needed to generate biomass [37]–[39].  In contrast to Early 
Exponential phase, lactate production was substantially reduced following Early Exponential 
phase and even reversed itself during Stationary phase. Whereas lactate represented 30% of the 
total outgoing carbon flux during Early Exponential phase, it accounted for 6% of the incoming 
carbon flux during Stationary phase. However, glucose consumption and overall glycolytic flux 
decreased by roughly one-third following Early Exponential phase and remained relatively 
constant throughout Late Exponential, Stationary, and Decline phases.   
 
Pentose Phosphate Pathway. Although essentially non-existent during Early Exponential 
phase, oxPPP flux was substantial during all later growth phases.  Even during Decline phase, 
when total incoming carbon flux was reduced by 65%, glucose-6-phosphate dehydrogenase 
(G6PDH) flux was still larger than during Early Exponential phase.  Further verification of 
changing oxPPP activity was provided in a parallel [1, 2-13C2]glucose study where only M+2 
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lactate mass isotopomers were observed during Early Exponential phase but substantial M+1 
labeling was observed during Stationary phase [20].   
Minimal oxPPP activity during exponential growth has been reported in other CHO cell 
MFA studies [17].  This does however raise the important question of where the necessary 
NAPDH for growth and maintenance of cellular redox was derived during Early Exponential 
phase.  It has been estimated that 1-2 moles of NADPH are required per mole of acetyl-CoA 
incorporated into lipid [40]. ATP-citrate lyase (ACL) is the key enzyme responsible for 
decomposing citrate into acetyl-CoA for lipid generation. We estimated an ACL flux of 0.537 
µmol/106 cells/day during Early Exponential phase.  Since the G6PDH flux is only 25% of ACL 
flux during this period, another pathway must be primarily responsible for generating NAPDH 
for growth. This could be attributed to NADP-dependent isoforms of malic enzyme or isocitrate 
dehydrogenase (refer to Cataplerosis and Anaplerosis section). 
Flux into oxPPP, via G6PDH, reached its peak during Late Exponential and Stationary 
phases.  A portion of the NAPDH generated was likely used for maintenance of lipid 
membranes, and a parallel study found evidence of elevated palmitate turnover during Stationary 
phase [20].  Other studies have also observed significant G6PDH flux during the stationary phase 
of a fed-batch CHO cell culture [19], where nearly all of the incoming glucose was diverted to 
the oxPPP.  In our work, all of the incoming glucose was diverted to the oxPPP during both Late 
Exponential and Stationary phases, which also corresponded with peak antibody production.  In 
fact, G6PDH flux was greater than hexokinase (HK) during these periods, which implies that the 
oxPPP was operating in a cyclic mode with net conversion of F6P to G6P.   
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TCA Cycle. With a significant pyruvate flux routed into lactate during Early Exponential 
phase, little remained to be transported into mitochondria for oxidation.  A parallel study found 
that multiple TCA metabolites derived substantial carbon from glutamine and asparagine during 
this period, leading to nearly half of the lipogenic palmitate being derived from these two amino 
acids [20].  Asparagine’s contribution to the TCA cycle, via conversion to aspartate, remained 
high throughout all growth phases (unlike glutamine).  Of the three NADH-producing 
dehydrogenase reactions in the TCA cycle, one of the three (malate dehydrogenase) was running 
in reverse, meaning that NADH was being consumed rather than generated.  Therefore, in spite 
of substantial glutaminolysis, there was minimal NADH production associated with TCA cycle 
activity during Early Exponential phase.  This result along with the high rate of lactate 
production indicates that minimal oxidative phosphorylation was taking place.  Conversely, 
incoming flux to the TCA cycle from glycolysis peaked during Late Exponential and Stationary 
phases.  Even in the Decline phase, absolute fluxes associated with TCA cycling were 
maintained at higher levels than during Early Exponential phase.  This was even more 
impressive considering that the total incoming carbon flux was reduced by almost two-thirds 
(Figure 3-3). 
One common trend across all phases was the correlation between oxPPP and TCA cycle 
fluxes.  When oxPPP flux was minimal, TCA flux was also minimal and vice versa.  One 
potential explanation for this trend could involve the role of NADPH in neutralizing 
mitochondrial-derived reactive oxygen species (ROS) through maintenance of reduced 
glutathione levels [19], [39].  ROS accumulation can lead to cell toxicity due to oxidation of 
cellular lipids, protein, and DNA [41], [42].  Therefore, increasing oxPPP flux could be an 
adaptive response to enhance antioxidant capacity in the presence of high mitochondrial activity.   
81 
 
Antibody Production. One significant result of our study was that increased antibody 
production (Figure 3-5) was closely associated with oxidative TCA cycle metabolism and oxPPP 
flux.   
  
82 
 
Figure 3-5. Intracellular redox ratios. A. Ratio of NADPH to NADP+ as a function of time. B. 
Ratio of reduced (GSH) to oxidized (GSSG) glutathione. C. Ratio of NADH to NAD+. 
 
To our knowledge, this is the first MFA study to examine this relationship between 
oxidative metabolism and antibody production.  Through comparison of four separate phases of 
the fed-batch process, we observed a positive correlation between antibody production and 
83 
isocitrate dehydrogenase (IDH) flux, which is representative of oxidative TCA cycle activity 
(Figure 3-6).   
 
 
Figure 3-6. Correlation between oxidative TCA cycle ﬂux and antibody production. Each 
point represents a separate phase of the fed-batch process, with TCA cycle and antibody ﬂuxes 
normalized to the corresponding total incoming carbon ﬂux reported in Figure 3-3. Oxidative 
TCA cycle ﬂux was calculated by summing the rates of all three CO2-producing TCA cycle 
reactions: PDH, IDH, and ADH. Error bars indicate standard errors. 
 
IDH is an indicator of TCA activity because it represents the glycolytic carbon (via 
pyruvate) to progress through the TCA cycle, and not the carbon lost for cytosolic lipid synthesis 
via ATP-citrate lyase, as was very much the case during Early Exponential phase.  On the other 
hand, peak growth corresponded with peak glycolytic flux but minimal oxidative metabolism.  
Based upon our results, metabolic engineering to increase flux to TCA cycle during production 
phase has potential to enhance rates of specific antibody formation. Additional steps may be 
required to simultaneously divert more flux into oxPPP in order to maintain redox homeostasis 
and avoid ROS accumulation. 
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Cataplerosis and Anaplerosis. During Early Exponential phase, substantial flux was 
diverted into mitochondrial cataplerotic and anaplerotic pathways.  Conversely, there was a large 
reduction in these fluxes during subsequent growth phases.  During Early Exponential phase, 
ATP-citrate lyase (ACL) accounted for more than 75% of the flux leaving citrate.  In another 
prior MFA study, ACL was determined to be a negligible flux during exponential phase [17] 
However, our work used a serum-free medium without substantial fatty acid content, so cell 
growth required de novo lipid synthesis that in turn relied on ACL to supply AcCoA building 
blocks. 
Substantial malic enzyme (ME) flux was also observed during Early Exponential phase, 
and although there was a large uncertainty associated with this value, closer examination of the 
95% confidence interval reveals that even the lower bound of 1.3 μmol/ 106 cells/day is high in 
comparison to most other fluxes estimated during this growth phase.  Like ME, 
phosphoenolpyruvate carboxykinase (PEPCK) could also be contributing cataplerotic flux from 
the TCA cycle to glycolysis; however, we cannot distinguish between these two pathways based 
upon our isotopomer measurements and have therefore lumped them together. ME in 
combination with anaplerotic pyruvate carboxylase (PC) flux effectively create a separate cycle 
overlapping with the TCA cycle.  PC was found to have substantial flux during Early 
Exponential phase, returning much of the pyruvate generated by ME to the TCA cycle.  PC can 
often be ignored in quiescent cells, but can carry a substantial flux in growing cultures [43].  Our 
analysis determined that the PC flux was at least as significant as pyruvate dehydrogenase (PDH) 
for channeling pyruvate into the TCA cycle during the initial growth period.  The activity of PC 
was independently confirmed in a separate experiment using [1-13C]pyruvate, the results of 
which can be found in the Supplementary Materials.   
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The high cycling through ME and PC could potentially explain the minimal oxPPP 
activity during Early Exponential phase, as NADP-dependent ME isoforms could have supplied 
the majority of cellular NADPH demands and thereby made additional oxPPP flux unnecessary.  
However, all three ME isoforms are known to exist in CHO cells [44] and our MFA results 
cannot distinguish between them.  Activity of the NADP-dependent ME1 isoform was confirmed 
for this study (results not shown), but results were inconclusive regarding the activity of ME2 
and ME3.  Therefore, it is difficult to state which isoform, if any, was dominant in catalyzing 
conversion of malate to pyruvate.  Lastly, in addition to ME, isocitrate dehydrogenase (IDH) is 
also capable of producing NADPH.  In general, the presence of multiple isoforms of both IDH 
and ME make it difficult to determine their contribution to the overall NAD(P)H production rates 
based on our MFA results. 
 
Conclusions 
As CHO cells transition from peak growth to peak antibody production, cell metabolism 
can change considerably over the course of a typical industrial fed-batch bioprocess.  We aimed 
to quantify these global metabolic alterations using 13C labeling experiments and metabolic flux 
analysis.  We found that high glycolytic flux positively correlated with peak growth, and specific 
lactate production was highest when specific growth rate was also highest.  On the contrary, a 
highly oxidative state of metabolism was associated with increased antibody production, a result 
that, to our knowledge, has not been previously reported in MFA studies.   During peak specific 
antibody production (i.e., during Stationary phase), TCA cycling was at its maximum and lactate 
production was at its minimum.  In fact, lactate was not produced at all, but instead was 
consumed.  Furthermore, high oxidative pentose phosphate pathway flux was found to positively 
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correlate with high TCA cycling and antibody production.  This suggests that promoting 
oxidative TCA cycle metabolism and pentose phosphate pathway flux may provide a possible 
strategy to increase specific antibody production and reduce lactate accumulation during the 
production phase of industrial fed-batch CHO cell cultures.  
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Nomenclature 
3PG: 3-Phosphoglycerate 
AcCoA: Acetyl-CoA 
ACL: ATP Citrate Lyase 
aKG: α-Ketoglutarate 
Ala: Alanine 
AMBIC: Ammonium Bicarbonate 
Arg: Arginine 
Asp: Aspartate 
ATP: Adenosine-5'-Triphosphate 
CHO: Chinese Hamster Ovary 
Cit: Citrate 
DHAP: Dihydroxyacetone Phosphate 
E4P: Erythrose-4-Phosphate 
F6P: Fructose 6-Phosphate 
Fum: Fumarate 
G6P: Glucose-6-Phosphate 
G6PDH: Glucose-6-Phosphate Dehydrogenase 
GAP: Glyceraldehyde-3-Phosphate 
GC-MS: Gas Chromatography-Mass Spectrometry 
Glc: Glucose 
Gln: Glutamine 
Glu: Glutamate 
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HK: Hexokinase 
HPLC: High Performance Liquid Chromatography 
Lac: Lactate 
mAb: Monoclonal Antibody 
Mal: Malate 
ME: Malic Enzyme 
MFA: Metabolic Flux Analysis 
MOX: Methoxyamine 
MTBSTFA: N-Methyl-N-(t-butyldimethylsilyl) trifluoroacetamide 
NADH: Nicotinamide Adenine Dinucleotide 
NADPH: Nicotinamide Adenine Dinucleotide phosphate 
OAA: Oxaloacetate 
PC: Pyruvate Carboxylase 
PEP: Phosphoenolpyruvate 
oxPPP: Oxidative Pentose Phosphate Pathway 
Pro: Proline 
Pyr.e: Extracellular Pyruvate 
Pyr: Pyruvate 
R5P: Ribose-5-Phosphate 
ROS: Reactive Oxygen species 
RPM: Revolutions Per Minute 
Ru5P: Ribulose-5-Phosphate 
S7P: Sedoheptulose-7-Phosphate 
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Suc: Succinate 
TBDMCS: Tert-Butyldimethylchlorosilane 
TCA Cycle: Tri-Carboxylic Acid Cycle 
VCD: Viable Cell Density 
X5P: Xylulose-5-Phosphate 
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Appendix 
Metabolic flux analysis assumptions 
The reaction network for all four models generated, including the reported fluxes and their 
associated 95% confidence intervals, can be found in a separate Excel spreadsheet.  The 
following assumptions were made in regards to generating the models: 
 
1. Metabolism is at a steady state during each of the four phases of the fed-batch.  The 
reported fluxes therefore represent averages over the corresponding time interval. 
2. Intracellular isotopic labeling has reached quasi-steady state at the time of sample 
quenching and removal.   
3. Succinate and fumarate are symmetric molecules that don’t retain any particular 
orientation when metabolized by TCA cycle enzymes. 
4. The labeling patterns of mitochondrial and cytosolic metabolites are assumed to be in 
isotopic equilibrium. 
5. Change in individual cell size (mass) over the fed-batch lifetime is assumed to be 
negligible. 
6. All major carbon sources of the complex industrial media have been included. 
7. The amount of carbon required for antibody glycosylation is assumed to be negligible. 
8. Exchange fluxes are employed to account for dilution by unlabeled carbon sources in the 
medium (e.g., lactate, alanine, aspartate).   
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Confirmation of pyruvate carboxylase (PC) activity 
Pyruvate carboxylase (PC) was found to have substantial flux during Early Exponential 
phase, returning much of the pyruvate generated by malic enzyme to the TCA cycle.  The 
activity of PC was also independently confirmed in a separate experiment using [1-13C] pyruvate.  
Here, the first carbon of pyruvate was labeled and spiked into the media either at Day 0 or Day 6, 
and intracellular metabolites were analyzed on either Day 2 or Day 7.  Metabolite labeling was 
assessed by GC-MS to determine the path of entry of pyruvate into the TCA cycle.  If PC was 
active, a portion of the labeled carbon from [1-13C] pyruvate would have appeared in 
oxaloacetate (OAA) and malate (Figure 3-A-1).  Alternatively, if pyruvate predominantly 
entered the TCA cycle through pyruvate dehydrogenase (PDH), there would be no 13C labeling 
in malate.  This is because the first carbon of pyruvate is lost to CO2 in the PDH reaction (Figure 
3-A-1).  As shown in Table 3-A-1, the results indicate that PC was active during Early 
Exponential phase but was inactive during Stationary phase. 
92 
 
Figure 3-A-1.  [1-13C] pyruvate experiment to determine path of entry to TCA cycle.  A. 
Expected labeling if pyruvate carboxylase (PC) is the dominant route of entry to TCA cycle.  B. 
Expected labeling if PDH is the dominant route of entry to the TCA cycle. 
 
Table 3-A-1.  Measured malate labeling in [1-13C] pyruvate experiments performed during 
Day 0-2 and Day 6-7 of the fed-batch culture. 
 
 Day 2 Day 7 
Malate M1 Labeling 0.12 ±0.01 Not Detectable 
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Additional stoichiometric analysis 
 
Figure 3-A-2. Stoichiometric analysis of measured nutrient uptake and product formation 
rates.  Carbon dioxide generation not measured. “Other” indicates the sum of several amino 
acids that make minor contributions to carbon flux. 
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Intracellular metabolites examined for labeling 
Table 3-A-2. Ion fragments quantified via GCMS for the purpose of MFA.  The number listed 
in the ion fragment column corresponds to the mass of fragment. 
 
Ion Fragment Node ID Labeled Atom Unlabeled Atom 
Lac 233 Lac 2 3 C8 H25 O2 Si2 
Lac 261 Lac 1 2 3 C8 H25 O2 Si2 
Ala 232 Ala 2 3 C8 H26 O N Si2 
Ala 260 Ala 1 2 3 C8 H26 O2 N Si2 
Ser 288 Ser 2 3 C12 H34 N O Si2 
Ser 302 Ser 1 2 C12 H32 N O2 Si2 
Ser 362 Ser 2 3 C14 H40 N O2 Si3 
Ser 390 Ser 1 2 3 C14 H40 N O3 Si3 
akG 346 aKG 1 2 3 4 5 C9 H28 O5 N Si2 
Mal 419 Mal 1 2 3 4 C14 H39 O5 Si3 
Asp 302 Asp 1 2 C12 H32 N O2 Si2 
Asp 376 Asp 1 2 C14 H38 N O3 Si3 
Asp 390 Asp 2 3 4 C14 H40 N O3 Si3 
Asp 418 Asp 1 2 3 4 C14 H40 O4 N Si3 
Glu 330 Glu 2 3 4 5 C14 H36 N O2 Si2 
Glu 358 Glu 1 2 3 4 5 C12 H36 N O3 Si2 
Glu 432 Glu 1 2 3 4 5 C14 H42 O4 N Si3 
Asn 417 Asn 1 2 3 4 C14 H41 N2 O3 Si3 
Gln 431 Gln 1 2 3 4 5 C14 H43 N2 O3 Si3 
Suc 289 Suc 1 2 3 4 C8 H25 O4 Si2 
Cit 459 Cit 1 2 3 4 5 6 C14 H39 O6 Si3 
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Carbon atom mapping of reaction network 
Table 3-A-3. Reaction network carbon transitions. 
 
Glycolysis 
PGI G6P (abcdef) <-> F6P (abcdef) 
PFK F6P (abcdef) -> DHAP (cba) + GAP (def) 
TPI DHAP (abc) <-> GAP (abc) 
GADPH GAP (abc) <-> 3PG (abc) 
Eno 3PG (abc) <-> PEP (abc) 
PK PEP (abc) -> Pyr (abc) 
HK Glc (abcdef) -> G6P (abcdef) 
LDH Reversible Lac (abc) <-> Pyr (abc) 
Pentose Phosphate Pathway 
6PGDH G6P (abcdef) -> Ru5P (bcdef) + CO2 (a) 
R5PE Ru5P (abcde) <-> X5P (abcde) 
R5PI Ru5P (abcde) <-> R5P (abcde) 
TK1 X5P (abcde) + R5P (fghij) <-> GAP (hij) + S7P (fgabcde) 
TK2 S7P (abcdefg) + GAP (hij) <-> E4P (defg) + F6P (abchij) 
TK3 X5P (abcde) + E4P (fghi) <-> GAP (cde) + F6P (abfghi) 
TCA Cycle 
PDH Pyr (abc) -> AcCoA (bc) + CO2 (a) 
CS OAA (abcd) + AcCoA (ef) -> Cit (dcbfea) 
IDH Cit (abcdef) -> aKG (abcde) + CO2 (f) 
ADH aKG (abcde) -> Suc (bcde) + CO2 (a) 
SDH Suc (abcd) <-> Fum (abcd) 
Fum Fum (abcd) <-> Mal (abcd) 
MDH Mal (abcd) <-> OAA (abcd) 
Transport 
Glc IN Glc.e (abcdef) -> Glc (abcdef) 
Glc Labeled Glc.l (abcdef) -> Glc.e (abcdef) 
Glc Unlabeled Glc.u (abcdef) -> Glc.e (abcdef) 
Lys IN Lys.e (abcdef) -> Lys (abcdef) 
Thr IN Thr.e (abcd) -> Thr (abcd) 
Phe IN Phe.e (abcdefghi) -> Phe (abcdefghi) 
Tyr IN Tyr.e (abcdefghi) -> Tyr (abcdefghi) 
Val IN Val.e (abcde) -> Val (abcde) 
Leu IN Leu.e (abcdef) -> Leu (abcdef) 
Ile IN Ile.e (abcdef) -> Ile (abcdef) 
Trp IN Trp.e (abcdefghijk) -> Trp (abcdefghijk) 
His IN His.e (abcdef) -> His (abcdef) 
Met IN Met.e (abcde) -> Met (abcde) 
aKG Produced via Glu DummyaKG <-> aKGSink 
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Anaplerotic reactions 
ME Mal (abcd) -> Pyr (abc) + CO2 (d) 
PYC Pyr (abc) + CO2 (d) -> OAA (abcd) 
ACL Cit (abcdef) -> AcCoA.c (ed) + Mal (fcba) 
Amino Acid Metabolism 
ASNS Asp (abcd) <-> Asn (abcd) 
CBXase + Mutase ProCoA (abc) + CO2 (d) -> Suc (abcd) 
GLS Gln (abcde) <-> Glu (abcde) 
GluPro Mtbl Glu (abcde) <-> Pro (abcde) 
GS + SHT CO2 (a) + MEETHF (b) -> Gly (ab) 
Met Mtbl Met (abcde) + Ser (fgh) -> Methyl (e) + Cys (fgh) + Suc (abcd) 
PheTyr Mtbl Phe (abcdefghi) -> Tyr (abcdefghi) 
SHT Ser (abc) <-> Gly (ab) + MEETHF (c) 
Thr Mtbl Thr (abcd) -> Pyr (abc) + CO2 (d) 
Trp Mtbl Trp (abcdefghijk) -> CO2 (d) + CO2 (e) + Ala (abc) + aKetoadi (fghijk) 
Trp2 Mtbl aKetoadi (abcdef) -> CO2 (a) + CO2 (f) + AcCoA (bc) + AcCoA (de) 
*GDH aKG (abcde) + DummyaKG <-> Glu (abcde) 
*ALT Ala (abc) + aKG (defgh) + DummyaKG <-> Pyr (abc) + Glu (defgh) 
*Ile Mtbl 
Ile (abcdef) + aKG (ghijk) + DummyaKG -> AcCoA (de) + CO2 (a) + ProCoA 
(bcf) + Glu (ghijk) 
*Leu Mtbl 
Leu (abcdef) + aKG (ghijk) + CO2 (l) + DummyaKG -> CO2 (a) + AcCoA (bc) 
+ AcCoA (ld) + AcCoA (ef) + Glu (ghijk) 
*Tyr Mtbl 
Tyr (abcdefghi) + aKG (jklmn) + DummyaKG -> CO2 (a) + Mal (defg) + 
AcCoA (bc) + AcCoA (hi) + Glu (jklmn) 
*AST OAA (abcd) + Glu (efghi) <-> Asp (abcd) + aKG (efghi) + DummyaKG 
*Arg Mtbl 
Arg (abcdef) + aKG (ghijk) + DummyaKG -> Glu (abcde) + Urea (f) + Glu 
(ghijk) 
*PST 3PG (abc) + Glu (defgh) -> Ser (abc) + aKG (defgh) + DummyaKG 
*Cys Mtbl Cys (abc) + aKG (defgh) + DummyaKG -> Pyr (abc) + Glu (defgh) 
Lumped Antibody Equation 
Antibody 
610.6*Ala + 213.6*Arg + 249.8*Asn + 323.1*Asp + 212.9*Cys + 333.2*Gln + 
331*Glu + 859.2*Gly + 110.9*His + 141.8*Ile + 568*Leu + 411.8*Lys + 
95.84*Met + 234.3*Phe + 597.6*Pro + 1118*Ser + 709.4*Thr + 105.3*Trp + 
221.3*Tyr + 758*Val -> Antibody 
Lumped Biomass Equation 
Biomass 329pg 
0.1552*Asp + 0.127*Glu + 0.0948*Asn + 0.1451*Ser + 0.047*His + 
0.2165*Gly + 0.124*Arg + 0.1974*Ala + 0.0599*Tyr + 0.0477*Cys + 
0.1369*Val + 0.0454*Met + 0.0721*Phe + 0.1066*Ile + 0.1856*Leu + 
0.1875*Lys + 0.1059*Gln + 0.0145*Trp + 0.103*Pro + 0.127*Thr + 
0.0839*MEETHF + 0.0766*CO2 + 0.8143*AcCoA.c + 0.04*DHAP + 
0.0766*R5P + 0.0949*G6P -> Biomass 
Transport Exchange 
DummySer Ser.e (abc) <-> Ser (abc) + dummySer 
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Ser IN dummySer -> Sink 
DummyAla Ala (abc) <-> Ala.e (abc) + dummyAla 
Ala OUT dummyAla -> Sink 
DummyArg Arg.e (abcdef) <-> Arg (abcdef) + dummyArg 
Arg IN dummyArg -> Sink 
DummyAsp Asp (abcd) <-> Asp.e (abcd) + dummyAsp 
Asp OUT dummyAsp -> Sink 
DummyCys Cys.e (abc) <-> Cys (abc) + dummyCys 
Cys IN dummyCys -> Sink 
DummyGlu Glu (abcde) <-> Glu.e (abcde) + dummyGlu 
Glu OUT dummyGlu -> Sink 
DummyGln Gln.e (abcde) <-> Gln (abcde) + dummyGln 
Gln IN dummyGln -> Sink 
DummyGly Gly.e (ab) <-> Gly (ab) + dummyGly 
Gly IN dummyGly -> Sink 
DummyPro Pro.e (abcde) <-> Pro (abcde) + dummyPro 
Pro IN dummyPro -> Sink 
DummyAsn Asn.e (abcd) <-> Asn (abcd) + dummyAsn 
Asn IN dummyAsn -> Sink 
DummyLac Lac.e (abc) <-> Lac (abc) + dummyLac 
Lac IN dummyLac -> Sink 
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95% confidence intervals associated with individual fluxes 
Table 3-A-4. Net fluxes associated with Figure 3-4a.  Early exponential phase of culture. 
 
Pathway Enzyme Rxn 
LB 
95% 
CI 
UB 
95% CI 
Value 
Glycolysis PGI  G6P <-> F6P 1.412 1.687 1.549 
  PFK F6P -> DHAP + GAP 1.542 1.675 1.609 
  TPI  DHAP <-> GAP 1.516 1.624 1.570 
  GAPDH GAP <-> 3PG 3.096 3.307 3.202 
  ENO 3PG <-> PEP 2.929 3.131 3.030 
  PK PEP -> Pyr 2.929 3.131 3.030 
  HK Glc -> G6P 1.641 1.772 1.707 
  LDH   Lac <-> Pyr -2.925 -2.767 -2.846 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.254 0.127 
  R5PE  Ru5P <-> X5P -0.035 0.146 0.056 
  R5PI  Ru5P <-> R5P 0.033 0.118 0.076 
  TK1  X5P + R5P <-> GAP + S7P -0.018 0.073 0.028 
  TK2  S7P + GAP <-> E4P + F6P -0.018 0.073 0.028 
  TK3  X5P + E4P <-> GAP + F6P -0.018 0.073 0.028 
TCA PDH Pyr -> AcCoA + CO2 0.584 0.713 0.649 
  SDH  Suc <-> Fum 0.779 0.992 0.886 
  FUM Fum <-> Mal 0.779 0.992 0.886 
  MDH  Mal <-> OAA -2.774 -0.037 -1.405 
  CS OAA + AcCoA -> Cit 0.608 0.713 0.660 
  ADH aKG -> Suc + CO2 0.778 0.990 0.884 
  IDH Cit -> aKG + CO2 0.075 0.183 0.129 
Transport Ser IN Ser.e -> Ser 0.121 0.157 0.139 
  Ala OUT Ala -> Ala.e 0.360 0.409 0.385 
  Arg IN Arg.e -> Arg 0.084 0.235 0.159 
  Asp OUT Asp -> Asp.e 0.119 0.154 0.137 
  Glu OUT Glu -> Glu.e 0.234 0.273 0.254 
  Gln IN Gln.e -> Gln 1.110 1.140 1.125 
  Pro IN Pro.e -> Pro 0.077 0.082 0.080 
  Asn IN Asn.e -> Asn 0.246 0.322 0.284 
  Gly OUT Gly -> Gly.e 2.767 2.925 2.846 
  Cys OUT Cys -> Cys.e 0.001 0.037 0.019 
  Pyr IN Pyr.e -> Pyr 0.019 0.055 0.037 
  Lys IN Lys.e -> Lys 0.127 0.136 0.131 
  Thr IN Thr.e -> Thr 0.093 0.100 0.096 
  Phe IN Phe.e -> Phe 0.050 0.065 0.057 
  Tyr IN Tyr.e -> Tyr 0.032 0.079 0.055 
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  Val IN Val.e -> Val 0.101 0.108 0.104 
  Leu IN Leu.e -> Leu 0.128 0.137 0.133 
  Ile IN Ile.e -> Ile 0.070 0.076 0.073 
  Trp IN Trp.e -> Trp 0.012 0.025 0.018 
  His IN His.e -> His 0.032 0.038 0.035 
  Met IN Met.e -> Met 0.031 0.054 0.043 
Anaplerosis ME Mal -> Pyr + CO2 1.321 4.252 2.787 
  PYC Pyr + CO2 -> OAA 0.578 3.466 2.022 
  ACL Cit -> AcCoA.c + Mal 0.520 0.557 0.538 
Amino GLS  Gln <-> Glu 1.033 1.064 1.049 
Acid ASNS  Asp <-> Asn -0.254 -0.178 -0.216 
Metabolism SHT  Ser <-> Gly + MEETHF 0.107 0.126 0.117 
  CYST  Ser <-> Cys 0.044 0.090 0.067 
  GS + SHT CO2 + MEETHF -> Gly 0.052 0.071 0.061 
  Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.023 0.012 
  PheTyr Mtbl Phe -> Tyr 0.000 0.012 0.006 
  Thr Mtbl Thr -> Pyr + CO2 0.000 0.004 0.002 
  Histidase His -> FormTHF + Glu 0.000 0.014 0.007 
  
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.000 0.010 0.005 
  Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.000 0.013 0.006 
  Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.000 0.012 0.006 
  GDH  aKG  <-> Glu -0.230 0.051 -0.089 
  ALT  Ala + aKG  <-> Pyr + Glu -0.549 -0.496 -0.523 
  Ile Mtbl 
Ile + aKG  -> AcCoA + CO2 + 
ProCoA + Glu 
0.000 0.011 0.006 
  Leu Mtbl 
Leu + aKG + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu 
0.000 0.006 0.003 
  Tyr Mtbl 
Tyr + aKG  -> CO2 + Mal + 
AcCoA + AcCoA + Glu 
0.000 0.038 0.019 
  Val Mtbl 
Val + aKG  -> Glu + CO2 + CO2 + 
ProCoA 
0.000 0.007 0.003 
  Lys Mtbl 
Lys + aKG + aKG  -> Glu + Glu + 
aKetoadi 
0.000 0.008 0.004 
  AST  OAA + Glu <-> Asp + aKG  -0.013 0.072 0.029 
  Arg Mtbl Arg + aKG  -> Glu + Urea + Glu 0.000 0.145 0.072 
  PST 3PG + Glu -> Ser + aKG  0.140 0.196 0.168 
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Biomass 
Production 
 Biomass 329pg 
0.1552*Asp + 0.127*Glu + 
0.0948*Asn + 0.1451*Ser + 
0.047*His + 0.2165*Gly + 
0.124*Arg + 0.1974*Ala + 
0.0599*Tyr + 0.0477*Cys + 
0.1369*Val + 0.0454*Met + 
0.0721*Phe + 0.1066*Ile + 
0.1856*Leu + 0.1875*Lys + 
0.1059*Gln + 0.0145*Trp + 
0.103*Pro + 0.127*Thr + 
0.0839*MEETHF + 0.0766*CO2 + 
0.8143*AcCoA.c + 0.04*DHAP + 
0.0766*R5P + 0.0949*G6P -> 
Biomass 
0.638 0.684 0.661 
Antibody 
Production 
Antibody 
610.6*Ala + 213.6*Arg + 
249.8*Asn + 323.1*Asp + 
212.9*Cys + 333.2*Gln + 331*Glu 
+ 859.2*Gly + 110.9*His + 
141.8*Ile + 568*Leu + 411.8*Lys + 
95.84*Met + 234.3*Phe + 
597.6*Pro + 1118*Ser + 709.4*Thr 
+ 105.3*Trp + 221.3*Tyr + 
758*Val -> Antibody 
1.72E-
05 
2.14E-
05 
1.93E-
05 
 
Table 3-A-5. Exchange fluxes associated with Figure 3-4a.  Early exponential phase of 
culture.  Only fluxes which could be determined are shown. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis LDH  Lac <-> Pyr 0.0E+00 4.4E+00 2.2E+00 
Amino GLS  Gln <-> Glu 1.0E-07 9.1E-01 4.5E-01 
Acid SHT  Ser <-> Gly + MEETHF 5.7E-01 3.1E+00 1.8E+00 
Metabolism ALT  Ala + aKG + DummyaKG <-> Pyr + Glu 0.0E+00 3.0E+00 1.5E+00 
  AST  OAA + Glu <-> Asp + aKG + DummyaKG 1.7E+01 5.8E+01 3.8E+01 
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Table 3-A-6. Net fluxes associated with Figure 3-4b.  Late exponential phase of culture. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI G6P <-> F6P -2.586 0.652 -0.967 
  PFK F6P -> DHAP + GAP 0.137 1.003 0.570 
  TPI DHAP <-> GAP 0.116 0.900 0.508 
  GAPDH GAP <-> 3PG 1.526 2.273 1.899 
  ENO 3PG <-> PEP 1.482 2.768 2.125 
  PK PEP -> Pyr 1.482 2.768 2.125 
  LDH Pyr <-> Lac 0.511 0.675 0.593 
  HK Glc -> G6P 1.006 1.537 1.272 
PPP 6PGDH G6P -> Ru5P + CO2 0.443 4.151 2.297 
  R5PE  Ru5P <-> X5P -0.027 2.475 1.224 
  R5PI  Ru5P <-> R5P 0.163 1.316 0.739 
  TK1 X5P + R5P <-> GAP + S7P -0.014 1.237 0.612 
  TK2 S7P + GAP <-> E4P + F6P -0.014 1.237 0.612 
  TK3 X5P + E4P <-> GAP + F6P -0.014 1.237 0.612 
TCA PDH Pyr -> AcCoA + CO2 1.308 2.181 1.744 
  CS OAA + AcCoA -> Cit 1.544 2.546 2.045 
  IDH Cit -> aKG + CO2 1.090 2.234 1.662 
  ADH aKG -> Suc + CO2 1.414 2.624 2.019 
  SDH Suc <-> Fum 1.490 2.728 2.109 
  FUM Fum <-> Mal 1.490 2.728 2.109 
  MDH Mal <-> OAA 1.212 2.557 1.884 
Transport Trp IN Trp.e -> Trp 0.012 0.040 0.026 
  Lys IN Lys.e -> Lys 0.103 0.145 0.124 
  His IN His.e -> His 0.026 0.055 0.041 
  Met IN Met.e -> Met 0.032 0.060 0.046 
  Thr IN Thr.e -> Thr 0.076 0.107 0.092 
  Phe IN Phe.e -> Phe 0.041 0.065 0.053 
  Tyr IN Tyr.e -> Tyr 0.011 0.036 0.023 
  Val IN Val.e -> Val 0.098 0.138 0.118 
  Leu IN Leu.e -> Leu 0.161 0.167 0.164 
  Ile IN Ile.e -> Ile 0.064 0.095 0.079 
  Ser IN Ser.e -> Ser 0.123 0.159 0.141 
  Ala OUT Ala -> Ala.e 0.048 0.090 0.069 
  Arg IN Arg.e -> Arg 0.155 0.254 0.205 
  Glu IN Glu .e -> Glu 0.000 0.017 0.008 
  Gln IN Gln.e-> Gln 0.157 0.249 0.203 
  Gly IN Gly.e-> Gly 0.029 0.062 0.046 
  Pro IN Pro.e-> Pro 0.125 0.202 0.164 
  Asn IN Asn.e-> Asn 0.271 0.376 0.324 
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  Asp OUT Asp -> Asp.e 0.016 0.044 0.030 
  Cys IN Cys.e -> Cys 0.051 0.080 0.065 
Anaplerosis ACL Cit -> AcCoA.c + Mal 0.300 0.445 0.372 
  ME Mal -> Pyr + CO2 0.510 1.014 0.762 
  PC Pyr + CO2 -> OAA 0.003 0.368 0.185 
Amino ASNS Asp <-> Asn -0.326 -0.219 -0.272 
Acid 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.023 0.094 0.057 
Metabolism GLS  Gln <-> Glu 0.096 0.191 0.144 
  GluPro Mtbl  Glu <-> Pro -0.137 -0.057 -0.097 
  GS + SHT CO2 + MEETHF -> Gly 0.010 0.032 0.022 
  Histidase His -> FormTHF + Glu 0.001 0.031 0.016 
  Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.008 0.038 0.023 
  PheTyr Mtbl Phe -> Tyr 0.002 0.029 0.013 
  SHT  Ser <-> Gly + MEETHF 0.041 0.076 0.060 
  Thr Mtbl Thr -> Pyr + CO2 0.000 0.032 0.010 
  Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.001 0.030 0.016 
  Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.010 0.072 0.041 
  ALT Ala + aKG  <-> Pyr + Glu -0.195 -0.129 -0.163 
  Arg Mtbl Arg + aKG  -> Glu + Urea + Glu 0.090 0.192 0.141 
  AST  OAA + Glu <-> Asp + aKG  -0.222 -0.103 -0.161 
  Cys Mtbl Cys + aKG  -> Pyr + Glu 0.037 0.082 0.059 
  GDH aKG  <-> Glu -0.949 -0.406 -0.654 
  Ile Mtbl 
Ile + aKG  -> AcCoA + CO2 + 
ProCoA + Glu 
0.008 0.045 0.026 
  Leu Mtbl 
Leu + aKG + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu 
0.044 0.082 0.061 
  Lys Mtbl 
Lys + aKG + aKG  -> Glu + Glu + 
aKetoadi 
0.000 0.054 0.025 
  PST 3PG + Glu -> Ser + aKG  0.018 0.078 0.044 
  Tyr Mtbl 
Tyr + aKG  -> CO2 + Mal + AcCoA + 
AcCoA + Glu 
0.000 0.025 0.000 
  Val Mtbl 
Val + aKG  -> Glu + CO2 + CO2 + 
ProCoA 
0.007 0.056 0.031 
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Biomass 
Production 
 Biomass 329pg 
0.1552*Asp + 0.127*Glu + 
0.0948*Asn + 0.1451*Ser + 0.047*His 
+ 0.2165*Gly + 0.124*Arg + 
0.1974*Ala + 0.0599*Tyr + 
0.0477*Cys + 0.1369*Val + 
0.0454*Met + 0.0721*Phe + 
0.1066*Ile + 0.1856*Leu + 
0.1875*Lys + 0.1059*Gln + 
0.0145*Trp + 0.103*Pro + 0.127*Thr 
+ 0.0839*MEETHF + 0.0766*CO2 + 
0.8143*AcCoA.c + 0.04*DHAP + 
0.0766*R5P + 0.0949*G6P -> 
Biomass 
0.368 0.547 0.457 
Antibody 
Production 
Antibody 
610.6*Ala + 213.6*Arg + 249.8*Asn + 
323.1*Asp + 212.9*Cys + 333.2*Gln 
+ 331*Glu + 859.2*Gly + 110.9*His + 
141.8*Ile + 568*Leu + 411.8*Lys + 
95.84*Met + 234.3*Phe + 597.6*Pro + 
1118*Ser + 709.4*Thr + 105.3*Trp + 
221.3*Tyr + 758*Val -> Antibody 
2.97E-
05 
3.62E-
05 
3.29E-
05 
 
Table 3-A-7. Exchange fluxes associated with Figure 3-4b.  Late exponential phase of culture.  
Only fluxes which could be determined are shown. 
 
Pathway Enzyme Rxn 
LB 95% 
CI 
UB 95% 
CI 
Value 
TCA SDH  Suc <-> Fum 7.4E-01 9.9E+00 5.3E+00 
 FUM Fum <-> Mal 8.4E-01 1.0E+07 5.0E+06 
  MDH  Mal <-> OAA 6.2E+01 1.0E+07 5.0E+06 
Amino SHT  Ser <-> Gly + MEETHF 0.088 0.4804 2.8E-01 
Acid ALT  Ala + aKG  <-> Pyr + Glu 0 4.3856 2.2E+00 
Metabolism AST  OAA + Glu <-> Asp + aKG 1.9013 4.6045 3.3E+00 
 
  
104 
Table 3-A-8. Net fluxes associated with Figure 3-4c.  Stationary phase of culture. 
 
Pathways Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI G6P <-> F6P -1.482 1.316 -0.083 
  PFK F6P -> DHAP + GAP 0.364 1.311 0.838 
  TPI DHAP <-> GAP 0.420 1.305 0.863 
  GAPDH GAP <-> 3PG 1.629 2.610 2.119 
  ENO 3PG <-> PEP 1.590 2.573 2.081 
  PK PEP -> Pyr 1.590 2.573 2.081 
  HK Glc -> G6P 1.276 1.344 1.310 
  LDH Lac <-> Pyr 0.194 0.313 0.253 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 2.785 1.392 
  R5PE  Ru5P <-> X5P -0.009 1.861 0.926 
  R5PI  Ru5P <-> R5P 0.008 0.821 0.415 
  TK1  X5P + R5P <-> GAP + S7P -0.005 0.931 0.463 
  TK2  S7P + GAP <-> E4P + F6P -0.005 0.931 0.463 
  TK3  X5P + E4P <-> GAP + F6P -0.005 0.931 0.463 
TCA PDH Pyr -> AcCoA + CO2 1.763 2.670 2.216 
  CS OAA + AcCoA -> Cit 1.887 2.961 2.424 
  IDH Cit -> aKG + CO2 1.754 2.806 2.280 
  ADH aKG -> Suc + CO2 1.704 2.817 2.260 
  SDH  Suc <-> Fum 1.725 2.411 2.068 
  Fum  Fum <-> Mal 1.725 2.411 2.068 
  MDH  Mal <-> OAA 1.794 2.847 2.321 
Transport Lys IN Lys.e -> Lys 0.047 0.058 0.053 
  Thr IN Thr.e -> Thr 0.054 0.062 0.058 
  Phe IN Phe.e -> Phe 0.024 0.034 0.029 
  Tyr IN Tyr.e -> Tyr 0.021 0.031 0.026 
  Val IN Val.e -> Val 0.058 0.066 0.062 
  Leu IN Leu.e -> Leu 0.076 0.114 0.095 
  Ile IN Ile.e -> Ile 0.034 0.050 0.042 
  Trp IN Trp.e -> Trp 0.008 0.017 0.012 
  His IN His.e -> His 0.012 0.015 0.014 
  Met IN Met.e -> Met 0.012 0.020 0.016 
  Ser IN Ser.e -> Ser 0.074 0.090 0.082 
  Ala OUT Ala -> Ala.e 0.118 0.152 0.135 
  Arg IN Arg.e -> Arg 0.028 0.044 0.036 
  Asp OUT Asp -> Asp.e 0.074 0.097 0.085 
  Cys IN Cys.e -> Cys 0.040 0.051 0.045 
  Glu OUT Glu  -> Glu.e 0.013 0.032 0.022 
  Gln IN Gln.e-> .Gln 0.041 0.084 0.062 
  Gly IN Gly.e-> Gly 0.009 0.029 0.019 
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  Pro IN Pro.e-> Pro 0.029 0.060 0.044 
  Asn IN Asn.e-> Asn 0.238 0.293 0.266 
Anaplerosis ME Mal -> Pyr + CO2 0.051 0.231 0.141 
  PYC Pyr + CO2 -> OAA 0.000 0.116 0.058 
  ACL Cit -> AcCoA.c + Mal 0.110 0.163 0.136 
Amino ASNS  Asp <-> Asn -0.265 -0.209 -0.237 
Acid 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.009 0.025 0.017 
Metabolism GLS  Gln <-> Glu 0.006 0.050 0.028 
  GluPro Mtbl  Glu <-> Pro -0.012 0.020 0.004 
  GS + SHT CO2 + MEETHF -> Gly 0.018 0.029 0.024 
  Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.008 0.004 
  PheTyr Mtbl Phe -> Tyr 0.000 0.010 0.005 
  SHT  Ser <-> Gly + MEETHF 0.031 0.044 0.038 
  Thr Mtbl Thr -> Pyr + CO2 0.000 0.003 0.001 
  Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.000 0.009 0.005 
  Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.000 0.009 0.005 
  GDH aKG  <-> Glu 0.002 0.140 0.071 
  ALT  Ala + aKG <-> Pyr + Glu -0.214 -0.176 -0.195 
  Ile Mtbl 
Ile + aKG  -> AcCoA + CO2 + 
ProCoA + Glu 
0.009 0.025 0.017 
  Leu Mtbl 
Leu + aKG + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu 
0.016 0.054 0.035 
  Tyr Mtbl 
Tyr + aKG  -> CO2 + Mal + AcCoA 
+ AcCoA + Glu 
0.002 0.018 0.010 
  AST  OAA + Glu <-> Asp + aKG  -0.140 -0.079 -0.109 
  Arg Mtbl Arg + aKG  -> Glu + Urea + Glu 0.000 0.013 0.006 
  PST 3PG + Glu -> Ser + aKG  0.027 0.053 0.040 
  Cys Mtbl Cys + aKG  -> Pyr + Glu 0.022 0.037 0.029 
Biomass 
Production 
Biomass 329pg 
0.1552*Asp + 0.127*Glu + 
0.0948*Asn + 0.1451*Ser + 
0.047*His + 0.2165*Gly + 
0.124*Arg + 0.1974*Ala + 
0.0599*Tyr + 0.0477*Cys + 
0.1369*Val + 0.0454*Met + 
0.0721*Phe + 0.1066*Ile + 
0.1856*Leu + 0.1875*Lys + 
0.1059*Gln + 0.0145*Trp + 
0.103*Pro + 0.127*Thr + 
0.0839*MEETHF + 0.0766*CO2 + 
0.8143*AcCoA.c + 0.04*DHAP + 
0.0766*R5P + 0.0949*G6P -> 
Biomass 
0.135 0.200 0.167 
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Antibody 
Production 
Antibody 
610.6*Ala + 213.6*Arg + 249.8*Asn 
+ 323.1*Asp + 212.9*Cys + 
333.2*Gln + 331*Glu + 859.2*Gly + 
110.9*His + 141.8*Ile + 568*Leu + 
411.8*Lys + 95.84*Met + 234.3*Phe 
+ 597.6*Pro + 1118*Ser + 
709.4*Thr + 105.3*Trp + 221.3*Tyr 
+ 758*Val -> Antibody 
4.700E-
05 
5.580E-
05 
5.140E-
05 
 
Table 3-A-9. Exchange fluxes associated with Figure 3-4c.  Stationary phase of culture.  Only 
fluxes which could be determined are shown. 
 
Pathway Enzyme Rxn 
LB 95% 
CI 
UB 95% 
CI 
Value 
Amino ASNS  Asp <-> Asn 0.0E+00 7.2E+00 3.6E+00 
Acid GLS  Gln <-> Glu 1.0E-07 3.7E+05 1.9E+05 
Metabolism GluPro Mtbl  Glu <-> Pro 1.0E-07 1.4E-01 7.2E-02 
 SHT  Ser <-> Gly + MEETHF 2.7E-02 1.4E-01 8.5E-02 
 ALT Ala + aKG  <-> Pyr + Glu 1.0E-07 8.2E+06 4.1E+06 
 AST  OAA + Glu <-> Asp + aKG 3.2E+00 7.3E+00 5.2E+00 
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Table 3-A-10. Net fluxes associated with Figure 3-4d.  Decline phase of culture. 
 
Pathways Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P -0.263 1.144 0.441 
  PFK F6P -> DHAP + GAP 0.479 1.144 0.811 
  TPI  DHAP <-> GAP 0.479 1.144 0.811 
  GAPDH  GAP <-> 3PG 1.215 2.288 1.752 
  Eno  3PG <-> PEP 1.201 2.276 1.738 
  PK PEP -> Pyr 1.201 2.276 1.738 
  LDH  Pyr <-> Lac 0.282 0.487 0.384 
  HK Glc -> G6P 0.730 1.146 0.938 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 1.302 0.651 
  R5PE  Ru5P <-> X5P 0.000 0.868 0.434 
  R5PI  Ru5P <-> R5P 0.000 0.434 0.217 
  TK1  X5P + R5P <-> GAP + S7P 0.000 0.434 0.217 
  TK2  S7P + GAP <-> E4P + F6P 0.000 0.434 0.217 
  TK3  X5P + E4P <-> GAP + F6P 0.000 0.434 0.217 
TCA PDH Pyr -> AcCoA + CO2 0.748 1.879 1.314 
  CS OAA + AcCoA -> Cit 0.809 1.998 1.404 
  IDH Cit -> aKG + CO2 0.809 1.998 1.403 
  ADH aKG -> Suc + CO2 0.787 1.993 1.390 
  SDH  Suc <-> Fum 0.796 2.006 1.401 
  Fum  Fum <-> Mal 0.796 2.006 1.401 
  MDH  Mal <-> OAA 0.713 1.892 1.302 
Transport Trp IN Trp.e -> Trp 0.003 0.005 0.004 
  Lys IN Lys.e -> Lys 0.012 0.038 0.025 
  His IN His.e -> His 0.003 0.012 0.008 
  Met IN Met.e -> Met 0.003 0.011 0.007 
  Thr IN Thr.e -> Thr 0.021 0.042 0.031 
  Phe IN Phe.e -> Phe 0.007 0.022 0.015 
  Tyr IN Tyr.e -> Tyr 0.011 0.023 0.017 
  Val IN Val.e -> Val 0.020 0.048 0.034 
  Leu IN Leu.e -> Leu 0.016 0.065 0.041 
  Ile IN Ile.e -> Ile 0.004 0.028 0.016 
  Ser IN Ser.e ->  Ser 0.019 0.049 0.034 
  Ala OUT Ala -> Ala.e 0.116 0.199 0.157 
  Arg IN Arg.e -> Arg 0.006 0.023 0.015 
  Glu OUT Glu -> Glu.e 0.015 0.042 0.028 
  Gln IN Gln.e -> Gln 0.001 0.067 0.034 
  Gly IN Gly.e ->  Gly 0.000 0.035 0.017 
  Pro IN Pro.e -> Pro 0.000 0.049 0.025 
  Asn IN Asn.e -> Asn 0.169 0.277 0.223 
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  Asp OUT Asp -> Asp.e 0.069 0.131 0.100 
  Cys IN Cys.e -> Cys 0.026 0.040 0.033 
Anaplerosis ACL Cit -> AcCoA.c + Mal 0.000 0.001 0.001 
  ME Mal -> Pyr + CO2 0.027 0.201 0.114 
  PC Pyr + CO2 -> OAA 0.000 0.053 0.027 
Amino ASNS  Asp <-> Asn -0.268 -0.160 -0.214 
Acid 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.000 0.035 0.017 
Metabolism GLS  Gln <-> Glu -0.011 0.055 0.022 
  GluPro Mtbl  Glu <-> Pro -0.028 0.024 -0.002 
  GS + SHT CO2 + MEETHF -> Gly 0.000 0.018 0.009 
  Histidase His -> FormTHF + Glu 0.000 0.008 0.004 
  Met Mtbl 
Met + Ser -> Methyl + Cys + 
Suc 
0.000 0.008 0.004 
  PheTyr Mtbl Phe -> Tyr 0.000 0.014 0.007 
  SHT  Ser <-> Gly + MEETHF 0.000 0.018 0.009 
  Thr Mtbl Thr -> Pyr + CO2 0.000 0.018 0.009 
  GDH  aKG  <-> Glu -0.093 0.140 0.023 
  ALT  Ala + aKG  <-> Pyr + Glu -0.221 -0.137 -0.179 
  Ile Mtbl 
Ile + aKG  -> AcCoA + CO2 + 
ProCoA + Glu 
0.000 0.023 0.012 
  Leu Mtbl 
Leu + aKG + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + 
Glu 
0.000 0.045 0.023 
  Tyr Mtbl 
Tyr + aKG  -> CO2 + Mal + 
AcCoA + AcCoA + Glu 
0.004 0.025 0.015 
  Val Mtbl 
Val + aKG  -> Glu + CO2 + 
CO2 + ProCoA 
0.000 0.022 0.011 
  Lys Mtbl 
Lys + aKG + aKG  -> Glu + Glu 
+ aKetoadi 
0.000 0.024 0.012 
  AST net OAA + Glu <-> Asp + aKG -0.163 -0.038 -0.101 
  Arg Mtbl 
Arg + aKG  -> Glu + Urea + 
Glu 
0.000 0.016 0.008 
  PST 3PG + Glu -> Ser + aKG  0.002 0.037 0.020 
  Cys Mtbl Cys + aKG  -> Pyr + Glu 0.018 0.037 0.027 
  Lys Mtbl2 
aKetoadi -> CO2 + CO2 + 
AcCoA + AcCoA 
0.000 0.024 0.012 
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Biomass 
Production 
 Biomass 329pg 
0.1552*Asp + 0.127*Glu + 
0.0948*Asn + 0.1451*Ser + 
0.047*His + 0.2165*Gly + 
0.124*Arg + 0.1974*Ala + 
0.0599*Tyr + 0.0477*Cys + 
0.1369*Val + 0.0454*Met + 
0.0721*Phe + 0.1066*Ile + 
0.1856*Leu + 0.1875*Lys + 
0.1059*Gln + 0.0145*Trp + 
0.103*Pro + 0.127*Thr + 
0.0839*MEETHF + 
0.0766*CO2 + 
0.8143*AcCoA.c + 0.04*DHAP 
+ 0.0766*R5P + 0.0949*G6P -> 
Biomass 
0.000 0.001 0.001 
Antibody 
Production 
Antibody 
610.6*Ala + 213.6*Arg + 
249.8*Asn + 323.1*Asp + 
212.9*Cys + 333.2*Gln + 
331*Glu + 859.2*Gly + 
110.9*His + 141.8*Ile + 
568*Leu + 411.8*Lys + 
95.84*Met + 234.3*Phe + 
597.6*Pro + 1118*Ser + 
709.4*Thr + 105.3*Trp + 
221.3*Tyr + 758*Val -> 
Antibody 
2.7E-05 4.4E-05 3.6E-05 
 
Table 3-A-11. Exchange fluxes associated with Figure 3-4d.  Decline phase of culture.  Only 
fluxes which could be determined are shown. 
 
Pathway Enzyme Rxn LB 95% CI UB 95% CI Value 
Amino ASNS  Asp <-> Asn 0.0E+00 1.6E+00 8.2E-01 
Acid SHT  Ser <-> Gly + MEETHF 2.9E-03 1.9E-01 9.6E-02 
Metabolism GDH  aKG  <-> Glu 1.0E-07 3.7E+00 1.9E+00 
 ALT  Ala + aKG  <-> Pyr + Glu 0.0E+00 3.7E+00 1.9E+00 
 AST  OAA + Glu <-> Asp + aKG  4.0E-02 4.7E-01 2.5E-01 
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IV: THE IMPACT OF ANTI-APOPTOTIC GENE BCL-2∆ EXPRESSION ON CHO 
CENTRAL METABOLISM 
 
Metabolic Engineering. 25 (2014) 92-102. 
Abstract 
Anti-apoptosis engineering is an established technique to prolong the viability of 
mammalian cell cultures used for industrial production of recombinant proteins.  However, the 
effect of overexpressing anti-apoptotic proteins on central carbon metabolism has not been 
systematically studied.  We transfected CHO-S cells to express Bcl-2∆, an engineered anti-
apoptotic gene, and selected clones that differed in their Bcl-2∆ expression and caspase activity.  
13C metabolic flux analysis (MFA) was then applied to elucidate the metabolic alterations 
induced by Bcl-2∆.  Expression of Bcl-2Δ reduced lactate accumulation by redirecting the fate of 
intracellular pyruvate toward mitochondrial oxidation during the lactate-producing phase, and it 
significantly increased lactate re-uptake during the lactate-consuming phase.  This flux 
redistribution was associated with significant increases in biomass yield, peak viable cell density 
(VCD), and integrated VCD.  Additionally, Bcl-2∆ expression was associated with significant 
increases in isocitrate dehydrogenase and NADH oxidase activities, both rate-controlling 
mitochondrial enzymes.  This is the first comprehensive 13C MFA study to demonstrate that 
expression of anti-apoptotic genes has a significant impact on intracellular metabolic fluxes, 
especially in controlling the fate of pyruvate carbon, which has important biotechnology 
applications for reducing lactate accumulation and enhancing productivity in mammalian cell 
cultures. 
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Introduction 
Chinese hamster ovary (CHO) cells have emerged as the most widely used mammalian 
cell line for recombinant protein production, accounting for nearly 70% of all biotherapeutics 
produced in what is approaching a $100 billion global marketplace [1,2].  This biologics market 
is growing at a rate 60% faster than the overall pharmaceutical market [2].  Some of the major 
advantages of CHO cells are their ability to secrete correctly folded and post-translationally 
modified recombinant proteins and their proven history of regulatory approval [3].  Increasing 
demand for biopharmaceutical products requires CHO hosts and culture systems to become more 
productive, as the costs associated with producing sufficient antibody to conduct clinical trials 
can account for a substantial portion of the total drug development cost [4,5].  Failure of the 
scientific community to develop rational approaches for increasing product titer and yield will 
result in high development costs that stymie both drug discovery and drug affordability.   
 Manipulating apoptotic pathways is one route that has been used to improve recombinant 
protein titers.  After all, volumetric protein productivity is directly proportional to the integrated 
viable cell density (IVCD) of the culture [6], and apoptosis accounts for up to 80% of cell death 
in a typical bioreactor run [7].  Overexpressing anti-apoptotic genes, such as Bcl-2 or Bcl-xL, to 
limit the progression of apoptosis was shown to be effective at maintaining cell viability in 
response to a variety of adverse bioreactor conditions [8–12].  More recently, CHO cells 
overexpressing anti-apoptotic genes E1B-19K, Aven, and an XIAP mutant (XIAP∆) provided a 
60% increase in IVCD and 80% increase in final product titer [13].  Interestingly, the apoptosis-
resistant clones were also found to accumulate less lactate during early-exponential phase and to 
be capable of faster lactate consumption during late-exponential and stationary phases [13].  This 
is a highly desirable trait for industrial bioprocesses, as a shift to lactate consumption during 
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production phase was found to be a prominent feature of high-titer runs identified through data-
mining of 243 production trains at Genentech’s Vacaville manufacturing facility [14].  Although 
it is known that proteins involved in apoptosis regulation may impinge on processes that control 
mitochondrial energy metabolism [15], the effects of these proteins on intracellular metabolic 
pathways have not been directly studied. 
 Several alternative approaches have been applied to directly engineer pathways involved 
in lactate production and energy metabolism, which have been summarized in a recent review 
[16]. These studies rely on quantitative analysis of cellular metabolic phenotypes to determine 
the impact of these genetic manipulations on carbon fluxes.  For example, stoichiometric 
analysis involves the application of mass balances to determine the specific rates and relative 
ratios of extracellular metabolite transport [17]. This can be useful for assessing nutrient uptake 
and product excretion by cell cultures.  13C metabolic flux analysis (MFA), on the other hand, 
leverages this stoichiometric information and combines it with 13C labeling measurements to 
calculate intracellular metabolic fluxes.  13C MFA has been previously used to map fluxes in 
both exponential [18,19] and stationary phase [18–20] CHO cultures.  However, its application 
to quantify metabolic alterations in apoptosis-resistant cell lines has not been explored. 
 In this study, we performed 13C labeling experiments and MFA on a commercially 
available CHO-S cell line and two apoptosis-resistant clones that were obtained by transfecting 
the parent CHO-S line with the engineered anti-apoptotic protein Bcl-2Δ.  The two clones 
significantly differed in their level of Bcl-2∆ expression and caspase 3/7 activation.  We 
observed significant rewiring of pyruvate metabolism in both Bcl-2Δ clones, with more pyruvate 
carbon directed toward mitochondrial oxidation rather than lactate production during the initial 
phase of growth.  This shift in pyruvate metabolism correlated directly with the level of Bcl-2∆ 
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expression observed in each clone.  It was also associated with an increase in carbon allocation 
to biomass relative to lactate in the Bcl-2Δ clones.  Eventually, all three cultures shifted from 
lactate production to consumption, but the apoptosis-resistant clone with the highest Bcl-2∆ 
expression consumed lactate at an elevated rate compared to the untransfected control.  Both 
Bcl-2Δ clones also exhibited increased activity of mitochondrial enzymes involved in the TCA 
cycle and oxidative phosphorylation, which may be partially responsible for the observed 
changes in flux.  To our knowledge, this is the first 13C MFA study to quantify the metabolic 
impacts of anti-apoptosis engineering, enabling a closer examination of the regulatory 
connections between metabolic and apoptotic pathways. 
 
Materials and Methods 
Clone generation 
A parent CHO-S cell line (Life Technologies, Carlsbad, CA) was transfected with 
plasmid DNA containing a G418 antibiotic resistance marker to constitutively express Bcl-2Δ.  
A human CMV promoter was used to achieve high expression of Bcl-2Δ.  Plasmid construction 
was previously described [21]. Following G418 selection, approximately 200 clonal populations 
were generated, and two clones were chosen for further study based upon caspase-3/7 activity.  
The highest Bcl-2Δ expressing clone (with the lowest caspase-3/7 activity) was designated as the 
“High-Expressing” (HE) clone, while another clone with moderate caspase activity and less Bcl-
2Δ expression was designated as the “Low-Expressing” (LE) clone.  The untransfected CHO-S 
parent was designated as the “Control” line.   
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Cell culture 
Batch cultures were grown in 125 mL shake flasks at a working volume of 50 mL, using 
an orbital shaker (145 RPM, 0.45 RCF) inside a humidified incubator maintained at 37°C and 
10% CO2.  Cultures were inoculated at 3 x 10
5 cells/mL and supplied glucose-free CD-CHO 
media (Life Technologies, Carlsbad, CA) supplemented with 50 mM glucose and 4 mM 
glutamine.  All growth experiments were carried out for 10 days following inoculation with five 
separate replicates (N=5).   
 
Caspase 3/7 activity assay 
The Apo-ONE homogeneous caspase-3/7 assay (Promega, Madison, WI) was used to 
assess caspase-3/7 activity.  Caspase activity was measured at days 5 and 8 of culture.  Cell 
samples were exposed to rhodamine and lysis buffer for 2 hours inside a 37°C humidified 
incubator, shaken at 0.08 RCF (155 RPM) on a microplate orbital shaker.  Measurements were 
promptly recorded using a fluorescence plate reader. 
 
Determination of extracellular exchange rates 
 Culture samples were collected 2-3 times daily for measurement of specific growth rate 
and extracellular exchange rates.  Viable cell density (VCD) was immediately determined using 
a trypan blue exclusion method with a Cedex XS automated counter (Roche, Basel, Switzerland).  
The remainder of the sample was promptly frozen.  Glucose and lactate concentrations were 
determined in culture supernatants using a YSI 2300 biochemical analyzer (YSI, Yellow Springs, 
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OH).  Amino acid concentrations were determined using an Agilent 1200 series high 
performance liquid chromatograph (HPLC).  To accurately quantify amino acid concentrations 
using ultraviolet (UV) absorbance detection, pre-injection derivatization with 
orthophthaldildehyde (OPA) was used, as described previously [22].   
 The net specific growth rate (µnet), specific death rate (kd), and gross growth rate (µg) 
were determined by regressing the viable cell density (X) and dead cell density (Xd) 
measurements using the following equations: 
𝑑𝑋
𝑑𝑡
= µ𝑛𝑒𝑡𝑋 (4-1) 
𝑑𝑋𝑑
𝑑𝑡
= 𝑘𝑑𝑋 (4-2) 
µ𝑛𝑒𝑡 = µ𝑔 − 𝑘𝑑 (4-3) 
The specific production rate of extracellular metabolites was determined by regressing the 
concentration measurements using the following equation: 
𝑑𝐶𝑖
𝑑𝑡
= 𝑞𝑖𝑋−𝑘𝑖𝐶𝑖 (4-4) 
Here, Ci represents the concentration of the ith measured metabolite, qi represents its specific 
production rate (negative if consumed), and ki is its first-order degradation constant.  The only 
component with a non-negligible chemical degradation rate was glutamine, and its half-life was 
found to be ~8 days.  Regression analysis was performed using the ETA software package [23]. 
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Determination of integrated viable cell density 
IVCD was determined by trapezoidal integration of the entire measured growth curve, 
using the following formula: 
𝐼𝑉𝐶𝐷 = ∑ [(𝑡𝑖+1 − 𝑡𝑖) (
𝑋𝑖+1+𝑋𝑖
2
)]𝑛𝑖=0   (4-5) 
where X is viable cell density, t is time, and n is the total number of VCD measurements.   
 
Isotope labeling experiments 
To initiate isotope labeling experiments, cells were centrifuged, washed, and resuspended 
in CD-CHO media supplemented with a mixture of 50% [1,2-13C2]glucose and 50% [U-
13C6]glucose at a total glucose concentration of 50 mM.  A minimum of 2.7 days were allowed 
prior to sampling, as we have previously found that isotopic steady state is achieved in CHO 
cells after ~2 days of glucose labeling under similar culture conditions (data not shown).  Cell 
culture samples containing approximately 10 million cells were removed and rapidly cold-
quenched using a solution of 60% methanol and 40% aqueous ammonium bicarbonate (AMBIC, 
0.85% w/v) pre-cooled to -40°C [24].  Cell pellets were extracted using a biphasic 
chloroform:methanol:water (8:4:3) solution immediately following removal of the quenching 
solution [25]. Polar metabolites were recovered in the methanol/water phase. 
 
Gas chromatography mass spectrometry (GCMS) analysis 
Evaporated polar samples were derivatized as described previously [19] and injected into 
an Agilent 7890 gas chromatograph equipped with a HP5-MS column (30m x 0.25mm i.d. x 
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0.25µm; Agilent J&W Scientific).  Injection volume was varied between 0.2-2µL, and purge 
times between 30-60 seconds were used to obtain acceptable signal-to-noise ratios for each 
fragment ion.  The GC outlet was fixed at 270°C, and helium flow rate was 1 mL/min.  The GC 
oven was initially set at 80°C and held for 5 minutes, ramped at 20°C/min to 140°C, ramped at 
4°C/min to 280°C, and held for 5 minutes.  Scan mode allowed all mass spectra between 100-
500 m/z to be recorded, and raw ion chromatograms were integrated using a custom MATLAB 
program which applied consistent integration bounds and baseline corrections to each fragment 
ion [26].   
 
Reaction network 
A reaction network was generated that included all major pathways of central carbon 
metabolism: glycolysis, pentose phosphate pathway (PPP), TCA cycle, anaplerotic/cataplerotic 
reactions, amino acid catabolic/anabolic reactions, and a lumped growth reaction.  We used the 
cell composition values from Sheikh et al. [27] and determined cell dry weight to be 398, 361, 
and 343 pg/cell for the control, LE, and HE clone, respectively.  This allowed the metabolite 
yield coefficients included in the lumped growth reaction to be identified [19].  Carbon atom 
transitions and subcellular compartmentation were specified for all reactions.  ATP and 
NAD(P)H balances were not included in the reaction network [28]. In total, there were 116 
reactions (including reversible reactions) in the network, 21 extracellular metabolites, and one 
macromolecular product (biomass). Refer to the supplementary material for a detailed 
description of the reaction network and modeling assumptions. 
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13C metabolic flux analysis (MFA) 
The INCA analysis platform was used to generate mass balances and isotopomer 
balances required to simulate 13C labeling within CHO central carbon metabolism [29] 
(accessible at http://mfa.vueinnovations.com/mfa). INCA applies an elementary metabolite unit 
(EMU) decomposition of the reaction network to efficiently simulate the effects of varying 
fluxes on the labeling of measurable metabolites [26,30].  We assumed that both metabolic and 
isotopic quasi-steady-state was obtained during the isotope labeling experiments. Metabolic 
fluxes were estimated by regression of experimentally determined mass isotopomer distributions 
(MIDs) and extracellular exchange rates using a Levenberg-Marquardt optimization algorithm.  
Flux estimation was repeated a minimum of 100 times from random initial values to ensure a 
global minimum was obtained.  All results were subjected to a chi-square statistical test to assess 
goodness-of-fit, and accurate 95% confidence intervals were computed for all flux parameters by 
evaluating the sensitivity of the sum-of-squared residuals to parameter variations [31].  To 
effectively visualize the reaction network, flux maps were generated using Cytoscape [32] 
(accessible at http://www.cytoscape.org). 
 
Enzyme activity assays 
An isocitrate dehydrogenase (IDH) assay kit (Abcam, Cambridge, MA) was used to 
measure NAD+ dependent IDH activity of whole CHO cells according to the manufacturer’s 
instructions.  Standards and samples were colorimetrically assayed on clear 96-well plates using 
a Genios plate reader (TECAN, Durham, NC) at 450 nm.  A chemiluminescence assay was used 
to measure Complex I (NADH oxidase) activity in whole CHO cells harvested in PBS.  
Suspended cells (5-6×105 cells per well) were placed on white 96-well plates in a solution 
123 
containing PBS and 20 µM lucigenin.  Luminescence was monitored for 5 min using a 
VICTOR3 plate reader (Perkin-Elmer, Waltham, MA) to establish a baseline reading.  Following 
stimulation with 45 µM NADH, luminescence was monitored for an additional 60 min.   
 
Western blot 
 Whole cell protein lysates were collected in RIPA buffer.  Following quantification of 
total protein concentration, 26 µg of total protein was loaded into a 4-20% Tris-HCl gel (Bio-
Rad, Hercules, CA).  Following electrophoresis and transfer, the membrane was blocked for 100 
min with 5% non-fat milk.  Next, the membrane was incubated with a Bcl-2 primary antibody 
that bound to both endogenous Bcl-2 and Bcl-2Δ (Santa Cruz Biotechnology, Santa Cruz, CA).  
Tubulin was used as a loading control.  Incubation with primary antibody was performed at 
1:900 (rabbit Bcl-2) and 1:6000 (mouse Tubulin) concentration in 5% non-fat milk for 60 min at 
room temperature.  Incubation with a HRP-labeled secondary antibody (Perkin-Elmer, Waltham, 
MA) followed, and was performed at 1:1800 (anti-rabbit) and 1:3000 (anti-mouse) concentration 
in 5% non-fat milk for 60 min at room temperature.  To visualize the bands through 
chemiluminescence, Western Lightning Plus ECL (Perkin Elmer, Waltham, MA) was used.  
Image quantification of the blots was performed using ImageJ [33]. 
 
Subcellular localization of Bcl-2 and Bcl-2Δ 
 Mitochondria-associated endoplasmic reticulum membrane (MAM) samples were 
prepared as described previously [34].  Following homogenization of the cultures grown on 15-
cm dishes, the nuclear/whole cell (P1), crude mitochondrial, and microsomal fractions (P3) were 
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prepared by differential centrifugation.  Supernatants were collected as the cytosolic fraction.  
The crude mitochondrial fraction in isolation buffer (250 mM mannitol, 5 mM HEPES, 0.5 mM 
EGTA, pH 7.4) was subjected to Percoll gradient centrifugation for separation of the MAM from 
mitochondria.  Once all fractions were collected, samples were boiled in 2X sample buffer and 
analyzed by SDS-PAGE and western blotting. 
 
Statistical analysis 
One-way ANOVA was used to compare the Control, LE, and HE cell lines.  If 
significance was found (α=0.05), we applied a Tukey-Kramer test to identify significant 
differences in mean values.  If significance was not found at α=0.05, we proceeded to test at 
α=0.1, as noted in the figures. 
 
Results 
Clone selection 
Two Bcl-2Δ expressing clones were selected that exhibited varying levels of apoptotic 
resistance based on a screen for caspase-3/7 activity (Figure 4-1a).   
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Figure 4-1. The relationship of caspase 3/7 activity and Bcl-2Δ expression.  A. Caspase 
activity at day 5 of culture.  Standard deviation is reported.  * Indicates statistically significant 
difference compared to the control (p=0.05).  + Indicates statistically significant difference 
between Low Expressing and High Expressing clones (p=0.05). B. Western blot for Bcl-2Δ at 
day 5 of culture.  The primary antibody bound to both endogenous Bcl-2 and engineered Bcl-2Δ.  
Bcl-2Δ expression was substantially greater than Bcl-2, explaining why only one band was 
visible.  For further confirmation of Bcl-2/Bcl-2Δ expression level, refer to Supplemental Figure 
4-A-1. 
 
Both clones exhibited significantly reduced caspase-3/7 activity compared to the untransfected 
control line at day 5 of culture.  Western blot analysis revealed that Bcl-2Δ expression was 
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significantly increased in the high-expressing (HE) clone, roughly double that of the low-
expressing (LE) clone (Figure 4-1b).  This result corroborated the result of Figure 4-1a, as the 
HE clone had roughly half the caspase-3/7 activity of the LE clone at the same time point.  
Increased expression of the endogenous Bcl-2 protein was observed in the LE clone, but the 
expression level was substantially less than that of Bcl-2Δ (Figure 4-A-1).  The localization of 
Bcl-2 was consistent with previously published data [35], and no differences in the subcellular 
distribution of Bcl-2 and Bcl-2Δ were observed (Figure 4-A-2).  To ensure that the relative 
caspase activity of the clones did not change in a time-dependent manner, we repeated the 
measurement after approximately 8 days of culture.  At this time, we found even more 
substantially reduced caspase-3/7 activity in both Bcl-2Δ expressing clones in comparison to the 
control (Figure 4-A-3).  
 
Stoichiometric analysis 
To investigate the metabolic consequences of Bcl-2Δ expression, we assessed cell growth 
rate (Figure 4-A-4) and extracellular exchange rates during two separate culture phases by 
expressing all rates on a C-mol basis (Figure 4-2).   
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Figure 4-2.  Major extracellular carbon fluxes.  Carbon flux is determined by multiplying the 
flux (specific uptake rate, production rate) by the number of carbons in the molecule.  Standard 
deviation is reported.  * Indicates statistically significant difference compared to the control 
(p=0.05).  + Indicates statistically significant difference between Low Expressing and High 
Expressing clones (p=0.05). A. Fluxes during the lactate-producing phase.  The biomass carbon 
output corresponded with the following gross growth rates: Control 1.00±0.04 day-1, Low 
Expressing 0.99±0.04 day-1, and High Expressing 0.84±0.03 day-1.  B. Ratio of biomass to 
lactate carbon fluxes during the lactate-producing phase.  C. Fluxes during the lactate-consuming 
phase.  The biomass carbon output corresponded with the following gross growth rates: Control 
0.05±0.02 day-1, Low Expressing 0.06±0.01 day-1, and High Expressing 0.03±0.01 day-1.  D. 
Ratio of incoming lactate carbon flux to total incoming carbon flux during the lactate-consuming 
phase. 
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Due to the fact that lactate flux switched from production to consumption during the course of 
the culture, an effect often observed in industrial CHO cell cultures [36], we examined the 
lactate-producing and lactate-consuming phases separately.  These corresponded roughly with 
the exponential and stationary phases, as previously reported in literature [37].   
 
Lactate-Producing Phase.  In the lactate-producing phase (Figure 4-2a), the HE clone 
produced lactate at a rate that was approximately half that of the control.  Alanine production 
also fell significantly in both the HE and LE clones.  Biomass production was the only other 
substantial carbon output during this phase, with a magnitude comparable to lactate on a C-mol 
basis.  However, while the control clone produced only 0.920.11 C-mol of biomass for every 1 
C-mol of lactate, the HE clone was 27% more efficient in its carbon utilization, producing 
1.170.15 C-mol of biomass for every 1 C-mol of lactate (Figure 4-2b).  In terms of carbon 
inputs, the HE clone consumed glucose at a significantly lower rate than the LE clone and nearly 
a third less compared to the control.  Glutamine consumption was significantly reduced in both 
Bcl-2Δ expressing clones.  In general, amino acid consumption was reduced in both Bcl-2Δ 
expressing clones, but with the exception of glutamine, none of the other amino acid fluxes 
contributed substantially to the overall carbon balance. 
 Examination of the culture growth rates reveals further insight into the metabolic impact 
of Bcl-2Δ expression.  The HE clone had a growth rate that was significantly reduced by 16% 
compared to the control (Figure 4-A-4).  Previous work has found Bcl-2 overexpression to have 
a similar negative impact on growth [38].  However, the LE clone did not differ significantly 
from the control in growth rate despite diminished lactate production and reduced glucose 
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consumption (Figure 4-2a).  This indicates that the reduction in nutrient uptake and lactate 
production in the LE clone reflects a direct effect of Bcl-2Δ expression on metabolic pathways 
rather than a growth-rate-dependent effect. Furthermore, the total incoming carbon flux was 
reduced by approximately 10% in the LE clone and by 30% in the HE clone during the lactate-
producing phase (Figure 4-3). 
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Figure 4-3. Total incoming carbon flux during each phase.  Standard deviation is reported.  * 
Indicates statistically significant differences compared to the control (p=0.05). + Indicates 
statistically significant differences between the Low Expressing and High Expressing clones 
(p=0.05).  
 
Lactate-consuming phase. The lactate-consuming phase was notably different from the 
lactate-producing phase.  The sum of the specific lactate and glucose consumption rates 
accounted for 7989% of the total carbon consumed in the three clones.  Outgoing carbon flux to 
biomass was limited during this phase, but was not negligible.  Nearly all of the extracellular 
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carbon substrates were consumed during this phase, including several metabolites previously 
excreted during the lactate-producing phase.  Incoming lactate flux was significantly higher in 
the HE line, while the LE clone consumed lactate at nearly the same rate as the control (Figure 4-
2c).  However, the glucose uptake rate was significantly reduced in both Bcl-2Δ expressing 
clones.  The lactate-to-glucose ratio was 54% greater in the HE clone when compared to the 
control (Figure 4-A-5).  Thus incoming lactate flux made up a significantly greater fraction of 
the total incoming carbon flux in the HE clone, a 44% increase compared to the control (Figure 
4-2d).  As expected, the culture was considerably less metabolically active relative to the lactate-
producing phase, as indicated by drastic reductions in total carbon consumption (Figure 4-3).   
  
 
13C metabolic flux analysis (13C MFA) 
With significant rerouting of extracellular fluxes observed during both the lactate-
producing and lactate-consuming phases, we sought to identify the fate of the incoming glucose 
carbon and to quantify the intracellular flux distributions of all three clones.  We performed a 13C 
labeling study followed by metabolic flux analysis (MFA) to calculate intracellular metabolic 
fluxes in both the lactate-producing and lactate-consuming phases. 
 
Lactate-producing phase. The flux maps obtained by 13C MFA during the lactate-
producing phase are shown in Figure 4-4.   
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Figure 4-4.  Metabolic flux maps during the lactate-producing phase.  The magnitude of 
each net carbon flux corresponds with the color and width of the reaction arrow.   
 
A few notable features are shared by all three clones.  Minimal oxidative pentose phosphate 
pathway (oxPPP) activity was observed, and nearly all of the glucose consumed was directed 
through glycolysis to pyruvate.  This result has been observed in previous 13C MFA studies of 
exponential-phase CHO cultures [18].  Flux through malic enzyme (ME) was the most 
substantial cataplerotic flux leaving the TCA cycle during this phase.  Still, nearly all of the 
pyruvate generated was attributable to the pyruvate kinase (PK) flux.  A substantial portion of 
the pyruvate generated was converted into lactate; however, the HE clone diverted less pyruvate 
toward lactate production than the other cell lines. 
 Despite decreased total carbon consumption by both Bcl-2Δ expressing clones (Figure 4-
3), TCA cycle fluxes were not significantly different among the three cell lines.  Therefore, we 
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examined how the incoming carbon was partitioned at the pyruvate node to maintain consistent 
TCA cycle activity, since pyruvate is a central metabolic hub where fermentative and oxidative 
pathways bifurcate.  To this end, we compared all incoming and outgoing pyruvate fluxes at the 
pyruvate node (Figure 4-5).   
 
 
Figure 4-5.  Distribution of flux at the pyruvate node during the lactate-producing phase.  
Cys, Ser, Thr represents the summed contributions of these three amino acids to pyruvate 
production. 
 
In the control line, 33±7% of carbon leaving the pyruvate node was transferred to the 
mitochondria through pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH).  However, 
as Bcl-2Δ expression level increased, a greater fraction of the incoming pyruvate was directed to 
the mitochondria, reaching as high as 44±7% in the HE clone.   
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 With a higher fraction of pyruvate oxidized in mitochondria, we hypothesized that more 
mitochondrial NADH would be generated per glucose consumed and more oxidative metabolism 
would be detected in the Bcl-2Δ expressing clones.  To test this hypothesis, and to identify a 
potential mechanism by which the Bcl-2Δ cells increased their mitochondrial activity, we 
measured the enzymatic activities of the mitochondrial enzymes isocitrate dehydrogenase (IDH) 
and NADH-coenzyme Q oxidoreductase (Complex I).  IDH is a rate-controlling step in the TCA 
cycle that catalyzes the oxidative conversion of citrate to alpha-ketoglutarate, with concomitant 
evolution of CO2 and generation of NADH.  As indicated in Figure 4-6a, the IDH activity was at 
least 60% higher in both engineered cell lines relative to the control, which indicates a shift 
toward increased oxidative capacity in response to Bcl-2Δ expression.   
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Figure 4-6.  Enzyme activity assays.  A. Relative enzymatic activity of isocitrate 
dehydrogenase (IDH).  B. Relative enzymatic activity of Complex I (NADH oxidase).  Standard 
deviation is reported.  * Indicates statistically significant difference compared to the control 
(p=0.05). + Indicates statistically significant difference between the Low Expressing and High 
Expressing clones (p=0.05). Comparisons of both assays are relative to the control enzymatic 
activity, and are only appropriate when compared within a specific phase (i.e., within the lactate-
producing phase or lactate-consuming phase).  ** Indicates statistically significant difference 
compared to the control (p=0.1). 
 
Similarly, both Bcl-2Δ expressing clones were determined to have significantly increased 
Complex I activity (Figure 4-6b).  This enzyme functions to oxidize NADH produced in the 
TCA cycle and is a vital component of the mitochondrial electron transport chain.   
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Lactate-consuming phase. During the lactate-consuming phase, growth slowed 
dramatically and the total incoming carbon flux decreased by nearly an order of magnitude.  This 
was due largely to decreased glucose consumption rates as all 3 clones transitioned into 
stationary phase (Figure 4-2c).  Past work has found similar reductions in glucose flux following 
a switch to lactate consumption [39].  The majority of incoming glucose was diverting to the 
oxPPP, with fluxes ranging from 76% of total carbon uptake in the control line to 61% in the HE 
clone (Figure 4-7). 
 
 
Figure 4-7.  Metabolic flux map of lactate-consuming phase.  The magnitude of each net 
carbon flux corresponds with the color and width of each reaction arrow. 
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Even so, the TCA cycle was the main focal point of central metabolism during the lactate-
consuming phase, with the majority of incoming carbon ultimately directed there for oxidation to 
CO2.   
 Figure 4-8 shows the distribution of carbon fluxes entering the pyruvate node 
during this phase.   
 
 
Figure 4-8.  Distribution of carbon flux at the pyruvate node during the lactate-consuming 
phase. 
 
Most of the incoming pyruvate carbon can be broken down into two components: the 
contribution from lactate and the contribution from glycolysis.  Lactate accounted for 39±1% of 
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the input carbon in the HE clone compared to only 29±4% in the control line.  The LE clone fell 
in the middle at 35±5%.  Whether viewed on an absolute (Figure 4-2c) or relative basis (Figure 
4-8), the utilization of lactate by the HE clone is significantly greater than the control.  Since all 
of the outgoing flux from pyruvate was directed to the mitochondria during this phase, we again 
became interested in whether changes in carbon partitioning at the pyruvate node were 
associated with changes in mitochondrial oxidative capacity.  Therefore, we measured IDH 
activity (Figure 4-6a) and Complex I activity (Figure 4-6b) in cells harvested during the lactate-
consuming phase.  As in the lactate-producing phase, the activities of both mitochondrial 
enzymes were significantly higher in the Bcl-2Δ expressing clones as compared to the control. 
 
Discussion 
Bcl-2 was originally known for its role as an oncogene, having been frequently found 
overexpressed in several different cancer cell types [40]—most notably B-cell lymphoma for 
which it is named.  More recently, the biotechnology industry became interested in Bcl-2 and 
other anti-apoptotic genes due to their ability to increase survival of industrial cell lines with a 
potential impact on enhancing product yields [10,41,42].  In 2000, multiple laboratories 
including our group [9,43] found that Bcl-2 expression indeed retards apoptotic progression in 
CHO cells, including those producing recombinant proteins.  Dorai et al. [13] later observed that 
antibody-producing CHO cells engineered to overexpress a variety of  different anti-apoptotic 
genes exhibited less lactate accumulation during early exponential phase and more rapid lactate 
consumption during late exponential and stationary phases.  
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The current study builds upon this previous work to examine the metabolic response of 
CHO cells to recombinant expression of Bcl-2Δ, an engineered variant of Bcl-2 where both the 
BH2 and BH3 motifs have been removed.  This serves to enhance protein stability, since several 
ubiquitination sites and regulatory motifs have been removed from the truncated sequence [41].  
Expression of Bcl-2∆ in CHO cells has been previously shown to surpass wild-type Bcl-2 in its 
ability to extend culture survival in response to diverse insults [41].  In this study, the expression 
of Bcl-2∆ was greatly enhanced in our clones relative to the endogenous Bcl-2 level of control 
cells (Figure 4-A-1), presumably due to both the use of a strong constitutive CMV promoter and 
the increased stability of Bcl-2∆.  This resulted in rewiring of metabolic fluxes at the pyruvate 
node, both during the lactate-producing and lactate-consuming phases of culture.  We sought to 
better understand the regulatory connections between these metabolic alterations and the known 
anti-apoptotic properties of Bcl-2. 
 Bcl-2 is known to regulate cell death by modulating mitochondrial membrane 
permeability [44] and is believed to function by preventing the release of cytochrome c from the 
intramembrane space, which is a committed step in several different apoptotic mechanisms [45].  
There are multiple hypotheses surrounding how mitochondrial permeability is regulated by Bcl-
2, as discussed in a recent review [46].  Some evidence supports a role for Bcl-2 in blocking 
permeability transition pore (PTP) activation, thus preventing dissipation of inner mitochondrial 
transmembrane potential (Δm) [47,48].  Bcl-2 has also been found to limit activity of the 
voltage-dependent anion channel (VDAC), a protein essential to the regulation of mitochondrial 
Ca2+ uptake [49]. These effects would be expected to simultaneously modulate metabolic 
pathway activities, since several mitochondrial enzymes are regulated by changes in Ca2+ and 
Δm [15].  These include IDH and Complex I enzymes that catalyze important redox reactions in 
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the TCA cycle and oxidative phosphorylation (OXPHOS), respectively. Furthermore, the effect 
of Bcl-2 to prevent loss of cytochrome c from the intramembrane space may also function to 
regulate OXPHOS, as cytochrome c is a required part of the mitochondrial electron transport 
chain. 
 Our measurements indicate that Bcl-2Δ expression increased enzymatic activities of both 
IDH and Complex I (Figure 4-6), potentially enhancing mitochondrial oxidative capacity.  The 
effect was accompanied by a greater fraction of pyruvate produced during the lactate-producing 
phase being directed to the mitochondria for oxidation (Figure 4-5).  In addition, there was a 
significant increase in the lactate consumption rate (Figure 4-2c) and a significant increase in the 
fraction of pyruvate carbon derived from lactate (Figure 4-8) during the lactate-consuming 
phase.  We hypothesize that these systems-level metabolic alterations stem, at least in part, from 
the changes in mitochondrial enzymatic activities we observed.   
 Bcl-2 has also been shown to enhance the activity of several Ca2+-dependent 
mitochondrial transporters, including adenine nucleotide translocator (ANT) [50].  ANT exists in 
the inner mitochondrial membrane and enables exchange of ADP/ATP with the cytosol.  Lack of 
mitochondrial ADP availability could lead to a potential bottleneck within the OXPHOS 
pathway of control cells.  Removal of this bottleneck could be another potential explanation for 
the increased pyruvate shuttled to the mitochondria and enhanced Complex I activity observed in 
the HE clone.  Others have found that there is a limitation in the Ca2+-dependent Asp/Glu 
transporter of CHO cells, which is responsible for transport of NAD+ equivalents into the cytosol 
as part of the malate-aspartate shuttle [51,52].  This could explain the reduced lactate production 
observed in the Bcl-2∆ clones, since the conversion of pyruvate to lactate by lactate 
dehydrogenase (LDH) provides an alternative pathway to oxidize NADH that is expected to 
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become less important as mitochondrial OXPHOS and malate-aspartate shuttle capacities 
increase.  Based upon the lactate/glucose ratio, both Bcl-2∆ expressing clones exhibited reduced 
reliance on lactate production for maintaining cytosolic redox during the lactate-producing phase 
(Figure 4-A-5).  Likewise, the enhanced lactate consumption exhibited by the HE clone after the 
lactate shift may be partially explained by increased mitochondrial transport and disposal of 
NADH equivalents generated by LDH acting in the reverse direction.  Taken together, the known 
role of anti-apoptotic proteins such as Bcl-2 to alter mitochondrial Ca2+ flux and Δm are 
important for regulating several aspects of mitochondrial metabolism that could explain our 
observations. 
 Even though recombinant expression of Bcl-2Δ did not positively impact the growth rate, 
it did clearly hinder the progression of cell death.  Bcl-2Δ expression led to increases in IVCD of 
40% in the HE culture and 20% in the LE culture (Figure 4-9).   
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Figure 4-9. Integrated viable cell density (IVCD) over the culture life.  Standard deviation is 
reported.  * Indicates statistically significant difference compared to the control (p=0.05).  + 
Indicates statistically significant difference between the Low Expressing and High Expressing 
clones (p=0.05).  
 
This is in agreement with prior studies where Bcl-2 was found to inhibit cell death without 
increasing cell proliferation [53,54].  Peak VCD was also increased by nearly 50% in the HE 
clone and nearly 40% in the LE clone (Figure 4-A-6).  This reflects an increase in biomass yield, 
as the Bcl-2∆ expressing cells directed more carbon flux to biomass production rather than 
lactate (Figure 4-2b). Additionally, glutamine consumption decreased significantly in the Bcl-2Δ 
clones, perhaps attributable to the redistribution of pyruvate carbon to the TCA cycle.  This 
increased carbon efficiency is likely a result of enhanced TCA cycle activity relative to 
glycolysis, since OXPHOS provides more ATP per glucose consumed than lactate production.  
Further evidence for this increased carbon efficiency is reflected in the fact that the reductions in 
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growth rate observed in both Bcl-2∆ clones (HE down 16%; LE unaffected) was substantially 
less than the reductions in their total carbon consumption rate (HE down 30%; LE down 10%).  
 In addition to the enhancements in biomass yield, the accompanying reduction in lactate 
production would be expected to have further benefits in an industrial bioprocess, since elevated 
lactate concentrations have been found to hamper both growth and antibody production of CHO 
cell cultures [55].  The HE line allowed lactate to accumulate to marginally less (<10%) 
concentrations than the control, despite achieving ~50% higher peak VCD (Supplemental 
Figures 4-A-6 and 4-A-7).  Furthermore, a culture capable of consuming the lactate that it 
previously produced is at an obvious advantage in a controlled bioreactor.  A lactate-consuming 
culture requires less base addition to maintain pH and results in less rise in osmolarity [56], 
which has also been found to negatively affect growth.  All cell lines examined in this study 
consumed previously produced lactate; however, the HE clone consumed lactate at a specific rate 
significantly greater than the others, confirming the result that Dorai et al. [13] obtained in their 
apoptosis-resistant lines. 
Although prior work by Meents et al. (2002) found that Bcl-2 overexpression did not 
increase specific protein productivity, Bcl-2Δ clones have the potential to outperform Bcl-2 
overexpressing clones in terms of protein production [41,42].  While the current study did not 
address the effects of Bcl-2Δ expression on protein production, recent work from our group has 
found a strong correlation between enhanced TCA cycling and peak antibody production [19].  
Therefore, we expect that anti-apoptosis engineering may offer a path toward improving specific 
protein productivity while reducing lactate accumulation and improving biomass yields, in 
addition to its well-known effects to extend culture longevity. 
144 
 The 13C flux analysis performed in this study was dependent on assumptions of both 
isotopic and metabolic steady state.  Although we did not obtain biomass samples during the 
initial two days of growth due to the low cell densities achieved during this period, multiple 
parallel experiments where tracers were administered to higher density cultures indicate that the 
13C enrichment of intracellular metabolites plateaus after ~2 days of labeling.  Therefore, all 
samples used for 13C isotopomer analysis were collected following more than two days of 
labeling, which we expect to be sufficient to achieve isotopic steady state. It is also possible that 
the metabolic steady-state assumption was violated due to dynamic changes that occur during the 
transition from lactate-producing to lactate-consuming phases of culture.  While this is indeed a 
concern, there are currently no established methods for performing fully dynamic 13C MFA 
under metabolic nonstationary conditions [1,57].  Therefore, in order to address industrially 
relevant culture conditions where metabolism is changing over time, it is necessary to invoke a 
quasi-steady-state assumption.  This involves the premise that, after the initial tracer 
equilibration period, further changes in isotope labeling will track closely with changes in 
metabolism and can be analyzed by steady-state 13C MFA to obtain a series of snapshots that 
describes the variation in metabolic fluxes over time.  This is similar to the approach used by 
Antoniewicz et al. [58] to profile dynamic changes in E. coli metabolism during a fed-batch 
culture that exhibited both glycerol-producing and glycerol-consuming phases.  Despite these 
limitations and assumptions, we expect that the 13C MFA results are reliable because (i) the main 
findings related to pyruvate partitioning are consistent with extracellular flux measurements and 
with direct measurements of mitochondrial enzyme activities, (ii) the enrichments of pyruvate 
and lactate were maintained near their maximal levels throughout both phases of culture, (iii) we 
did not utilize samples collected immediately following the lactate shift, and (iv) the average 13C 
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enrichments of metabolites from the control and HE lines were consistent within each phase, 
despite being collected at different times due to the delayed onset of lactate consumption in the 
HE culture (Figure 4-A-8).  
 
Conclusions 
Host cell engineering through recombinant Bcl-2Δ expression has considerable potential 
for industrial applications.  It notably improves the total IVCD by delaying the onset of 
apoptosis.  In addition, this study has shown that Bcl-2Δ expression promotes a shift toward 
increased mitochondrial oxidation of incoming carbon substrates.  Bcl-2Δ’s ability to limit 
lactate production and enhance lactate consumption is an especially attractive property, and will 
only become more so, as industry continues to push toward higher peak VCDs and longer culture 
lifespans.  To our knowledge, this is the first 13C MFA study to quantify the metabolic impact of 
Bcl-2Δ expression, enabling a closer examination of the interplay between apoptotic and 
metabolic regulatory functions of Bcl-2Δ through comprehensive analysis of central carbon 
metabolism. 
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Nomenclature 
3PG: 3-Phosphoglycerate 
AcCoA: Acetyl-CoA 
ACL: ATP Citrate Lyase 
aKG: α-Ketoglutarate 
Ala.e: Alanine.extracellular 
AMBIC: Ammonium Bicarbonate 
ANT: Adenine Nucleotide Translocator 
Asn.e: Asparagine.extracellular 
ATP: Adenosine-5'-Triphosphate 
Bcl-2: B-cell lymphoma 2 
CHO: Chinese Hamster Ovary 
Cit: Citrate 
DHAP: Dihydroxyacetone Phosphate 
E4P: Erythrose-4-Phosphate 
EMU: Elementary Metabolite Unit 
F6P: Fructose 6-Phosphate 
Fum: Fumarate 
G6P: Glucose-6-Phosphate 
G6PDH: Glucose-6-Phosphate Dehydrogenase 
GAP: Glyceraldehyde-3-Phosphate 
GCMS: Gas Chromatography-Mass Spectrometry 
Glc: Glucose 
Gln.e: Glutamine.extracellular 
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HE: High Expressing (of Bcl-2Δ) 
HPLC: High Performance Liquid Chromatography 
HRP: Horseradish Peroxidase 
IDH: Isocitrate Dehydrogenase 
IVCD: Integrated Viable Cell Density 
Lac.e: Lactate.extracellular 
Lac: Lactate 
LDH: Lactate Dehydrogenase 
LE: Low Expressing (of Bcl-2Δ) 
Leu.e: Leucine.extracellular 
Lys.e: Lysine.extracellular 
Mal: Malate 
ME: Malic Enzyme 
MFA: Metabolic Flux Analysis 
MID: Mass Isotopomer Distribution 
MOX: Methoxyamine 
MTBSTFA: N-Methyl-N-(t-butyldimethylsilyl) trifluoroacetamide 
NADH: Nicotinamide Adenine Dinucleotide 
NADPH: Nicotinamide Adenine Dinucleotide phosphate 
OAA: Oxaloacetate 
OPA: Orthophthaldildehyde 
OXPHOS: Oxidative Phosphorylation 
oxPPP: oxidative Pentose Phosphate Pathway 
PC: Pyruvate Carboxylase 
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PDH: Pyruvate Dehydrogenase 
PEP: Phosphoenolpyruvate 
PPP: Pentose Phosphate Pathway 
Pro: Proline 
PTP: Permeability Transition Pore 
Pyr: Pyruvate 
R5P: Ribose-5-Phosphate 
RCF: Relative Centrifugation Force 
ROS: Reactive Oxygen species 
Ru5P: Ribulose-5-Phosphate 
S7P: Sedoheptulose-7-Phosphate 
Ser.e: Serine.extracellular 
Suc: Succinate 
TBDMCS: Tert-Butyldimethylchlorosilane 
TCA Cycle: Tri-Carboxylic Acid Cycle 
Val.e: Valine.extracellular 
VCD: Viable Cell Density 
VDAC: Voltage Dependent Anion Channel 
X5P: Xylulose-5-Phosphate 
XIAP: X-linked Inhibitor of Apoptosis Protein 
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Appendix 
Metabolic flux analysis assumptions 
The reaction network for all three models generated, including the reported fluxes and their 
associated 95% confidence intervals, can be found in a separate Excel spreadsheet.  The 
following assumptions were made in regards to generating the models: 
 
1. Metabolism is at a steady state during each of the two phases of the batch culture.  The 
reported fluxes therefore represent averages over the corresponding time interval. 
2. Intracellular isotopic labeling has reached quasi-steady state at the time of sample 
quenching and removal.   
3. Succinate and fumarate are symmetric molecules that don’t retain any particular 
orientation when metabolized by TCA cycle enzymes. 
4. Change in individual cell size (mass) over the fed-batch lifetime is assumed to be 
negligible. 
5. All major carbon sources of the complex industrial media have been included. 
6. Exchange fluxes are employed to account for dilution by unlabeled carbon sources in the 
medium (e.g., lactate, alanine, aspartate).   
7. As a consequence of conducting the isotope labeling experiments for 5 days of time to 
reach the lactate-consuming phase, secondary tracers emerged as byproducts of the 
primary glucose tracer.  This required mass spectral measurements of extracellular 
lactate, and the specification of secondary tracers entering the reaction network during 
the lactate-consuming phase.  The secondary tracer sources for lactate were specified 
based upon the measured lactate labeling during the preceding lactate-producing phase.   
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Supplemental figures 
 
Figure 4-A-1.  Western Blot of Bcl-2 and Bcl-2Δ (Isoform 2: 1G5O/1GJH).  Low and High 
correspond with the expression level of Bcl-2Δ in the two transfected clones.  Bcl-2 was 
expressed at considerably lower levels than Bcl-2Δ at all three sample times.  To visualize Bcl-2, 
Bcl-2Δ had to be oversaturated. 
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Figure 4-A-2.  Subcellular localization of Bcl-2 and Bcl-2Δ.  Cell fractionation study of 
control and Bcl-2Δ expressing clones showing P1 (whole cell and nuclear), mitochondrial 
(MITO), MAM, P3 (microsomal), and cytosolic (CYTO) fractions.  Markers for known nuclear, 
mitochondrial, ER, and MAM proteins are used to validate the purity of fractions.  The percent 
distribution of Bcl-2 and Bcl-2Δ in the LE and HE clones are graphed for each subcellular 
fraction in comparison to Bcl-2 expression in control cells.  Data is representative of the varying 
levels of protein samples between all fractions collected and cannot be used as a comparison of 
total protein levels between cell lines. 
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Figure 4-A-3.  Caspase3/7 activity at day 8 of culture.  Inset compares LE to HE clone.  
Standard deviation shown. * Indicates statistically significant difference compared to the control 
(p=0.05). 
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Figure 4-A-4.  Net specific growth rate during the lactate-producing phase.  Standard 
deviation shown.  * Indicates statistically significant difference compared to the control 
(p=0.05).  + Indicates statistically significant differences between the Low Expressing and High 
Expressing clones (p=0.05).  
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Figure 4-A-5.  Comparison of lactate to glucose flux, on a carbon basis, which is a proxy of 
net cytosolic NADH balance.  In the lactate-producing phase, a higher percentage indicates 
greater reliance upon lactate production for maintaining cytosolic redox.  During this stage, 
glycolysis reduces NAD+ to NADH and lactate dehydrogenase (LDH) re-oxidizes NADH to 
NAD+.  In the lactate-consuming phase, a higher percentage indicates greater mitochondrial 
capacity to transport and dispose of LDH-derived NADH.  During this stage, both glycolysis and 
lactate consumption generate NADH.  Standard deviation shown.  * Indicates statistically 
significant difference compared to the control (p=0.05).  + Indicates statistically significant 
difference between the Low Expressing and High Expressing clones (p=0.05).  ** Indicates 
statistically significant difference compared to the control (p=0.1). 
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Figure 4-A-6.  Viable cell density (VCD) over time.  Standard deviation shown. 
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Figure 4-A-7.  Lactate concentration over time.  Standard deviation shown. 
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Figure 4-A-8.  Average 13C enrichments of intracellular metabolites at time points analyzed 
by 13C MFA. The HE culture was sampled at later times due to delayed onset of lactate 
consumption. The red line shows the maximum enrichment achievable from the administered 
tracers (i.e., a 50:50 mixture of [U-13C6] and [1,2-
13C2] glucose tracers).  
  
158 
Intracellular metabolites examined for labeling 
Table 4-A-1. Ion fragments quantified via GCMS for the purpose of MFA.  The number listed 
in the ion fragment column corresponds to the mass of fragment. 
 
Ion Fragment  
Node 
ID 
Labeled Atom Unlabeled Atom 
Pyr 174 Pyr 1 2 3 C3 H12 O3 N Si 
Lac 233 Lac 2 3 C8 H25 O2 Si2 
Lac 261 Lac 1 2 3 C8 H25 O2 Si2 
Ala 232 Ala 2 3 C8 H26 O N Si2 
Ala 260 Ala 1 2 3 C8 H26 O2 N Si2 
Gly 218 Gly 2 C8 H24 N O2 Si2 
Gly 246 Gly 1 2 C8 H24 N O2 Si2 
Suc 289 Suc 1 2 3 4 C8 H25 O4 Si2 
Ser 288 Ser 2 3 C12 H34 N O Si2 
Ser 362 Ser 2 3 C14 H40 N O2 Si3 
Ser 390 Ser 1 2 3 C14 H40 N O3 Si3 
Mal 419 Mal 1 2 3 4 C14 H39 O5 Si3 
Asp 302 Asp 1 2 C12 H32 N O2 Si2 
Asp 376 Asp 1 2 C14 H38 N O3 Si3 
Asp 390 Asp 2 3 4 C14 H40 N O3 Si3 
Asp 418 Asp 1 2 3 4 C14 H40 O4 N Si3 
Glu 330 Glu.ms 2 3 4 5 C14 H36 N O2 Si2 
Glu 358 Glu.ms 1 2 3 4 5 C12 H36 N O3 Si2 
Glu 432 Glu.ms 1 2 3 4 5 C14 H42 O4 N Si3 
Asn 417 Asn 1 2 3 4 C14 H41 N2 O3 Si3 
Gln 431 Gln 1 2 3 4 5 C14 H43 N2 O3 Si3 
Cit 459 Cit 1 2 3 4 5 6 C14 H39 O6 Si3 
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Carbon atom mapping of reaction network 
Table 4-A-2. Reaction network carbon transitions. 
 
Glycolysis 
PGI G6P (abcdef) <-> F6P (abcdef) 
PFK F6P (abcdef) -> DHAP (cba) + GAP (def) 
TPI DHAP (abc) <-> GAP (abc) 
GADPH GAP (abc) <-> 3PG (abc) 
Eno 3PG (abc) <-> PEP (abc) 
PK PEP (abc) -> Pyr (abc) 
HK Glc (abcdef) -> G6P (abcdef) 
LDH Lac (abc) <-> Pyr (abc) 
Pentose Phosphate Pathway 
6PGDH G6P (abcdef) -> Ru5P (bcdef) + CO2 (a) 
R5PE Ru5P (abcde) <-> X5P (abcde) 
R5PI Ru5P (abcde) <-> R5P (abcde) 
TK1 X5P (abcde) + R5P (fghij) <-> GAP (hij) + S7P (fgabcde) 
TK2 S7P (abcdefg) + GAP (hij) <-> E4P (defg) + F6P (abchij) 
TK3 X5P (abcde) + E4P (fghi) <-> GAP (cde) + F6P (abfghi) 
TCA Cycle 
PDH Pyr (abc) -> AcCoA (bc) + CO2 (a) 
SDH Suc (abcd) <-> Fum (abcd) 
Fum Fum (abcd) <-> Mal (abcd) 
MDH Mal (abcd) <-> OAA (abcd) 
CS OAA (abcd) + AcCoA (ef) -> Cit (dcbfea) 
ADH aKG.m (abcde) -> Suc (bcde) + CO2 (a) 
IDH Cit (abcdef) <-> aKG.m (abcde) + CO2 (f) 
Transport 
Glc IN Glc.e (abcdef) -> Glc (abcdef) 
Glc Labeled Glc.l (abcdef) -> Glc.e (abcdef) 
Lys IN Lys.e (abcdef) -> Lys (abcdef) 
Thr IN Thr.e (abcd) -> Thr (abcd) 
Phe IN Phe.e (abcdefghi) -> Phe (abcdefghi) 
Tyr IN Tyr.e (abcdefghi) -> Tyr (abcdefghi) 
Val IN Val.e (abcde) -> Val (abcde) 
Leu IN Leu.e (abcdef) -> Leu (abcdef) 
Ile IN Ile.e (abcdef) -> Ile (abcdef) 
Trp IN Trp.e (abcdefghijk) -> Trp (abcdefghijk) 
His IN His.e (abcdef) -> His (abcdef) 
Met IN Met.e (abcde) -> Met (abcde) 
160 
R *aKG Produced DummyaKG <-> aKGSink 
Glu/Asp Antiporter Glu.c (abcde) -> Glu.m (abcde) 
Mal/aKG Antiporter aKG.m (abcde) -> aKG.c (abcde) 
Glu.c Contribution 0*Glu.c (abcde) -> Glu.ms (abcde) 
Glu.m Contribution 0*Glu.m (abcde) -> Glu.ms (abcde) 
Glu Sink Glu.ms (abcde) -> PhoneyBaloneyGluSink (abcde) 
Anaplerotic reactions 
ME Mal (abcd) -> Pyr (abc) + CO2 (d) 
PC Pyr (abc) + CO2 (d) -> OAA (abcd) 
ACL Cit (abcdef) -> AcCoA.c (ed) + Mal (fcba) 
Amino Acid  Metabolism 
GLS Gln (abcde) <-> Glu.m (abcde) 
ASNS Asp (abcd) <-> Asn (abcd) 
SHT Ser (abc) <-> Gly (ab) + MEETHF (c) 
CYST Ser (abc) <-> Cys (abc) 
GS + SHT CO2 (a) + MEETHF (b) -> Gly (ab) 
Met Mtbl Met (abcde) + Ser (fgh) -> Methyl (e) + Cys (fgh) + Suc (abcd) 
PheTyr Mtbl Phe (abcdefghi) -> Tyr (abcdefghi) 
Thr Mtbl Thr (abcd) -> Pyr (abc) + CO2 (d) 
Histidase His (abcdef) -> FormTHF (f) + Glu.c (abcde) 
CBXase + Mutase ProCoA (abc) + CO2 (d) -> Suc (abcd) 
Trp Mtbl Trp (abcdefghijk) -> CO2 (d) + CO2 (e) + Ala (abc) + aKetoadi (fghijk) 
Trp2 Mtbl aKetoadi (abcdef) -> CO2 (a) + CO2 (f) + AcCoA (bc) + AcCoA (de) 
*GDH aKG.m (abcde) + DummyaKG <-> Glu.m (abcde) 
*ALT Ala (abc) + aKG.c (defgh) + DummyaKG <-> Pyr (abc) + Glu.c (defgh) 
*Ile Mtbl 
Ile (abcdef) + aKG.c (ghijk) + DummyaKG -> AcCoA (de) + CO2 (a) + 
ProCoA (bcf) + Glu.c (ghijk) 
*Leu Mtbl 
Leu (abcdef) + aKG.c (ghijk) + CO2 (l) + DummyaKG -> CO2 (a) + AcCoA 
(bc) + AcCoA (ld) + AcCoA (ef) + Glu.c (ghijk) 
*Tyr Mtbl 
Tyr (abcdefghi) + aKG.c (jklmn) + DummyaKG -> CO2 (a) + Mal (defg) + 
AcCoA (bc) + AcCoA (hi) + Glu.c (jklmn) 
*Val Mtbl 
Val (abcde) + aKG.c (fghij) + DummyaKG -> Glu.c (fghij) + CO2 (a) + CO2 
(e) + ProCoA (bcd) 
*Lys Mtbl 
Lys (abcdef) + aKG.c (ghijk) + aKG.c (lmnop) + DummyaKG + DummyaKG 
-> Glu.c (ghijk) + Glu.c (lmnop) + aKetoadi (abcdef) 
*AST OAA (abcd) + Glu.c (efghi) <-> Asp (abcd) + aKG.c (efghi) + DummyaKG 
*Arg Mtbl 
Arg (abcdef) + aKG.c (ghijk) + DummyaKG -> Glu.c (abcde) + Urea (f) + 
Glu.c (ghijk) 
*PST 3PG (abc) + Glu.c (defgh) -> Ser (abc) + aKG.c (defgh) + DummyaKG 
*Cys Mtbl Cys (abc) + aKG.c (defgh) + DummyaKG -> Pyr (abc) + Glu.c (defgh) 
Lumped Biomass Equation 
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New Biomass 363pg 
0.2178*Ala + 0.1368*Arg + 0.1712*Asp + 0.1046*Asn + 0.0526*Cys + 
0.1168*Gln + 0.1401*Glu.c + 0.2389*Gly + 0.0519*His + 0.1176*Ile + 
0.2048*Leu + 0.2069*Lys + 0.0501*Met + 0.0796*Phe + 0.1136*Pro + 
0.1601*Ser + 0.1401*Thr + 0.016*Trp + 0.0661*Tyr + 0.151*Val + 
0.1047*G6P + 0.0845*R5P + 0.0926*MEETHF + 0.0441*DHAP + 
0.8985*AcCoA.c -> Biomass 
Transport Exchange 
Ser Flux Ser.e (abc) <-> Ser (abc) 
Ala Flux Ala.e (abc) <-> Ala (abc) 
Arg Flux Arg.e (abcdef) <-> Arg (abcdef) 
Asp Flux Asp.e (abcd) <-> Asp (abcd) 
Gln Flux Gln.e (abcde) <-> Gln (abcde) 
Pro Flux Pro.e (abcde) <-> Pro (abcde) 
Asn Flux Asn.e (abcd) <-> Asn (abcd) 
Lac Flux Lac.e (abc) <-> Lac (abc) 
Gly Flux Gly.e (ab) <-> Gly (ab) 
Cys Flux Cys.e (abc) <-> Cys (abc) 
Glu Flux Glu.e (abcde) <-> Glu.c (abcde) 
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95% confidence intervals associated with individual fluxes 
Table 4-A-3. Net fluxes of control during lactate producing phase.  Associated with Figure 4-
4. 
 
Pathway Enzyme Rxn 
LB 95% 
CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P 3.604 4.377 3.991 
 PFK F6P -> DHAP + GAP 3.544 4.317 3.931 
 TPI  DHAP <-> GAP 3.497 4.271 3.884 
 GADPH  GAP <-> 3PG 7.011 8.559 7.785 
 Eno  3PG <-> PEP 6.836 8.316 7.576 
 PK PEP -> Pyr 6.836 8.316 7.576 
 HK Glc -> G6P 3.716 4.488 4.102 
 LDH  Lac <-> Pyr -7.096 -4.498 -5.797 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.295 0.147 
 R5PE  Ru5P <-> X5P -0.064 0.133 0.034 
 R5PI  Ru5P <-> R5P 0.056 0.158 0.107 
 TK1  X5P + R5P <-> GAP + S7P -0.032 0.066 0.017 
 TK2  S7P + GAP <-> E4P + F6P -0.032 0.066 0.017 
 TK3  X5P + E4P <-> GAP + F6P -0.032 0.066 0.017 
TCA PDH Pyr -> AcCoA + CO2 1.831 4.030 2.931 
 SDH  Suc <-> Fum 2.080 4.459 3.269 
 Fum  Fum <-> Mal 2.080 4.459 3.269 
 MDH  Mal <-> OAA 1.642 4.012 2.827 
 CS OAA + AcCoA -> Cit 2.133 4.381 3.257 
 ADH aKG.m -> Suc + CO2 1.928 4.287 3.108 
  IDH Cit <-> aKG.m + CO2 1.180 3.430 2.305 
Transport Glc IN Glc.e -> Glc 3.716 4.488 4.102 
 Lys IN Lys.e -> Lys 0.249 0.366 0.308 
 Thr IN Thr.e -> Thr 0.138 0.178 0.158 
 Phe IN Phe.e -> Phe 0.087 0.129 0.108 
 Tyr IN Tyr.e -> Tyr 0.025 0.067 0.046 
 Val IN Val.e -> Val 0.197 0.319 0.258 
 Leu IN Leu.e -> Leu 0.202 0.316 0.259 
 Ile IN Ile.e -> Ile 0.116 0.185 0.151 
 Trp IN Trp.e -> Trp 0.044 0.109 0.076 
 His IN His.e -> His 0.071 0.127 0.099 
 Met IN Met.e -> Met 0.086 0.167 0.126 
 Ser Flux  Ser.e <-> Ser 0.696 0.952 0.824 
 Ala Flux  Ala.e <-> Ala -0.771 -0.537 -0.654 
 Arg Flux  Arg.e <-> Arg 0.164 0.289 0.227 
 Asp Flux  Asp.e <-> Asp -0.078 0.005 -0.036 
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 Gln Flux  Gln.e <-> Gln 0.832 1.058 0.945 
 Pro Flux  Pro.e <-> Pro 0.112 0.129 0.121 
 Asn Flux  Asn.e <-> Asn 0.351 0.522 0.437 
 Lac Flux  Lac.e <-> Lac -7.096 -4.498 -5.797 
 Gly Flux  Gly.e <-> Gly -0.377 -0.262 -0.319 
 Cys Flux  Cys.e <-> Cys 0.056 0.153 0.104 
 Glu Flux  Glu.e <-> Glu.c 0.011 0.091 0.051 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.000 0.148 0.074 
 
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.100 0.050 
Anaplerosis ME Mal -> Pyr + CO2 1.173 1.703 1.438 
 PC Pyr + CO2 -> OAA 0.111 0.550 0.330 
  ACL Cit -> AcCoA.c + Mal 0.886 1.021 0.953 
Amino GLS  Gln <-> Glu.m 0.708 0.934 0.821 
Acid ASNS  Asp <-> Asn -0.410 -0.241 -0.326 
Metabolism SHT  Ser <-> Gly + MEETHF 0.305 0.367 0.336 
 CYST  Ser <-> Cys 0.269 0.662 0.465 
 GS + SHT CO2 + MEETHF -> Gly 0.208 0.267 0.237 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.033 0.114 0.073 
 PheTyr Mtbl Phe -> Tyr 0.004 0.045 0.024 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.029 0.014 
 Histidase His -> FormTHF + Glu.c 0.016 0.073 0.044 
 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.037 0.174 0.105 
 Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.027 0.092 0.059 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.083 0.209 0.146 
 *GDH  aKG.m  <-> Glu.m -0.997 -0.713 -0.855 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.944 -0.708 -0.826 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.000 0.060 0.030 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu.c 
0.000 0.096 0.048 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal.c + 
AcCoA + AcCoA + Glu.c 
0.000 0.019 0.010 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + 
CO2 + ProCoA 
0.037 0.158 0.098 
 *Lys Mtbl 
Lys + aKG.c + aKG.c   -> Glu.c + 
Glu.c + aKetoadi 
0.031 0.145 0.088 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.200 -0.016 -0.108 
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 *Arg Mtbl 
Arg + aKG.c  -> Glu.c + Urea + 
Glu.c 
0.020 0.144 0.082 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.105 0.389 0.247 
 *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.402 0.773 0.588 
Biomass 
Production 
Biomass 398 pg 
0.2388*Ala + 0.15*Arg + 
0.1877*Asp + 0.1147*Asn + 
0.0577*Cys + 0.1281*Gln + 
0.1536*Glu.c + 0.2619*Gly + 
0.0569*His + 0.129*Ile + 
0.2245*Leu + 0.2268*Lys + 
0.0549*Met + 0.0872*Phe + 
0.1246*Pro + 0.1755*Ser + 
0.1536*Thr + 0.0175*Trp + 
0.0725*Tyr + 0.1656*Val + 
0.1148*G6P + 0.0927*R5P + 
0.1015*MEETHF + 0.0484*DHAP 
+ 0.9851*AcCoA.c -> Biomass 
0.899 1.036 0.967 
 
Table 4-A-4. Exchange fluxes of control during lactate producing phase.  Associated with 
Figure 4-4. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
TCA IDH  Cit <-> aKG.m + CO2 0.000 0.7155 0.358 
Amino GLS  Gln <-> Glu.m 0.000 1.485 0.743 
Acid ASNS  Asp <-> Asn 0.000 3.8813 1.941 
Metabolism SHT  Ser <-> Gly + MEETHF 0.372 1.6458 1.009 
 ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 2.8246 1.412 
  AST  OAA + Glu.c <-> Asp + aKG.c  0.087 1.5429 0.815 
Transport Ser Flux  Ser.e <-> Ser 0.000 1.8807 0.940 
 Ala Flux  Ala.e <-> Ala 0.000 0.1416 0.071 
 Asp Flux  Asp.e <-> Asp 0.000 3.9289 1.964 
 Lac Flux  Lac.e <-> Lac 0.000 0.1355 0.068 
 Gly Flux  Gly.e <-> Gly 0.077 0.6427 0.360 
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Table 4-A-5. Net fluxes of low expressing (LE) during lactate producing phase.  Associated 
with Figure 4-4. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P 3.165 4.029 3.597 
 PFK F6P -> DHAP + GAP 3.113 3.973 3.543 
 TPI  DHAP <-> GAP 3.069 3.929 3.499 
 GADPH  GAP <-> 3PG 6.153 7.874 7.014 
 Eno  3PG <-> PEP 5.977 7.630 6.803 
 PK PEP -> Pyr 5.977 7.630 6.803 
 HK Glc -> G6P 3.273 4.133 3.703 
 LDH  Lac <-> Pyr -6.151 -3.833 -4.992 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.305 0.152 
 R5PE  Ru5P <-> X5P -0.060 0.147 0.043 
 R5PI  Ru5P <-> R5P 0.052 0.158 0.105 
 TK1  X5P + R5P <-> GAP + S7P -0.030 0.073 0.022 
 TK2  S7P + GAP <-> E4P + F6P -0.030 0.073 0.022 
  TK3  X5P + E4P <-> GAP + F6P -0.030 0.073 0.022 
TCA PDH Pyr -> AcCoA + CO2 1.758 3.654 2.706 
 SDH  Suc <-> Fum 1.621 3.879 2.750 
 Fum  Fum <-> Mal 1.621 3.879 2.750 
 MDH  Mal <-> OAA 1.603 3.635 2.619 
 CS OAA + AcCoA -> Cit 1.977 4.125 3.051 
 ADH aKG.m -> Suc + CO2 1.539 3.722 2.631 
 IDH Cit <-> aKG.m + CO2 1.083 3.230 2.156 
Transport Glc IN Glc.e -> Glc 3.273 4.133 3.703 
 Lys IN Lys.e -> Lys 0.218 0.374 0.296 
 Thr IN Thr.e -> Thr 0.131 0.222 0.177 
 Phe IN Phe.e -> Phe 0.087 0.142 0.114 
 Tyr IN Tyr.e -> Tyr 0.006 0.059 0.032 
 Val IN Val.e -> Val 0.163 0.340 0.251 
 Leu IN Leu.e -> Leu 0.191 0.326 0.258 
 Ile IN Ile.e -> Ile 0.110 0.235 0.173 
 Trp IN Trp.e -> Trp 0.015 0.071 0.043 
 His IN His.e -> His 0.064 0.135 0.100 
 Met IN Met.e -> Met 0.047 0.112 0.080 
 Ser Flux  Ser.e <-> Ser 0.539 0.831 0.685 
 Ala Flux  Ala.e <-> Ala -0.608 -0.410 -0.509 
 Arg Flux  Arg.e <-> Arg 0.131 0.267 0.199 
 Asp Flux  Asp.e <-> Asp -0.064 0.022 -0.021 
 Gln Flux  Gln.e <-> Gln 0.619 0.814 0.716 
 Pro Flux  Pro.e <-> Pro 0.106 0.121 0.113 
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 Asn Flux  Asn.e <-> Asn 0.320 0.555 0.437 
 Lac Flux  Lac.e <-> Lac -6.151 -3.833 -4.992 
 Gly Flux  Gly.e <-> Gly -0.280 -0.188 -0.234 
 Cys Flux  Cys.e <-> Cys 0.055 0.127 0.091 
 Glu Flux  Glu.e <-> Glu.c -0.130 -0.008 -0.069 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.000 0.164 0.082 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.008 0.261 0.134 
Anaplerosis ME Mal -> Pyr + CO2 0.811 1.297 1.054 
 PC Pyr + CO2 -> OAA 0.128 0.469 0.298 
 ACL Cit -> AcCoA.c + Mal 0.836 0.956 0.896 
Amino GLS  Gln <-> Glu.m 0.503 0.698 0.600 
Acid ASNS  Asp <-> Asn -0.450 -0.217 -0.333 
Metabolism SHT  Ser <-> Gly + MEETHF 0.257 0.308 0.282 
 CYST  Ser <-> Cys 0.260 0.664 0.462 
 GS + SHT CO2 + MEETHF -> Gly 0.167 0.213 0.190 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.062 0.031 
 PheTyr Mtbl Phe -> Tyr 0.008 0.062 0.035 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.083 0.042 
 Histidase His -> FormTHF + Glu.c 0.013 0.083 0.048 
 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.020 0.250 0.135 
 Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.000 0.055 0.028 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.021 0.188 0.104 
 *GDH  aKG.m  <-> Glu.m -0.776 -0.503 -0.639 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.816 -0.604 -0.710 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.000 0.118 0.059 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu.c 
0.000 0.120 0.060 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + 
AcCoA + AcCoA + Glu.c 
0.000 0.029 0.014 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + 
CO2 + ProCoA 
0.013 0.189 0.101 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + 
Glu.c + aKetoadi 
0.013 0.167 0.090 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.263 -0.019 -0.141 
 *Arg Mtbl 
Arg + aKG.c  -> Glu.c + Urea + 
Glu.c 
0.000 0.130 0.065 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.091 0.414 0.252 
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  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.327 0.717 0.522 
Biomass 
Production 
Biomass 363 pg 
0.2178*Ala + 0.1368*Arg + 
0.1712*Asp + 0.1046*Asn + 
0.0526*Cys + 0.1168*Gln + 
0.1401*Glu.c + 0.2389*Gly + 
0.0519*His + 0.1176*Ile + 
0.2048*Leu + 0.2069*Lys + 
0.0501*Met + 0.0796*Phe + 
0.1136*Pro + 0.1601*Ser + 
0.1401*Thr + 0.016*Trp + 
0.0661*Tyr + 0.151*Val + 
0.1047*G6P + 0.0845*R5P + 
0.0926*MEETHF + 0.0441*DHAP 
+ 0.8985*AcCoA.c -> Biomass 
0.930 1.064 0.997 
 
Table 4-A-6. Exchange fluxes of low expressing (LE) during lactate producing phase.  
Associated with Figure 4-4. 
 
Pathway Enzyme Rxn 
LB 95% 
CI 
UB 95% 
CI 
Value 
TCA IDH  Cit <-> aKG.m + CO2 0 1.1067 0.55335 
Amino GLS  Gln <-> Glu.m 0 1.089 0.5445 
Acid ASNS  Asp <-> Asn 0 2.6921 1.34605 
Metabolism ALT  Ala + aKG.c  <-> Pyr + Glu.c 0 2.3776 1.1888 
  AST  OAA + Glu.c <-> Asp + aKG.c  0.1499 1.092 0.62095 
Transport Ser Flux  Ser.e <-> Ser 0 2.4757 1.23785 
 Ala Flux  Ala.e <-> Ala 0 0.2092 0.1046 
 Asp Flux  Asp.e <-> Asp 0 3.4407 1.72035 
 Lac Flux  Lac.e <-> Lac 0 0.1598 0.0799 
 Gly Flux  Gly.e <-> Gly 0 0.4771 0.23855 
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Table 4-A-7. Net fluxes of high expressing (HE) during lactate producing phase.  Associated 
with Figure 4-4. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P 2.434 3.003 2.719 
 PFK F6P -> DHAP + GAP 2.413 2.960 2.687 
 TPI  DHAP <-> GAP 2.380 2.927 2.653 
 GADPH  GAP <-> 3PG 4.772 5.867 5.319 
 Eno  3PG <-> PEP 4.686 5.773 5.230 
 PK PEP -> Pyr 4.686 5.773 5.230 
 HK Glc -> G6P 2.534 3.081 2.807 
 LDH  Lac <-> Pyr -3.982 -2.464 -3.223 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.237 0.119 
 R5PE  Ru5P <-> X5P -0.045 0.116 0.035 
 R5PI  Ru5P <-> R5P 0.039 0.121 0.080 
 TK1  X5P + R5P <-> GAP + S7P -0.023 0.058 0.018 
 TK2  S7P + GAP <-> E4P + F6P -0.023 0.058 0.018 
  TK3  X5P + E4P <-> GAP + F6P -0.023 0.058 0.018 
TCA PDH Pyr -> AcCoA + CO2 1.900 3.313 2.607 
 SDH  Suc <-> Fum 1.927 3.470 2.699 
 Fum  Fum <-> Mal 1.927 3.470 2.699 
 MDH  Mal <-> OAA 1.686 3.103 2.395 
 CS OAA + AcCoA -> Cit 2.095 3.577 2.836 
 ADH aKG.m -> Suc + CO2 1.914 3.449 2.681 
 IDH Cit <-> aKG.m + CO2 1.423 2.903 2.163 
Transport Glc IN Glc.e -> Glc 2.534 3.081 2.807 
 Lys IN Lys.e -> Lys 0.215 0.309 0.262 
 Thr IN Thr.e -> Thr 0.098 0.134 0.116 
 Phe IN Phe.e -> Phe 0.060 0.094 0.077 
 Tyr IN Tyr.e -> Tyr 0.015 0.049 0.032 
 Val IN Val.e -> Val 0.105 0.137 0.121 
 Leu IN Leu.e -> Leu 0.143 0.179 0.161 
 Ile IN Ile.e -> Ile 0.082 0.113 0.097 
 Trp IN Trp.e -> Trp 0.011 0.047 0.029 
 His IN His.e -> His 0.062 0.112 0.087 
 Met IN Met.e -> Met 0.036 0.081 0.058 
 Ser Flux  Ser.e <-> Ser 0.330 0.499 0.414 
 Ala Flux  Ala.e <-> Ala -0.461 -0.355 -0.408 
 Arg Flux  Arg.e <-> Arg 0.096 0.161 0.128 
 Asp Flux  Asp.e <-> Asp -0.113 -0.052 -0.082 
 Gln Flux  Gln.e <-> Gln 0.579 0.746 0.663 
 Pro Flux  Pro.e <-> Pro 0.079 0.091 0.085 
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 Asn Flux  Asn.e <-> Asn 0.337 0.455 0.396 
 Lac Flux  Lac.e <-> Lac -3.982 -2.464 -3.223 
 Gly Flux  Gly.e <-> Gly 0.079 0.116 0.098 
 Cys Flux  Cys.e <-> Cys 0.050 0.102 0.076 
 Glu Flux  Glu.e <-> Glu.c -0.025 0.054 0.014 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.000 0.066 0.033 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.101 0.051 
Anaplerosis ME Mal -> Pyr + CO2 0.820 1.175 0.998 
 PC Pyr + CO2 -> OAA 0.189 0.487 0.338 
 ACL Cit -> AcCoA.c + Mal 0.626 0.719 0.672 
Amino GLS  Gln <-> Glu.m 0.490 0.659 0.575 
Acid ASNS  Asp <-> Asn -0.376 -0.259 -0.317 
Metabolism SHT  Ser <-> Gly + MEETHF 0.065 0.087 0.076 
 CYST  Ser <-> Cys 0.191 0.410 0.300 
 GS + SHT CO2 + MEETHF -> Gly 0.000 0.016 0.008 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.043 0.022 
 PheTyr Mtbl Phe -> Tyr 0.000 0.035 0.017 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.029 0.015 
 Histidase His -> FormTHF + Glu.c 0.023 0.073 0.048 
 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.000 0.026 0.013 
 Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.000 0.035 0.017 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.071 0.166 0.118 
 *GDH  aKG.m  <-> Glu.m -0.666 -0.491 -0.579 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.619 -0.502 -0.561 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.000 0.025 0.012 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu.c 
0.000 0.025 0.012 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + 
AcCoA + AcCoA + Glu.c 
0.000 0.016 0.008 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + 
CO2 + ProCoA 
0.000 0.024 0.012 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + 
Glu.c + aKetoadi 
0.062 0.152 0.107 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.172 -0.042 -0.107 
 *Arg Mtbl 
Arg + aKG.c  -> Glu.c + Urea + 
Glu.c 
0.000 0.057 0.029 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.071 0.176 0.123 
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  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.252 0.461 0.357 
Biomass 
Production 
Biomass 341 pg 
0.2046*Ala + 0.1285*Arg + 
0.1609*Asp + 0.0983*Asn + 
0.0494*Cys + 0.1098*Gln + 
0.1316*Glu.c + 0.2244*Gly + 
0.0487*His + 0.1105*Ile + 
0.1924*Leu + 0.1943*Lys + 
0.0471*Met + 0.0747*Phe + 
0.1068*Pro + 0.1504*Ser + 
0.1316*Thr + 0.015*Trp + 
0.0621*Tyr + 0.1419*Val + 
0.0984*G6P + 0.0794*R5P + 
0.087*MEETHF + 0.0415*DHAP + 
0.844*AcCoA.c -> Biomass 
0.7414 0.8518 0.7966 
 
Table 4-A-8. Exchange fluxes of high expressing (HE) during lactate producing phase.  
Associated with Figure 4-4. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
TCA IDH  Cit <-> aKG.m + CO2 0.0411 1.5426 0.79185 
Amino GLS  Gln <-> Glu.m 0 0.445 0.2225 
Acid ASNS  Asp <-> Asn 0 1.8344 0.9172 
Metabolism SHT  Ser <-> Gly + MEETHF 0.2508 0.673 0.4619 
 ALT  Ala + aKG.c  <-> Pyr + Glu.c 0 1.7645 0.88225 
  AST  OAA + Glu.c <-> Asp + aKG.c  0.4405 1.2755 0.858 
Transport Lac Flux  Lac.e <-> Lac 0 0.1112 0.0556 
 Ser Flux  Ser.e <-> Ser 0 0.4395 0.21975 
 Ala Flux  Ala.e <-> Ala 0 0.1405 0.07025 
 Asp Flux  Asp.e <-> Asp 0 2.8274 1.4137 
 Gly Flux  Gly.e <-> Gly 0 0.0915 0.04575 
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Table 4-A-9. Net fluxes of control during lactate consuming phase.  Associated with Figure 
4-7. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P -1.099 0.941 -0.079 
 PFK F6P -> DHAP + GAP 0.124 0.938 0.531 
 TPI  DHAP <-> GAP 0.159 0.936 0.547 
 GADPH  GAP <-> 3PG 0.864 1.872 1.368 
 Eno  3PG <-> PEP 0.678 1.564 1.121 
 PK PEP -> Pyr 0.678 1.564 1.121 
 HK Glc -> G6P 0.680 0.960 0.820 
 LDH  Lac <-> Pyr 0.563 0.716 0.640 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 2.091 1.045 
 R5PE  Ru5P <-> X5P -0.005 1.307 0.651 
 R5PI  Ru5P <-> R5P 0.002 0.643 0.322 
 TK1  X5P + R5P <-> GAP + S7P -0.002 0.653 0.325 
 TK2  S7P + GAP <-> E4P + F6P -0.002 0.653 0.325 
  TK3  X5P + E4P <-> GAP + F6P -0.002 0.653 0.325 
TCA PDH Pyr -> AcCoA + CO2 1.452 2.497 1.974 
 SDH  Suc <-> Fum 1.449 2.595 2.022 
 Fum  Fum <-> Mal.m 1.449 2.595 2.022 
 MDH  Mal.m <-> OAA 1.449 2.595 2.022 
 CS OAA + AcCoA -> Cit 1.550 2.674 2.112 
 ADH aKG.m -> Suc + CO2 1.431 2.571 2.001 
 IDH Cit <-> aKG.m + CO2 1.537 2.630 2.083 
Transport Glc IN Glc.e -> Glc 0.680 0.960 0.820 
 Lys IN Lys.e -> Lys 0.005 0.020 0.013 
 Thr IN Thr.e -> Thr 0.006 0.033 0.020 
 Phe IN Phe.e -> Phe 0.002 0.014 0.008 
 Tyr IN Tyr.e -> Tyr 0.001 0.013 0.007 
 Val IN Val.e -> Val 0.004 0.024 0.014 
 Leu IN Leu.e -> Leu 0.032 0.069 0.050 
 Ile IN Ile.e -> Ile 0.007 0.032 0.020 
 Trp IN Trp.e -> Trp 0.001 0.017 0.009 
 His IN His.e -> His 0.002 0.016 0.009 
 Met IN Met.e -> Met 0.002 0.016 0.009 
 Ser Flux  Ser.e <-> Ser 0.027 0.051 0.039 
 Ala Flux  Ala.e <-> Ala 0.032 0.122 0.077 
 Arg Flux  Arg.e <-> Arg 0.004 0.017 0.010 
 Asp Flux  Asp.e <-> Asp -0.005 0.015 0.005 
 Gln Flux  Gln.e <-> Gln -0.070 0.014 -0.028 
 Pro Flux  Pro.e <-> Pro 0.003 0.010 0.006 
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 Asn Flux  Asn.e <-> Asn -0.104 0.003 -0.051 
 Lac Flux  Lac.e <-> Lac 0.563 0.716 0.640 
 Gly Flux  Gly.e <-> Gly -0.108 -0.052 -0.080 
 Cys Flux  Cys.e <-> Cys 0.000 0.014 0.007 
 Glu Flux  Glu.e <-> Glu.c -0.060 -0.011 -0.035 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.000 0.102 0.051 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.009 0.135 0.072 
Anaplerosis ME Mal.c -> Pyr + CO2 0.026 0.084 0.055 
 PC Pyr + CO2 -> OAA 0.086 0.238 0.162 
 ACL Cit -> AcCoA.c + Mal.c 0.023 0.077 0.050 
Amino GLS  Gln <-> Glu.m -0.076 0.007 -0.035 
Acid ASNS  Asp <-> Asn 0.004 0.109 0.056 
Metabolism SHT  Ser <-> Gly + MEETHF 0.036 0.064 0.050 
 CYST  Ser <-> Cys 0.080 0.429 0.254 
 GS + SHT CO2 + MEETHF -> Gly 0.030 0.058 0.044 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.013 0.007 
 PheTyr Mtbl Phe -> Tyr 0.000 0.007 0.004 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.026 0.013 
 Histidase His -> FormTHF + Glu.c 0.000 0.013 0.006 
 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.000 0.034 0.017 
 Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.000 0.016 0.008 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.000 0.019 0.009 
 *GDH  aKG.m  <-> Glu.m -0.075 0.077 0.001 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.028 0.120 0.074 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.000 0.026 0.013 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu.c 
0.020 0.058 0.039 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal.c + 
AcCoA + AcCoA + Glu.c 
0.002 0.010 0.006 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + 
CO2 + ProCoA 
0.000 0.016 0.008 
 *Lys Mtbl 
Lys + aKG.c + aKG.c   -> Glu.c + 
Glu.c + aKetoadi 
0.000 0.008 0.004 
 *AST  OAA + Glu.c <-> Asp + aKG.c  0.008 0.112 0.060 
 *Arg Mtbl 
Arg + aKG.c  -> Glu.c + Urea + 
Glu.c 
0.000 0.010 0.005 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.107 0.469 0.288 
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  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.089 0.453 0.271 
Biomass 
Production 
Biomass 398 pg 
0.2388*Ala + 0.15*Arg + 
0.1877*Asp + 0.1147*Asn + 
0.0577*Cys + 0.1281*Gln + 
0.1536*Glu.c + 0.2619*Gly + 
0.0569*His + 0.129*Ile + 
0.2245*Leu + 0.2268*Lys + 
0.0549*Met + 0.0872*Phe + 
0.1246*Pro + 0.1755*Ser + 
0.1536*Thr + 0.0175*Trp + 
0.0725*Tyr + 0.1656*Val + 
0.1148*G6P + 0.0927*R5P + 
0.1015*MEETHF + 0.0484*DHAP 
+ 0.9851*AcCoA.c -> Biomass 
0.024 0.078 0.051 
 
Table 4-A-10. Exchange fluxes of control during lactate consuming phase.  Associated with 
Figure 4-7. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
TCA IDH  Cit <-> aKG.m + CO2 0 0.156 0.078 
Amino ASNS  Asp <-> Asn 0 1.0698 0.5349 
Acid SHT  Ser <-> Gly + MEETHF 0.601 3.6638 2.1324 
Metabolism AST  OAA + Glu.c <-> Asp + aKG.c  0.0122 0.3127 0.16245 
Transport Ser Flux  Ser.e <-> Ser 0 0.5414 0.2707 
  Ala Flux  Ala.e <-> Ala 0 0.1874 0.0937 
  Asp Flux  Asp.e <-> Asp 0 0.8411 0.42055 
  Lac Flux  Lac.e <-> Lac 4.9912 26.9638 15.9775 
  Gly Flux  Gly.e <-> Gly 0.0818 0.5432 0.3125 
  Cys Flux  Cys.e <-> Cys 0 3.795 1.8975 
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Table 4-A-11. Net fluxes of low expressing (LE) during lactate consuming phase.  
Associated with Figure 4-7. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P -0.963 0.683 -0.140 
 PFK F6P -> DHAP + GAP 0.101 0.680 0.390 
 TPI  DHAP <-> GAP 0.098 0.681 0.389 
 GADPH  GAP <-> 3PG 0.696 1.355 1.025 
 Eno  3PG <-> PEP 0.431 1.081 0.756 
 PK PEP -> Pyr 0.431 1.081 0.756 
 HK Glc -> G6P 0.564 0.708 0.636 
 LDH  Lac <-> Pyr 0.526 0.687 0.606 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 1.621 0.811 
 R5PE  Ru5P <-> X5P -0.004 1.077 0.536 
 R5PI  Ru5P <-> R5P 0.003 0.544 0.273 
 TK1  X5P + R5P <-> GAP + S7P -0.002 0.539 0.268 
 TK2  S7P + GAP <-> E4P + F6P -0.002 0.539 0.268 
  TK3  X5P + E4P <-> GAP + F6P -0.002 0.539 0.268 
TCA PDH Pyr -> AcCoA + CO2 1.252 1.992 1.622 
 SDH  Suc <-> Fum 1.245 2.042 1.643 
 Fum  Fum <-> Mal.m 1.245 2.042 1.643 
 MDH  Mal.m <-> OAA 1.245 2.042 1.643 
 CS OAA + AcCoA -> Cit 1.343 2.112 1.727 
 ADH aKG.m -> Suc + CO2 1.236 2.026 1.631 
 IDH Cit <-> aKG.m + CO2 1.280 2.063 1.671 
Transport Glc IN Glc.e -> Glc 0.564 0.708 0.636 
 Lys IN Lys.e -> Lys 0.009 0.018 0.013 
 Thr IN Thr.e -> Thr 0.006 0.016 0.011 
 Phe IN Phe.e -> Phe 0.003 0.009 0.006 
 Tyr IN Tyr.e -> Tyr 0.001 0.008 0.004 
 Val IN Val.e -> Val 0.007 0.014 0.010 
 Leu IN Leu.e -> Leu 0.027 0.054 0.040 
 Ile IN Ile.e -> Ile 0.007 0.025 0.016 
 Trp IN Trp.e -> Trp 0.002 0.014 0.008 
 His IN His.e -> His 0.002 0.010 0.006 
 Met IN Met.e -> Met 0.003 0.014 0.008 
 Ser Flux  Ser.e <-> Ser 0.019 0.038 0.028 
 Ala Flux  Ala.e <-> Ala 0.008 0.053 0.030 
 Arg Flux  Arg.e <-> Arg 0.006 0.014 0.010 
 Asp Flux  Asp.e <-> Asp 0.001 0.017 0.009 
 Gln Flux  Gln.e <-> Gln -0.004 0.007 0.001 
 Pro Flux  Pro.e <-> Pro 0.005 0.010 0.007 
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 Asn Flux  Asn.e <-> Asn 0.025 0.037 0.031 
 Lac Flux  Lac.e <-> Lac 0.526 0.687 0.606 
 Gly Flux  Gly.e <-> Gly -0.089 -0.061 -0.075 
 Cys Flux  Cys.e <-> Cys 0.000 0.011 0.006 
 Glu Flux  Glu.e <-> Glu.c -0.040 -0.016 -0.028 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.000 0.063 0.032 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.027 0.093 0.060 
Anaplerosis ME Mal.c -> Pyr + CO2 0.039 0.075 0.057 
 PC Pyr + CO2 -> OAA 0.024 0.099 0.062 
 ACL Cit -> AcCoA.c + Mal.c 0.039 0.075 0.057 
Amino GLS  Gln <-> Glu.m -0.012 -0.001 -0.006 
Acid ASNS  Asp <-> Asn -0.031 -0.018 -0.024 
Metabolism SHT  Ser <-> Gly + MEETHF 0.040 0.056 0.048 
 CYST  Ser <-> Cys 0.085 0.437 0.261 
 GS + SHT CO2 + MEETHF -> Gly 0.035 0.049 0.042 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.011 0.005 
 PheTyr Mtbl Phe -> Tyr 0.000 0.003 0.002 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.007 0.004 
 Histidase His -> FormTHF + Glu.c 0.000 0.007 0.003 
 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.000 0.017 0.009 
 Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.001 0.013 0.007 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.001 0.013 0.007 
 *GDH  aKG.m  <-> Glu.m -0.059 0.012 -0.024 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.001 0.047 0.024 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.000 0.017 0.009 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu.c 
0.014 0.040 0.027 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal.c + 
AcCoA + AcCoA + Glu.c 
0.000 0.004 0.002 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + 
CO2 + ProCoA 
0.000 0.004 0.002 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + 
Glu.c + aKetoadi 
0.000 0.003 0.002 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.033 -0.012 -0.022 
 *Arg Mtbl 
Arg + aKG.c  -> Glu.c + Urea + 
Glu.c 
0.000 0.006 0.003 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.120 0.470 0.295 
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  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.092 0.444 0.268 
Biomass 
Production 
Biomass 363 pg 
0.2178*Ala + 0.1368*Arg + 
0.1712*Asp + 0.1046*Asn + 
0.0526*Cys + 0.1168*Gln + 
0.1401*Glu.c + 0.2389*Gly + 
0.0519*His + 0.1176*Ile + 
0.2048*Leu + 0.2069*Lys + 
0.0501*Met + 0.0796*Phe + 
0.1136*Pro + 0.1601*Ser + 
0.1401*Thr + 0.016*Trp + 
0.0661*Tyr + 0.151*Val + 
0.1047*G6P + 0.0845*R5P + 
0.0926*MEETHF + 0.0441*DHAP 
+ 0.8985*AcCoA.c -> Biomass 
0.043 0.084 0.063 
 
Table 4-A-12. Exchange fluxes of low expressing (LE) during lactate consuming phase.  
Associated with Figure 4-7. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Amino ASNS  Asp <-> Asn 0.0258 0.6596 0.3427 
Acid SHT  Ser <-> Gly + MEETHF 0.5905 3.2054 1.89795 
Metabolism AST  OAA + Glu.c <-> Asp + aKG.c  0.1124 0.4211 0.26675 
Transport Ala Flux  Ala.e <-> Ala 0 0.2283 0.11415 
 Asp Flux  Asp.e <-> Asp 0 0.6642 0.3321 
 Asn Flux  Asn.e <-> Asn 0 26.6412 13.3206 
 Gly Flux  Gly.e <-> Gly 0.0806 0.529 0.3048 
 Cys Flux  Cys.e <-> Cys 0 5.4663 2.73315 
 Lac Flux  Lac.e <-> Lac 6.0184 251.1219 128.57 
 Ser Flux  Ser.e <-> Ser 0 0.5697 0.28485 
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Table 4-A-13. Net fluxes of high expressing (HE) during lactate consuming phase.  
Associated with Figure 4-7. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
Glycolysis PGI  G6P <-> F6P -0.679 0.685 0.003 
 PFK F6P -> DHAP + GAP 0.196 0.683 0.439 
 TPI  DHAP <-> GAP 0.174 0.681 0.428 
 GADPH  GAP <-> 3PG 0.811 1.363 1.087 
 Eno  3PG <-> PEP 0.391 0.985 0.688 
 PK PEP -> Pyr 0.391 0.985 0.688 
 HK Glc -> G6P 0.573 0.696 0.634 
 LDH  Lac <-> Pyr 0.697 0.826 0.761 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 1.384 0.692 
 R5PE  Ru5P <-> X5P -0.003 0.881 0.439 
 R5PI  Ru5P <-> R5P 0.001 0.443 0.222 
 TK1  X5P + R5P <-> GAP + S7P -0.001 0.441 0.220 
 TK2  S7P + GAP <-> E4P + F6P -0.001 0.441 0.220 
  TK3  X5P + E4P <-> GAP + F6P -0.001 0.441 0.220 
TCA PDH Pyr -> AcCoA + CO2 1.471 2.087 1.779 
 SDH  Suc <-> Fum 1.570 2.202 1.886 
 Fum  Fum <-> Mal.m 1.570 2.202 1.886 
 MDH  Mal.m <-> OAA 1.570 2.202 1.886 
 CS OAA + AcCoA -> Cit 1.630 2.233 1.931 
 ADH aKG.m -> Suc + CO2 1.552 2.184 1.868 
 IDH Cit <-> aKG.m + CO2 1.577 2.206 1.891 
Transport Glc IN Glc.e -> Glc 0.573 0.696 0.634 
 Lys IN Lys.e -> Lys 0.003 0.011 0.007 
 Thr IN Thr.e -> Thr 0.002 0.009 0.006 
 Phe IN Phe.e -> Phe 0.001 0.007 0.004 
 Tyr IN Tyr.e -> Tyr 0.000 0.007 0.004 
 Val IN Val.e -> Val 0.002 0.011 0.006 
 Leu IN Leu.e -> Leu 0.033 0.055 0.044 
 Ile IN Ile.e -> Ile 0.011 0.025 0.018 
 Trp IN Trp.e -> Trp 0.003 0.012 0.007 
 His IN His.e -> His 0.001 0.009 0.005 
 Met IN Met.e -> Met 0.002 0.012 0.007 
 Ser Flux  Ser.e <-> Ser 0.034 0.049 0.042 
 Ala Flux  Ala.e <-> Ala 0.038 0.066 0.052 
 Arg Flux  Arg.e <-> Arg 0.003 0.011 0.007 
 Asp Flux  Asp.e <-> Asp 0.004 0.016 0.010 
 Gln Flux  Gln.e <-> Gln -0.062 0.014 -0.024 
 Pro Flux  Pro.e <-> Pro 0.002 0.006 0.004 
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 Asn Flux  Asn.e <-> Asn -0.129 -0.034 -0.081 
 Lac Flux  Lac.e <-> Lac 0.697 0.826 0.761 
 Gly Flux  Gly.e <-> Gly -0.094 -0.068 -0.081 
 Cys Flux  Cys.e <-> Cys -0.001 0.009 0.004 
 Glu Flux  Glu.e <-> Glu.c -0.016 -0.001 -0.008 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.000 0.055 0.028 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.063 0.032 
Anaplerosis ME Mal.c -> Pyr + CO2 0.014 0.047 0.030 
 PC Pyr + CO2 -> OAA 0.075 0.180 0.128 
 ACL Cit -> AcCoA.c + Mal.c 0.013 0.045 0.029 
Amino GLS  Gln <-> Glu.m -0.066 0.010 -0.028 
Acid ASNS  Asp <-> Asn 0.038 0.131 0.084 
Metabolism SHT  Ser <-> Gly + MEETHF 0.039 0.053 0.046 
 CYST  Ser <-> Cys 0.212 0.564 0.388 
 GS + SHT CO2 + MEETHF -> Gly 0.036 0.049 0.043 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.010 0.005 
 PheTyr Mtbl Phe -> Tyr 0.000 0.004 0.002 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.005 0.003 
 Histidase His -> FormTHF + Glu.c 0.000 0.007 0.004 
 
CBXase + 
Mutase 
ProCoA + CO2 -> Suc 0.007 0.023 0.015 
 Trp Mtbl 
Trp -> CO2 + CO2 + Ala + 
aKetoadi 
0.002 0.012 0.007 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA 
+ AcCoA 
0.002 0.012 0.007 
 *GDH  aKG.m  <-> Glu.m -0.033 0.066 0.016 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.037 0.067 0.052 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.007 0.021 0.014 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + 
AcCoA + AcCoA + AcCoA + Glu.c 
0.026 0.048 0.037 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal.c + 
AcCoA + AcCoA + Glu.c 
0.000 0.006 0.003 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + 
CO2 + ProCoA 
0.000 0.006 0.003 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + 
Glu.c + aKetoadi 
0.000 0.003 0.002 
 *AST  OAA + Glu.c <-> Asp + aKG.c  0.034 0.124 0.079 
 *Arg Mtbl 
Arg + aKG.c  -> Glu.c + Urea + 
Glu.c 
0.000 0.007 0.004 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.226 0.578 0.402 
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  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.227 0.571 0.399 
Biomass 
Production 
Biomass 341 pg 
0.2046*Ala + 0.1285*Arg + 
0.1609*Asp + 0.0983*Asn + 
0.0494*Cys + 0.1098*Gln + 
0.1316*Glu.c + 0.2244*Gly + 
0.0487*His + 0.1105*Ile + 
0.1924*Leu + 0.1943*Lys + 
0.0471*Met + 0.0747*Phe + 
0.1068*Pro + 0.1504*Ser + 
0.1316*Thr + 0.015*Trp + 
0.0621*Tyr + 0.1419*Val + 
0.0984*G6P + 0.0794*R5P + 
0.087*MEETHF + 0.0415*DHAP + 
0.844*AcCoA.c -> Biomass 
0.016 0.053 0.034 
 
Table 4-A-14. Exchange fluxes of high expressing (HE) during lactate consuming phase.  
Associated with Figure 4-7. 
 
Pathway Enzyme Rxn 
LB 
95% CI 
UB 95% 
CI 
Value 
TCA SDH Suc <-> Fum 0 1.2803 0.64015 
 IDH Cit <-> aKG.m + CO2 0 0.2198 0.1099 
Amino GLS Gln <-> Glu.m 0.2211 0.5161 0.3686 
Acid ASNS Asp <-> Asn 0 1.0827 0.54135 
Metabolism SHT Ser <-> Gly + MEETHF 0.9106 2.6605 1.78555 
  AST  OAA + Glu.c <-> Asp + aKG.c  0 0.2804 0.1402 
Transport Ser Flux Ser.e <-> Ser 0 0.6406 0.3203 
 Ala Flux Ala.e <-> Ala 0 0.2297 0.11485 
 Asp Flux Asp.e <-> Asp 0 0.8068 0.4034 
 Gly Flux Gly.e <-> Gly 0.1709 0.6083 0.3896 
 Cys Flux Cys.e <-> Cys 0 0.6056 0.3028 
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V: GLUTAMINE EXHAUSTION INDUCES LACTATE CONSUMPTION 
 
Abstract 
The push toward higher cell densities and product titers in mammalian cell bioprocesses 
is often accompanied by accumulation of inhibitory metabolites such as lactate. Accumulation of 
these toxic by-products is a predominant cause of cell death.  Additionally, lactate accumulation 
is an indication that carbon sources are being used inefficiently, thus reducing yields of antibody 
and biomass. Therefore, we are investigating the causes of lactate accumulation and how it can 
be reversed by genetic engineering and/or medium optimization strategies.   
We and others have observed that CHO (Chinese Hamster Ovary) cells are capable of not 
only producing but also consuming lactate under certain conditions. The switch to lactate 
consumption often accompanies the depletion of a preferred carbon source (such as glucose or 
glutamine) from the growth medium. In shake flask experiments, we observed that the specific 
lactate production rate was halved when the medium glutamine concentration was reduced from 
8 to 4 mM.  This corresponded with more efficient growth (30% higher specific growth rate and 
40% higher peak viable cell density) as well as a 70% decrease in specific glucose consumption 
rate.  Therefore, by reducing glutamine availability we were able to shift cell culture to a more 
efficient metabolic state involving both increased growth rate and decreased nutrient uptake.   
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Introduction  
The increasing demand for protein based drugs, specifically monoclonal antibodies, has 
neatly corresponded with their clinical value in treatment of an increasing variety of diseases [1].  
In 1987, with the protein therapeutic production market still largely in its infancy, the industry 
standard was 100 mg/L final antibody concentration.  In 2007, significant progress had been 
made as select antibodies were reaching a final concentration of 5 g/L [2].  However, demands 
for this class of drug are still rising.  In 1995 antibodies were 1% of the biopharmaceutical 
market.  They were 22% of the market in 2002.  Currently biopharmaceuticals (antibodies 
included) represent 10-25% of all new drugs to hit the US market  [3].  This type of growth will 
not remain sustainable, as costs to the consumer are already remarkably high, without continued 
process innovation [4]. 
Lactate production from animal cell cultures has inhibited product generation for the past 
30 years.  In spite of all the innovation, lactate inhibition continues to be a significant problem.  
It not only requires energy from the cell that could have been used to produce antibody (poor 
efficiency), but additionally can begin to limit culture viability if sufficient concentrations are 
reached [2].  Additionally, there is less biomass generation as much of the incoming flux is going 
to produce lactate  Traditionally companies have combated lactate accumulation by controlling 
the glucose feed, as when glucose is limiting the culture produces less lactate [5].  However, 
even though the lactate problem might be solved, another is created.  When glucose is limited, 
many other fluxes are limited as well, including antibody production.   
To control lactate production, other techniques that impose less consequences upon 
antibody production, are being explored.  One method is limiting a specific nutrient’s availability 
to determine if lactate accumulation can be halted or even reversed.  We will quantify the impact 
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of nutrient availability through metabolic flux analysis (MFA) [6], a technique that is 
surprisingly uncommon in the cell culture industry.  This makes our work novel to the industry.  
This lab seeks to measure the changes brought about by environmental changes to the cell wide 
metabolism.  Only when a metabolic network is developed, can the holistic impact be determined 
on the cell.   
Chinese hamster ovary (CHO) cells are used in this study as they are widely used in the 
industry for monoclonal antibody production.  Currently, this cell line produces over 25 protein 
therapeutics, many of them being monoclonal antibodies [2].  They remain a popular choice for 
monoclonal antibody production because of their relative ease to perform a stable genetic 
modification upon (many genetic modifications are transient). 
 
Materials and Methods 
Cell line and medium 
CHO-S, obtained from Invitrogen, is exclusively used for this study.  CHO-S was 
cultured in CD-CHO, a proprietary Invitrogen media.  Its contents, though widely known 
through independent measurement and quantification by this lab, are not accessible to the general 
public.   
 
Shake Flask operation 
A batch shake flask setup was developed to separately culture CHO-S in different 
experimental conditions.  To do this, 125mL glass Erlenmeyer flasks were used.  The culture is 
buffered from a filtered 10% CO2 (mixed with air) feed into the head space of the flask and gases 
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are released into environment.  The temperature and agitation rate are controlled by a Thermo 
Scientific Max Q 4000.  Samples are taken through a hypodermic needle at regular intervals.   
 
Analytical Methods 
To determine amino acid concentrations of the media as they were cultured over time, an 
Agilent 1200 Series HPLC was used with a C18 column and multiple wavelength UV detector.  
A precolumn derivitization took place using OPA (O-phthaldialdehyde), as described in 
published method [7].  Glucose and lactate concentrations were determined using an YSI 2300 
STAT Plus.  Viable cell density was determined using a hemocytometer using 0.1% (w/v) trypan 
blue to dilute and stain.  To determine intracellular metabolite concentrations an Agilent 7890A 
gas chromatography was used in conjunction with an Agilent 5975C mass spec. 
 
Extracellular Metabolite Flux 
Determination of extracellular fluxes is critical to the constraint of your overall metabolic 
network.  Intracellular fluxes are inherently constrained by the incoming and outgoing fluxes of 
the cell.  This equation assumes that the culture is at steady state in growth rate as well as 
metabolic flux of interest.  The equation is reported as found in the literature [8].  The qs term is 
the specific rate of production (or consumption), and the µ term specific growth rate.  S is the 
substrate concentration, and S0 the initial concentration.  X0 is the initial cell concentration. 
[𝑆] = [𝑆]0 +
𝑞𝑠𝑋0
µ
(𝑒µ𝑡 − 1) (5-1) 
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Glutamine degrades spontaneously in addition to the cellular uptake of it, so it has a different 
version of the above equation for determination of extracellular flux [9].  The decomposition was 
determined to be first order with respect to glutamine concentration, and was experimentally 
determined to be 0.081 days-1.  The equation used for glutamine flux is: 
[𝐺𝐿𝑁] = [𝐺𝐿𝑁]0𝑒
−𝑘𝑡 +
𝑞𝐺𝐿𝑁(𝑒
−𝑘𝑡−𝑒µ𝑡)
𝑘+µ
𝑋0 (5-2) 
There is only one time in the cell growth cycle that steady state exists: the exponential phase.  
Subsequently, all the flux measurements are specific to the exponential phase of cell growth. 
 
Intracellular Metabolite Determination 
To determine intracellular metabolite concentration, the following process was used in 
the stated order.  Quenching is first and required to cease all metabolic activity.  To this end, 
ammonium bicarbonate (AMBIC) (0.85% w/v) is mixed in a 60/40 methanol/Water solution and 
cooled to -40°C [10] and the temperature maintained in a CaCl solution [11].  After drawing 
enough media to quench 10 million cells, the cell laden media is forcefully ejected into the 
quench solution to allow for rapid cooling.  
Extraction is then required to remove all the metabolites from the cell [12].  
Derivatization is necessary as without it the metabolites of interest are not volatile enough to be 
analyzed in GC/MS [13].  A MOX-TBDMS (tert-butyl-dimethy-silyl) derivatization is used.   
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Results and Discussion 
In the cell culture world, there are several variants of CHO.  Some exhibit the ability to 
readily consume lactate, many do not.  The reason why some cells have this ability can be as 
simple as enzyme expression (notably lactate dehydrogenase) to convert lactate back into 
pyruvate.  However, even when the cell does express the enzyme, lactate production still occurs, 
sometimes at a rate that becomes toxic to the cell.  Increased lactate production is a common trait 
in nearly all immortalized cell lines, but for reasons that are not fully understood.  One of the 
more common explanations has to do with managing the redox balance (in NADH/NAD+) 
associated with energy production of ATP, the central energy currency of biology.   
Methods for limiting lactate accumulation in the industry are straightforward, limit 
glucose availability and lactate levels will remain low [14].  Inherently, this limits antibody 
production.  This is the reason why the ability of a culture to consume the lactate that it produces 
is a huge advantage.  CHO-S has this native ability, where other varieties such as CHO-K1, will 
largely accumulate lactate.  We and others have observed this effect [15].   
 
Figure 5-1. Lactate and glutamine profiles (8 mM [GLN]).  Bar chart is representative of 
fluxes of lactate and glutamine.   
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Taking note of Figure 5-1, one can see when the glutamine is close to being exhausted 
from the culture, net lactate production switches to net consumption.  It also represents a novel 
way to approach the lactate problem.  If one could limit the amount of glutamine available, it 
might be possible to continually force the cell to consume the lactate that it had produced.  This 
is a concept that to our knowledge has not been directly explored at this point based upon 
existing literature.  As can be seen in Figure 5-2, glutamine is exhausted and lactate consumed 
while the culture is exiting exponential growth.  This represents a significant shift in intracellular 
fluxes as the incoming nutrient source has changed.  A glucose profile and flux is also 
determined to exhibit the most significant incoming flux in the cell.  As mentioned prior, glucose 
availability is a significant factor in lactate production. 
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A. 
B.  
Figure 5-2.  Growth and glucose profiles (8 mM [GLN]).  A.  Growth profile and growth rate 
of CHO-S.  B.  Glucose concentration profile and representative flux. 
 
The potential of limiting glutamine to limit lactate was further explored.  To do so, a 
similar experiment was designed where the initial glutamine concentration was halved to 4mM.  
Lactate was further reduced, and interestingly enough, again corresponded with the exhaustion of 
glutamine from the culture (Figure 5-3).   
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Figure 5-3.  Lactate and glutamine profiles (4 mM [GLN]).  Fluxes of lactate and glutamine 
plotted on same scale as 8mM [GLN]. 
 
These results indicate a lactate production rate that is less than half of the higher glutamine 
concentration.  Upon observation of the growth profile (Figure 5-4), it can be seen that in spite of 
reduced nutrient availability, the culture was able to thrive, maintain, and even slightly increase 
growth rate.  The fact that glucose consumption was reduced and growth rate was maintained in 
spite of limited glutamine suggests that the cell was forced into a more efficient state of 
metabolism.  Less lactate was made and more biomass was generated. 
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A.  
B.  
Figure 5-4.  Growth and glucose characterization.  A.  Growth profile and growth rate of 
CHO-S with 4mM initial concentration of glutamine.  B.  Glucose concentration profile and 
representative flux. 
 
The reprogramming of the metabolic network occurring during the lactate “switch” is of 
utmost interest.  Metabolic flux analysis would provide a fundamental understanding of how a 
cell is performing in these specific conditions.  To this end, an appropriate quenching method 
was explored.  As mentioned in the methods, a NaCl quench [16] and AMBIC quench were each 
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Figure 5-5. Total ion counts (y-axis) of various metabolites as determined with GC/MS.  Direct 
comparison between quenching methods to determine which method provides greater recovery. 
 
Each of the isotopic fragments (bound to TBDMS derivative) shown are what separated 
into the polar phase during extraction (both organic and polar phases are generated).  These are 
the total ion counts that were measured for with within the range of 300,000-and 30,000,000.  
Other metabolites that did not fall inside this range are not shown, as the ion detector used is not 
accurate outside of this range.  It should be noted that the total ion counts achieved for the NaCl 
quench were in general high enough to accurately measure for.  However, it is more difficult to 
say whether or not the composition measured for in the GC/MS is comparable to the composition 
inside a cell due to the low recovery.   
 
Conclusions 
Metabolic flux analysis has already proven its resourcefulness in determining 
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metabolic network will provide new information regarding the causes of lactate accumulation, an 
issue that has troubled the protein therapeutic industry for 30 years.  With a metabolic network, 
media compositions can be optimized or genetic modifications can appropriately be made.  To 
this end, future work will involve quantifying the differences between the wild type CHO and 
CHO that has been engineered to over express proteins that provide death pathway resistance.  
Other research has already shown the advantages to doing this [15], especially when multiple 
genes are expressed.  This is another research pursuit that will be attacked in parallel with media 
formulations.  Having a reliable means to measure for metabolite concentrations, which has now 
been determined, will prove to be a critical marker in further applying MFA.  
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VI: THE METABOLIC REPROGRAMMING OF INDUSTRIAL ANTIBODY EXPRESSING 
CHO 
 
Abstract 
Eleven CHOK1SV clones were cultured in three-liter fed-batch reactors, and 13C MFA 
was applied to assess the early stationary phase of metabolism.  Eight of the clones used the 
glutamine synthetase (GS) expression system to express IgG.  Four of the clones were 
genetically manipulated to be apoptosis-resistant, expressing engineered Bcl-2Δ.  Central 
metabolism was significantly altered in response to the added metabolic load of antibody 
production.  As net NADH production by TCA cycle and glycolysis increased in CHOK1SV, 
specific antibody production likewise increased.  The expression of Bcl-2Δ led to a further 
increase in NADH production that was accompanied by even greater specific mAb productivity.  
Increased TCA cycling, and decreased lactate production, were also independently associated 
with specific productivity.  However, while lactate production was reduced in high-producing 
clones, total glycolytic flux increased in relation to specific productivity.  Furthermore, high-
producing clones generated recombinant protein at a rate roughly equivalent to that of biomass-
associated protein (carbon molar basis).  These findings underscore the connection between 
oxidative metabolic states and recombinant antibody generation, and define the unique metabolic 
alterations inherent in industrial cell culture. 
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Introduction 
 
In previous work, metabolic flux analysis (MFA) has been successfully applied to 
individual IgG producing CHO clones cultured in fed-batch.  GS-CHO lines were studied in 
five-liter bioreactors, where dissolved oxygen, partial CO2 pressure, and temperature were 
optimized [1] for the stationary phase.  It was later applied to a DHFR-CHO line grown in 24 
deep-well plates, and assessed at four different stages of culture, including the stationary phase 
[2].  Since culture conditions change substantially over the time course of a fed-batch, multiple 
phases were considered to determine how central metabolism rewires itself over the course of a 
run.  MFA has also been applied to better understand the relationship between metabolism and 
apoptosis [3], and anti-apoptosis engineering has been successfully applied to increase final 
product titer in fed-batch culture [4].   
In this work, we sought to find common metabolic phenotypes associated with high 
specific productivity.  We examined the early stationary phase, as specific productivity was 
previously determined to begin to peak during this phase.  Since Bcl-2Δ expression has been 
previously shown to have increased mitochondrial enzymatic activity and reduced lactate 
production, traits associated with increased specifc productivity, we also assess the utility of 
expressing Bcl-2Δ expressing clones.  A total of four unique IgGs were produced, both by 
CHOK1SV-GS and a Bcl-2Δ clone, making for a total of eight clones.  Additionally, non-
producing CHOK1SV and Bcl-2Δ clones are considered to better understand how central 
metabolism responds to forced IgG expression. While this study is by no means a large scale 
study for industrial cell culture work, it is to our knowledge the largest 13C MFA study ever 
conducted upon IgG producing CHO cells.  This large scale 13C MFA was conducted to 
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differentiate between the metabolic phenotypes unique to individual clones, and the observable 
metabolic trends amongst multiple producing clones. 
 
Materials and Methods 
 
Cell Culture 
 Eleven different Lonza CHOK1-SV lines were cultured at Janssen.  Three of the lines 
functionally served as non-producing controls: CHOK1SV, CHOK1SV-GS, and Bcl-2Δ.  
CHOK1SV served as the parent to the other ten lines, and in addition to not producing antibody, 
is the only heterogenous (non-clonal) line.  The other ten lines are clonal.  CHOK1SV-GS was 
transfected with a blank GS plasmid, and it contained neither light nor heavy chain.  Bcl-2Δ was 
generated by transfecting CHOK1SV with the engineered anti-apoptotic protein of the same 
name, and following G418 selection, screening for minimal caspase 3/7 activity.  Eight of the 
lines were antibody secreting, all transfected using Lonza’s GS system.  A total of four separate 
monoclonal antibodies were produced, denoted M1M4.  Two of these antibodies are IgG1, one 
IgG2, and one IgG4.  The lineage of the eleven lines is described in Figure 6-1.  
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Figure 6-1.  Cell lines.  A. Genetic lineage of the 11 clones used in this study. B.  Specific 
productivity of 8 IgG producing clones. 
 
All antibody producing clones were screened for productivity, expression stability, and 
product quality.  Between five to ten thousand clones were examined to obtain a high 
performance clone. 
 
Fed-batch reactor conditions 
 Three -liter Millipore Mobius fed-batch reactors with pH, temperature, agitation, and 
dissolved oxygen (DO) controls were used for cell culture.  pH was set to 7 and maintained 
between 6.9 and 7.1.  Temperature was held at 36.5°C for the entire experiment.  Agitation was 
set to 200 RPM.  Oxygen was set to sparge at 40% DO, maintaining DO between 40-100%.  
Initially, cultures were inoculated into a 1-liter working volume.  Culture volume rose to a final 
working volume of no higher than 1.2 L.  Cultures were grown in batch mode for the first 3 days.  
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Reactors were fed on Day 3 and 4 with glucose, amino acids, vitamins, and minerals. At each 
daily feed addition, glucose was fed to reach 3 g/L concentration.  The non-GS clones, namely 
the parental CHOK1SV and the Bcl-2Δ daughter, were fed glutamine to 6 mM concentration.  
The GS-clones were not supplemented with glutamine.   
 On Day 5 the feeding scheme changed, when glucose was fed to 6 g/L in all reactors and 
glutamine to 8 mM concentration in the non-GS clones.  At day 5, the 13C tracer was introduced, 
and 2 days passed without any additional feeds to the reactor.  A summary of the experimental 
timeline is provided in Table 6-1. 
Table 6-1.  Experimental timeline.  Days 5-7 are shaded to indicate the presence of 13C glucose. 
 
Day 0 1 2 3 4 5 6 7 
Event Inoculate at 4E5 cell/mL    Feed Feed Feed 13C    Final Quench 
 
Cultures were sampled throughout the 7 days, with an increased sampling frequency following 
exposure to 13C glucose. 
 
Determination of specific consumption/production rates 
An Innovatis Cedex was used to determine the cell density.  Amino acid concentration 
was determined using an Agilent 1200 series high performance liquid chromatograph (HPLC).  
Amino acid concentration was accurately quantified by UV absorbance detection, following pre-
injection sample derivatization with orthophthaldildehyde (OPA), according to protocol [5].  
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Glucose, lactate, ammonia, glutamate, glutamine, and IgG concentration were determined using 
a Roche Cedex BioHT.  Specific growth rate was determined by application of the following 
three equations: 
 
𝑑𝑋
𝑑𝑡
= µ𝑛𝑒𝑡𝑋 (6-1) 
𝑑𝑋𝑑
𝑑𝑡
= 𝑘𝑑𝑋 (6-2) 
µ𝑛𝑒𝑡 = µ𝑔 − 𝑘𝑑 (6-3) 
Where net specific growth rate (µnet), specific death rate (kd), and gross growth rate (µg) were 
determined by regressing the viable cell density (X) and dead cell density (Xd).  Specific 
production/consumption rates were determined using the following equation: 
𝑑𝐶𝑖
𝑑𝑡
= 𝑞𝑖𝑋−𝑘𝑖𝐶𝑖 (6-4) 
Where Ci represents the metabolite concentration at the ith measured time, qi the specific 
production rate (negative if consumed), and ki the first order degradation content.  Glutamine 
was the only amino acid found to have a non-negligible degradation constant, with a half life of 
approximately 8 days.  Regression to determine specific rates was performed using the ETA 
software package. 
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Isotope labeling experiments 
 On day 5 of culture, the glucose concentration was raised to 6 g/L.  This glucose addition 
was a 50/50 (by molarity) mixture of [1,2-13C2]glucose and [U-
13C6]glucose, beginning the 
13C 
labeled experiment (Figure 6-A-1).  Since there was no media exchange, natural glucose made 
up between 30-50% of the final glucose concentration post 13C glucose feed.  Cultures were 
quenched several times over the next two days, in order to assess isotopic steady state.  Sufficient 
volume was removed from the reactor to obtain approximately 10 million cells, which were 
immediately quenched in a 60% methanol, 40% ammonium bicarbonate aqueous solution pre-
cooled to -40°C [6].  Once the quenching solution had been removed, polar metabolites were 
extracted using an 8:4:3 chloroform: methanol: water solution [7].  Chloroform and 
water/methanol form a biphasic solution, with the metabolites of interest partitioning to the less 
dense aqueous upper phase. 
 
Gas chromatography mass spectroscopy (GCMS) analysis 
After extraction, the samples were derivatized as described previously [2].  Derivatized 
polar metabolites were injected via split mode into an Agilent 7890B gas chromatograph 
employing an Agilent HP5-MS column (30m x 0.25mm i.d. x 0.25µm).  The split ratio was 
varied from 1:2 to 1:10 in order to achieve accurately quantifiable signal (i.e., sufficient signal-
to-noise ratio without oversaturating the detector).  For the same reason, injection volume was 
varied from 0.5 to 2µL.  The GC inlet was fixed at 270°C, and helium flow rate was 1 mL/min.  
The GC oven was initially set at 80°C and held for 5 minutes, ramped at 20°C/min to 140°C, 
ramped at 4°C/min to 280°C, and held for 5 minutes.  To manage widely varying sample 
metabolite concentrations, the Agilent 5977A MS gain factor was adjusted in timed event mode.  
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Scan mode allowed all mass spectra between 100-500 m/z to be recorded, and raw ion 
chromatograms were integrated using a custom MATLAB program which applied consistent 
integration bounds and baseline corrections to each fragment ion [8].   
 To determine the relative ratio of [1,2-13C2]glucose, [U-
13C6]glucose, and natural glucose, 
Di-O-isopropylidene propionate derivatization was performed.  An Agilent 7890 gas 
chromatograph was used with an Agilent DB-5MS column (30m x 0.25mm i.d. x 0.25µm).  1 µL 
of sample was injected in splitless mode.  Following injection, the GC oven was held at 80°C for 
1 minute, ramped at 20°C/min to 280°C and held for 4 minutes, and again ramped by 40°C/min 
to 325°C and held for 0 minutes. 
 
Reaction network  
A reaction network was generated as described previously [3].  Individual cell dry mass 
was determined for each of the 13 clones used in this study.  In total, there were 111 reactions, 
22 extracellular metabolites, and two macromolecular products (biomass and antibody).   
 
13C metabolic flux analysis (MFA) 
INCA was used to fit a metabolic model [9] to the experimental data, as described 
previously [3].  All models generated were overdetermined with approximately 100 degrees of 
freedom.  Isotopic and metabolic steady-state were independently verified for all 13 cell lines.  
Model visualization was aided by Cytoscape [10].   
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Two-way hierarchical clustering 
 Ward’s method was used to first cluster cell lines, based upon their respective flux map.  
Then, individual reactions were clustered together (making the analysis two-way).  To generate 
the heat map, Z-scores were generated by using the following equation: 
𝑍 =  
𝑉𝑖,𝑗 − 𝑉?̅?
𝑠𝑖,𝑗
 
Where 𝑉𝑖,𝑗 represents an individual carbon flux (e.g., VHK,CHOK1SV), 𝑉?̅? the average carbon flux 
calculated over all cell lines, and 𝑠𝑖,𝑗 the standard deviation associated with flux 𝑉𝑖,𝑗.   
 
Results  
13C metabolic flux analysis was performed upon a parental CHOK1SV line and ten 
daughter clones.  Eight of the eleven lines were selected by Lonza’s glutamine synthetase (GS) 
system, and then industrially screened for immunoglobulin (IgG) expression.  All eight 
producing clones were generated independently, starting from the polyclonal CHOK1SV line.  
Amongst the eight clones, four model IgGs were produced.  Two clones produced IgG1, one 
clone IgG2, and another clone IgG4.  Past experiments concluded that specific productivity was 
at or near its peak during day 5-7 (data not shown).  Therefore, this phase was intentionally 
examined to assess the unique demands posed to central metabolism by antibody production in a 
3L fed-batch reactor.  Fundamentally, the determination of a shared metabolic phenotype among 
high-producing clones is the central objective of this work. 
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Trends of productivity 
 To make for straightforward comparison, the clones have been ranked in order of specific 
productivity (Figure 6-1).  Each IgG is produced by one CHOK1SV and one Bcl-2Δ clone.  For 
this reason, the two clones producing the same IgG are often compared head-to-head.  In ¾ of 
the cases explored in this study, the Bcl-2Δ clone significantly outperformed the CHOK1SV 
clone in specific productivity.   
 To provide insight about the increased metabolic demands required of the cell to produce 
an IgG for industrial purposes, a stoichiometric comparison was performed [11].  Here, the 
protein requirements for biomass production are compared to the antibody production 
requirements (Figure 6-2).   
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Figure 6-2.  Protein demands.  Relative comparison of protein production rates.  Antibody 
production is compared relative to biomass (specifically, the protein content of cellular biomass).  
A ratio of 1 indicates equivalent rates of protein synthesis associated with either biomass or 
antibody production. 
 
By utilizing a compositional analysis of biomass [12], and experimentally determining growth 
rate and dry cell mass, the rate of protein synthesis for biomass on a C-molar basis was 
quantified.  Likewise, the measured specific rate of antibody production was converted to a C-
molar basis by determination of the antibody’s amino acid composition.  In multiple instances, 
protein demand for antibody synthesis exceeded that of biomass.  When the ratio of 
antibody/biomass synthesis is equal to 1, the total protein demand upon the cell doubles. 
 The GS system augments the endogenous capacity of the cell to produce glutamine, 
providing a selectable marker for isolation of stable clones [13].  However, GS was found to also 
lead to the secretion of glutamine into the extracellular media (Figure 6-3A), indicative of 
glutamine synthesis in excess of anabolic demand for protein synthesis.   
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Figure 6-3. Metrics of Glutamine Synthetase (GS) overexpression.  A. Glutamine production. 
Negative values indicate consumption. B. Ammonia consumption. Negative values indicate 
production. 
 
Interestingly, the rate of extracellular glutamine flux was found to correspond negatively with 
specific productivity.  In contrast to the GS-clones, the parental CHOK1SV and Bcl-2Δ lines 
were found to consume glutamine, with Bcl-2Δ consuming glutamine at roughly half the rate of 
the control CHOK1SV.  This was in agreement with previous work using CHO-S [3].   
 Corresponding with glutamine synthesis, the majority of the producing clones consumed 
ammonia.  To produce glutamine, GS adds an amine group to glutamate, which can be provided 
by ammonia.  Ammonia consumption positively correlated with specific productivity, especially 
in the CHOK1SV background (Figure 6-3-B).  The two lines considered without the GS system 
were both found to produce ammonia at rates similar to the ammonia consumption rate of the GS 
clone. 
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Metabolic flux analysis (MFA) 
 Figure 6-4 represents the flux map from 3 separate CHOK1SV lines.  When GS was 
overexpressed, the relative amount of carbon directed to the mitochondria increased.   
 
 
Figure 6-4.  Metabolic flux analysis.  Major carbon fluxes are shown.  Both width and color of 
directional arrows are proportional to the magnitude of carbon flux.   
 
This can largely be attributed to a reduction in lactate production, which was reduced by over 
50% in CHOK1SV-GS when compared to CHOK1SV.  All the more impressive is the impact 
upon central metabolism when a GS-CHO cell is forced to produce antibody.  While total carbon 
consumption decreased by 30% in CHOK1SV-M3 (Figure 6-A-2), increased flux to the TCA 
cycle exceeded 30%.  If the CO2 generating reactions of the TCA cycle were summed together, 
CO2 generation nearly doubled (Figure 6-A-3).  Much of this increase to the TCA cycle can be 
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attributed to a net lactate consumption flux.  As Figure 6-4 demonstrates, an upregulated TCA 
cycle was a hallmark of high specific productivity. 
 Like CHOK1SV-M3, Bcl-2Δ clones demonstrated significantly increased TCA cycling.  
However, not only was the TCA cycle upregulated relative to the parental Bcl-2Δ clone, it was 
upregulated relative to the CHOK1SV producing the equivalent IgG.  This is best represented in 
the heat map of Figure 6-5.   
 
 
Figure 6-5.  Central metabolism fluxes and specific antibody production.  Maps generated 
by two-way hierarchical clustering using Ward’s method. 
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Here, a two-way hierarchical clustering was performed upon the Z-scores of each individual 
metabolic reaction.  Based upon hierarchical clustering, the most similarility was found between 
the control, Bcl-2Δ, and CHOK1SV groups.  Notably, CHOK1SV-M3 was placed into the Bcl-
2Δ group.  Clustering was then applied to the individual fluxes.  While the pathways were 
grouped together, the individual reactions were all free to be sorted.  Considerable separation 
amongst the clones was observed in glycolysis and the TCA cycle. 
Two rate limiting reactions [14] of the TCA cycle are considered further in Figure 6-6.   
 
 
Figure 6-6.  TCA Cycle fluxes.  A. Pyruvate dehydrogenase (PDH) flux. B.  Isocitrate 
dehydrogenase (IDH) flux. 
 
Both in the case of pyruvate dehydrogenase (PDH) and isocitrate dehydrogenase (IDH), overall 
flux increased as specific productivity increased.  Among the top three producing clones, PDH 
and IDH flux increased significantly relative to their respective parental control.  In CHOK1SV-
M3, PDH and IDH flux increased by 80% and 90% respectively.  Additionally, glycolysis was 
also found to be upregulated in high producing clones, especially in Bcl-2Δ clones.  Two rate 
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limiting glycolytic reactions, hexokinase (HK) and phosphofructokinase (PFK), both 
significantly increased in all Bcl-2Δ producers when compared to their control (Figure 6-7) [14].   
 
 
Figure 6-7.  Glycolytic fluxes.  A.  Hexokinase (HK) flux. B. Phosphofructokinase (PFK) flux. 
 
As reported by Figure 6-5, specific productivity corresponded with lactate dehydrogenase 
(LDH) more strongly than any other flux.  When glycolytic flux is increased and carbon 
allocation to the mitochondria was increased, however, it often corresponded with higher specific 
productivity (Figure 6-8A).   
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Figure 6-8. The mitochondria and NADH production. A. Carbon directed from pyruvate to 
mitochondria. Percentage determined based upon mass balance of the pyruvate node. B. Net 
NADH production.  Net production was determined by summing together: glyceraldehyde-6-
phosphate dehydrogenase (GAPDH), lactate dehydrogenase (LDH), pyruvate dehydrogenase 
(PDH), isocitrate dehydrogenase (IDH), alpha-ketoglutarate dehydrogenase (ADH), and malate 
dehydrogenase (MDH).  Redox reactions outside of the TCA cycle and glycolysis were not 
included in the NADH flux reported. 
 
Relative to CHOK1SV, Bcl-2 clones consistently had higher carbon allocation to the 
mitochondria.  When the carbon of pyruvate is directed to the mitochondria, it can lead to the 
reduction of NAD+ in the TCA cycle.  When pyruvate is directed to lactate, however, it is 
associated with the oxidation of NADH.  For this reason, it is often meaningful to consider the 
impact of glycolysis and the TCA cycle upon redox (Figure 6-8B).  Here, net NADH production 
was determined, an indicator for oxidative phosphorylation (OXPHOS).  Of all the reactions 
considered, only LDH was found to oxidize NADH in this study.  When net NADH production 
was highest, it corresponded with the highest specific productivity in both CHOK1SV and Bcl-
2Δ.   
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Discussion 
Oxidative metabolism 
 A common theme of this work was the relationship between oxidative metabolism and 
specific productivity.  All of the clones considered here employ the CHOK1SV-GS system.  
Previous work in DHFR based expression in CHO has found similar results [2].  While only a 
single clone was considered in that study, snapshots of the metabolic phenotype of the different 
stages of a fed-batch process were captured.  During the stationary (peak productivity) phase, 
TCA cycle flux was found to peak (similar to the phase considered in this study).  Additionally, 
the NADH/NAD+ ratio was reported to fall.  For this to happen, the rate of OXPHOS would 
likely be in excess of the TCA cycle (and other NAD+ reducing reactions).  TCA cycling 
simultaneously peaked with specific productivity both in GS and DHFR CHO clones.   
 In this work, peak NADH flux was observed in the highest producing clones from both 
CHOK1SV and Bcl-2Δ.  As NADH flux was reduced in CHOK1SV, specific productivity 
consistently followed suit.  If quasi-metabolic steady state is assumed, then the net production 
(reduction) of NADH must be met by equivalent consumption (oxidation).  While oxidation can 
actually be in excess of reduction in CHO fed-batch culture [2], the positive correlation with 
enhanced specific productivity still holds.   
 Synthesis of protein is energetically expensive.  3 ATP equivalents are necessary to form 
one peptide bond [15].  This does not consider the energy necessary to package and secrete a 
protein.  To generate this ATP, the cell has multiple pathways at its disposal.  Independently 
engaging the glycolytic pathway, fermenting glucose to produce lactate, is a viable means for 
ATP generation.  ATP is generated and while NAD+ is reduced to NADH by glyceraldehyde-3-
phosphate dehydrogenase, it is oxidized back to NAD+ by LDH [16].  Thus glycolysis, in this 
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energetic sense, can operate independently of other pathways.  However, this metabolic behavior 
is not typically associated with higher titers [17].  The presence of lactate as a byproduct in 
solution is not typically sufficient to harm growth or titers [18].  After all, lactate has 
successfully been fed to control pH in a CHO fed-batch reactor [19].  Instead, it is the metabolic 
phenotype associated with the production of lactate that correlates with poor productivity [20].  
Alternatively, the cell can direct glycolytic flux to the mitochondria and engage the TCA cycle in 
conjunction with OXPHOS to generate ATP.  Considering the respiratory quotients typically 
observed in CHO cells [21], a highly active TCA cycle generating CO2 strongly corresponds 
with high oxygen uptake rates.  Likewise, higher rates of oxygen uptake rate strongly correspond 
with high antibody production rates in CHO cells [22].  Considering the quantified increase in 
protein demand (Figure 6-2) and the associative required energy, it is rational that the cell would 
engage more efficient catabolic pathways for energy production.  Efforts to increase the 
oxidative activity of the cell have clear potential to increase specific productivity.   
Increased flux through the pentose phosphate pathway (PPP) often correlates with 
increased TCA cycling [1,2].  As much as 100% of glucose consumed can be directed through 
the PPP.  In this study, as much as 30% of glucose consumed was directed to the PPP, but no 
more.  This was actually in agreement with previous work examining CHO-K1 clones in the 
stationary phase of growth [23,24].  As to why more flux wasn’t directed to the PPP in this GS-
CHO study, it is possible that the experimental timing played a significant factor.  This 
experiment ended at day seven while producing cultures ranged from 92-98% viability (Figure 6-
A-4).  The full production run time typically lasts eighteen days. 
 In relative terms, Bcl-2Δ clones directed more carbon flux to the mitochondria (Figure 6-
8A), corroborating prior work [3].  This was true when carbon flux was expressed on either an 
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absolute or relative basis (Figure 6-6).  This was not only true for the controls, but all IgG 
producing clones as well.  Bcl-2Δ is known to modulate and maintain mitochondrial 
permeability by preventing the release of cytochrome-c into the intramembrane space [25].  Not 
only is the integrity of the mitochondrial membrane upheld, cytochrome-c is more readily 
available to participate in the electron transport chain of OXPHOS.  While cytochrome c was not 
specifically measured in this work, there are molecular reasons for Bcl-2Δ to allow for enhanced 
oxidative metabolism.   
With Bcl-2Δ clones directing greater flux (absolute basis) to the mitochondria, increased 
glycolytic flux coincided.  The fact that Bcl-2Δ IgG producing clones consistently exhibited 
significantly increased glycolytic flux (Figure 6-7), yet directed more of it to the mitochondria 
(6-8A), clearly indicates that the additional glucose consumed was not directed to lactate.  This 
finding, in conjunction with greater net NADH production (Figure 6-8B), may relate to the 
mitochondria of Bcl-2Δ clones having a greater capacity for redox exchange compared to their 
CHOK1SV pair.  As discussed prior, lactate production oxidizes NADH making it possible for 
glycolysis to continue.  However, so does OXPHOS.  Yet NAD+ cannot freely cross the 
mitochondrial membranes.  The Aspartate/Glutamate shuttle provides this function allowing for 
NAD+ equivalents to be transported back to the cytosol.  Prior work has already shown lactate 
production to decrease in the presence of increased Asp/Glu expression [26,27].   
 Increased glycolytic flux alone doesn’t necessarily lead to increased specific productivity.  
When comparing the CHOK1SV lines, the IgG producing clones all exhibited lesser glycolytic 
flux than their parental control.  Yet in the case where increased glycolytic flux leads to an 
increased percentage of flux directed to the mitochondria, as was the case in Bcl-2Δ, this often 
corresponded with increased specific productivity (relative to CHOK1SV). 
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Practical applications 
 
 Genetic targets.  Bcl-2Δ was consistently associated with enhanced oxidative 
metabolism, and has significant potential for industrial application.  Of the four varieties of IgG 
being considered for this study, it increased specific productivity by an average of 70%.  
Considering the general lack of increase in cell specific productivity over the past twenty years, 
and the fact that this was accomplished in the widely used CHOK1SV-GS system, this finding 
was substantial [28,29].  While Bcl-2Δ is associated with reduced peak exponential growth, it 
overall leads to increased integral viable cell density (IVCD), by hindering the progression of 
apoptosis [3].  As has been reported previously, final titer often directly correlates to IVCD [30].   
 In addition to Bcl-2Δ, two TCA cycle enzymes have been identified for genetic 
modification.  Both PDH and IDH have been identified as rate limiting steps of the TCA cycle 
[14].  Overexpression of PDH would increase the amount of carbon directed into the 
mitochondria.  However, expression of PDH may be difficult, as PDH is an enzyme complex.  
For this reason, so far efforts have been made to inhibit PDH kinase (PDHK) through RNA 
interference.  Encouragingly, they have been met with success increases to specific productivity 
[31].  Still, overexpression of PDH is not impossible, as similar efforts have been made to 
optimize the ratio of LC:HC [32].  Overexpression of IDH would also serve to bolster the TCA 
cycle, and it is not a complex.  IDH which uses NAD+ as a cofactor (IDH3) is of interest here, 
but the specific isoform still will need to be determined, as all three isoforms of IDH3 were 
previously identified in CHO transcriptomic work [33].  Since IDH3α was more highly 
expressed (than the other isozymes) in previous CHO transcriptomic work [34], 
overexpressingIDHβ or IDHγ may prove effective. 
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 Increasing glycolytic flux at least has conditional industrial application.  The fact that it 
corresponded with enhanced specific productivity is contrary to previous work that has attempted 
to limit glycolytic flux by controlled feeding of glucose to fed-batch CHO cultures.  Increasing 
either HK or PFK, both rate limiting enzymes of glycolysis, will only be effective if the 
mitochondria has the increased capacity for redox exchange (involving the Asp/Glu transporter).  
This is why we state only conditional industrial application.  After all, the control CHOK1SV 
line had increased glycolytic flux but also generated considerably more lactate (and produced no 
IgG).  Figure 6-8B suggests increased mitochondrial redox capacity was the case for all Bcl-2Δ 
clones.  Regardless, while limiting glucose availability in media in an effort to limit lactate 
production may be effective (to that end) [30,35], it may limit specific productivity (Figure 6-1 
and 6-7). 
 
 Screening methods.  Both ammonia production and glutamine production can serve as 
viable screening methods for clones capable of achieving higher titers (Figure 6-3).  Assuming 
that the push for higher viable cell densities continues [36], ammonia will become more and 
more of an obstacle to higher titers.  This is because ammonia negatively affects growth rate.  
The ammonia concentrations achieved even in this seven day study were high enough to 
potentially impact growth rate, as indicated by previous work [18,37]   Here, we find a strong 
correlation among high ammonia consumption and high specific productivity in CHOK1SV 
clones.  Therefore, selecting clones with high ammonia consumption will benefit IVCD in 
addition to specific productivity. 
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 Production of glutamine corresponded negatively with specific productivity.  When 
glutamine is produced from glutamate, it demands ATP.  This is desirable for the purpose of cell 
growth and antibody production, but undesirable when the excess glutamine is directed to 
excretion.  Additionally, the secretion of glutamine into the media poses risk for cell line 
stability.  This is because it is the absence of glutamine from media that serves as the selective 
criteria for GS-transfected CHO cells.  A loss of stability poses a substantial risk, as it can lead to 
inconsistent batch to batch performance.  Excreted glutamine may not be a harmless byproduct 
of GS-CHO cells. 
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Appendix 
 
 
Figure 6-A-1.  
13
C labeled culture profile.  A. Viable cell density (VCD) over culture life.  B. 
Antibody concentration (titer) over culture life. 
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Figure 6-A-2.  Total carbon consumption.  All consumed metabolites included. 
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Figure 6-A-3.  Total CO2 production.  All CO2 producing and consuming reactions included. 
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Figure 6-A-4.  Viability at Day 7.  End of experiment.   
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95% confidence intervals associated with individual fluxes 
Table 6-A-1. Net fluxes of CHOK1SV.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Value 
Glycolysis PGI  G6P <-> F6P 0.784 1.488 1.136 
 PFK F6P -> DHAP + GAP 1.180 1.483 1.332 
 TPI  DHAP <-> GAP 1.176 1.480 1.328 
 GADPH  GAP <-> 3PG 2.553 2.960 2.757 
 Eno  3PG <-> PEP 1.801 2.890 2.345 
 PK PEP -> Pyr 1.801 2.890 2.345 
 HK Glc -> G6P 1.334 1.497 1.415 
 LDH  Lac <-> Pyr 
-
1.400 
-
1.037 
-
1.219 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.623 0.311 
 R5PE  Ru5P <-> X5P 
-
0.006 
0.411 0.202 
 R5PI  Ru5P <-> R5P 0.004 0.212 0.108 
 TK1  X5P + R5P <-> GAP + S7P 
-
0.003 
0.205 0.101 
 TK2  S7P + GAP <-> E4P + F6P 
-
0.003 
0.205 0.101 
  TK3  X5P + E4P <-> GAP + F6P 
-
0.003 
0.205 0.101 
TCA PDH Pyr -> AcCoA + CO2 1.366 1.973 1.670 
 SDH  Suc <-> Fum 1.743 2.375 2.059 
 Fum  Fum <-> Mal 1.743 2.375 2.059 
 MDH  Mal <-> OAA 1.553 2.190 1.872 
 CS OAA + AcCoA -> Cit 1.638 2.234 1.936 
 ADH aKG.m -> Suc + CO2 1.709 2.334 2.021 
 IDH  Cit <-> aKG.m + CO2 1.557 2.165 1.861 
Transport Glc IN Glc.e -> Glc 1.334 1.497 1.415 
 Lys IN Lys.e -> Lys 0.013 0.023 0.018 
 Thr IN Thr.e -> Thr 0.009 0.014 0.012 
 Phe IN Phe.e -> Phe 0.007 0.016 0.012 
 Tyr IN Tyr.e -> Tyr 0.008 0.019 0.013 
 Val IN Val.e -> Val 0.011 0.027 0.019 
 Leu IN Leu.e -> Leu 0.058 0.093 0.075 
 Ile IN Ile.e -> Ile 0.009 0.037 0.023 
 Trp IN Trp.e -> Trp 0.014 0.025 0.019 
 His IN His.e -> His 0.004 0.014 0.009 
 Met IN Met.e -> Met 0.017 0.027 0.022 
 Ser Flux  Ser.e <-> Ser 0.073 0.087 0.080 
 Ala Flux  Ala.e <-> Ala 
-
0.143 
-
0.108 
-
0.125 
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 Arg Flux  Arg.e <-> Arg 0.025 0.037 0.031 
 Asp Flux  Asp.e <-> Asp 
-
0.049 
-
0.032 
-
0.040 
 Gln Flux  Gln.e <-> Gln 0.091 0.118 0.105 
 Pro Flux  Pro.e <-> Pro 0.007 0.012 0.010 
 Asn Flux  Asn.e <-> Asn 0.087 0.102 0.094 
 Lac Flux  Lac.e <-> Lac 
-
1.400 
-
1.037 
-
1.219 
 Gly Flux  Gly.e <-> Gly 
-
0.058 
-
0.044 
-
0.051 
 Cys Flux  Cys.e <-> Cys 
-
0.002 
0.009 0.004 
 Glu Flux  Glu.e <-> Glu.c 0.021 0.082 0.052 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.042 0.170 0.106 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.092 0.046 
Anaplerosis ME Mal -> Pyr + CO2 0.194 0.409 0.302 
 PC Pyr + CO2 -> OAA 0.000 0.159 0.079 
 ACL Cit -> AcCoA.c + Mal 0.056 0.095 0.075 
Amino GLS  Gln <-> Glu.m 0.081 0.109 0.095 
Acid ASNS  Asp <-> Asn 
-
0.093 
-
0.078 
-
0.086 
Metabolism SHT  Ser <-> Gly + MEETHF 0.034 0.044 0.039 
 CYST  Ser <-> Cys 0.022 1.141 0.581 
 GS + SHT CO2 + MEETHF -> Gly 0.028 0.035 0.032 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.013 0.023 0.018 
 PheTyr Mtbl Phe -> Tyr 0.000 0.010 0.005 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.003 0.001 
 Histidase His -> FormTHF + Glu.c 0.000 0.010 0.005 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.002 0.036 0.019 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.013 0.023 0.018 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.013 0.025 0.019 
 *GDH  aKG.m  <-> Glu.m 
-
0.268 
-
0.134 
-
0.201 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 
-
0.145 
-
0.107 
-
0.126 
 *Ile Mtbl 
Ile + aKG.c + -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.000 0.027 0.013 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.040 0.076 0.058 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.005 0.021 0.013 
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 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.015 0.007 
 *Lys Mtbl 
Lys + aKG.c + aKG.c +  -> Glu.c + 
Glu.c + aKetoadi 
0.000 0.006 0.003 
 *AST  OAA + Glu.c <-> Asp + aKG.c  
-
0.043 
-
0.018 
-
0.031 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.013 0.027 0.020 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.014 1.132 0.573 
 *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.039 1.158 0.599 
Biomass 
Production 
Biomass 233pg 
0.1099*Asp + 0.0899*Glu.c + 
0.0671*Asn + 0.1028*Ser + 0.0333*His 
+ 0.1533*Gly + 0.0878*Arg + 
0.1398*Ala + 0.0424*Tyr + 0.0338*Cys 
+ 0.0969*Val + 0.0322*Met + 
0.051*Phe + 0.0755*Ile + 0.1314*Leu + 
0.1328*Lys + 0.075*Gln + 0.0103*Trp 
+ 0.0729*Pro + 0.0899*Thr + 
0.0594*MEETHF + 0.0543*CO2 + 
0.5767*AcCoA.c + 0.0284*DHAP + 
0.0543*R5P + 0.0672*G6P -> Biomass 
0.097 0.164 0.130 
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Table 6-A-2. Exchange fluxes of CHOK1SV.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Value 
PPP TK3  X5P + E4P <-> GAP + F6P 
0.00
0 
1.517 0.758 
Amino GLS  Gln <-> Glu.m 
0.62
3 
2.746 1.684 
Acid ASNS  Asp <-> Asn 
0.00
0 
1.060 0.530 
Metabolis
m 
SHT  Ser <-> Gly + MEETHF 
0.18
9 
25.12
2 
12.65
6 
Transport Ser Flux  Ser.e <-> Ser 
0.00
0 
7.468 3.734 
 Ala Flux  Ala.e <-> Ala 
0.00
0 
2.005 1.002 
 Asp Flux  Asp.e <-> Asp 
0.00
0 
1.009 0.505 
 Gln Flux  Gln.e <-> Gln 
5.92
3 
92.46
1 
49.19
2 
 Lac Flux  Lac.e <-> Lac 
0.00
0 
1.774 0.887 
 Gly Flux  Gly.e <-> Gly 
0.05
1 
5.291 2.671 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 
0.00
0 
12.93
1 
6.466 
 *AST  OAA + Glu.c <-> Asp + aKG.c  
0.28
6 
20.81
1 
10.54
8 
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Table 6-A-3. Net fluxes of CHOK1SV-GS.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 0.679 1.146 0.912 
  PFK F6P -> DHAP + GAP 0.937 1.138 1.038 
  TPI  DHAP <-> GAP 0.931 1.132 1.032 
  GADPH  GAP <-> 3PG 1.981 2.267 2.124 
  Eno  3PG <-> PEP 1.447 2.190 1.818 
  PK PEP -> Pyr 1.447 2.190 1.818 
  HK Glc -> G6P 1.049 1.160 1.105 
  LDH  Lac <-> Pyr 
-
0.634 
-0.497 -0.565 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.411 0.205 
  R5PE  Ru5P <-> X5P 
-
0.009 
0.266 0.129 
  R5PI  Ru5P <-> R5P 0.007 0.145 0.076 
  TK1  X5P + R5P <-> GAP + S7P 
-
0.004 
0.133 0.064 
  TK2  S7P + GAP <-> E4P + F6P 
-
0.004 
0.133 0.064 
  TK3  X5P + E4P <-> GAP + F6P 
-
0.004 
0.133 0.064 
TCA PDH Pyr -> AcCoA + CO2 1.470 1.814 1.642 
  SDH  Suc <-> Fum 1.795 2.236 2.016 
  Fum  Fum <-> Mal 1.795 2.236 2.016 
  MDH  Mal <-> OAA 1.552 2.098 1.825 
  CS OAA + AcCoA -> Cit 1.820 2.213 2.017 
  ADH aKG.m -> Suc + CO2 1.754 2.180 1.967 
  IDH  Cit <-> aKG.m + CO2 1.695 2.099 1.897 
Transport Glc IN Glc.e -> Glc 1.049 1.160 1.105 
  Lys IN Lys.e -> Lys 0.024 0.036 0.030 
  Thr IN Thr.e -> Thr 0.016 0.021 0.019 
  Phe IN Phe.e -> Phe 0.010 0.021 0.015 
  Tyr IN Tyr.e -> Tyr 0.016 0.031 0.023 
  Val IN Val.e -> Val 0.018 0.038 0.028 
  Leu IN Leu.e -> Leu 0.097 0.144 0.120 
  Ile IN Ile.e -> Ile 0.021 0.059 0.040 
  Trp IN Trp.e -> Trp 0.012 0.025 0.019 
  His IN His.e -> His 0.006 0.018 0.012 
  Met IN Met.e -> Met 0.020 0.032 0.026 
  Ser Flux  Ser.e <-> Ser 0.043 0.061 0.052 
  Ala Flux  Ala.e <-> Ala 
-
0.152 
-0.124 -0.138 
  Arg Flux  Arg.e <-> Arg 0.036 0.052 0.044 
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  Asp Flux  Asp.e <-> Asp 
-
0.017 
0.003 -0.007 
  Gln Flux  Gln.e <-> Gln 
-
0.018 
-0.006 -0.012 
  Pro Flux  Pro.e <-> Pro 0.013 0.017 0.015 
  Asn Flux  Asn.e <-> Asn 0.123 0.147 0.135 
  Lac Flux  Lac.e <-> Lac 
-
0.634 
-0.497 -0.565 
  Gly Flux  Gly.e <-> Gly 
-
0.020 
-0.005 -0.013 
  Cys Flux  Cys.e <-> Cys 
-
0.001 
0.017 0.008 
  Glu Flux  Glu.e <-> Glu.c 0.055 0.116 0.085 
  
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.138 0.271 0.205 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.056 0.162 0.109 
Anaplerosis ME Mal -> Pyr + CO2 0.183 0.542 0.363 
  PC Pyr + CO2 -> OAA 0.000 0.309 0.155 
  ACL Cit -> AcCoA.c + Mal 0.104 0.138 0.121 
Amino GLS  Gln <-> Glu.m 
-
0.034 
-0.021 -0.027 
Acid ASNS  Asp <-> Asn 
-
0.133 
-0.109 -0.121 
Metabolism SHT  Ser <-> Gly + MEETHF 0.024 0.034 0.029 
  CYST  Ser <-> Cys 0.006 0.686 0.346 
  GS + SHT CO2 + MEETHF -> Gly 0.012 0.020 0.016 
  Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.013 0.025 0.019 
  PheTyr Mtbl Phe -> Tyr 0.000 0.010 0.005 
  Thr Mtbl Thr -> Pyr + CO2 0.000 0.002 0.001 
  Histidase His -> FormTHF + Glu.c 0.000 0.011 0.005 
  CBXase + Mutase ProCoA + CO2 -> Suc 0.006 0.052 0.029 
  Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.010 0.023 0.016 
  Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.010 0.027 0.018 
  *GDH  aKG.m  <-> Glu.m 
-
0.245 
-0.109 -0.177 
  *ALT  Ala + aKG.c  <-> Pyr + Glu.c 
-
0.167 
-0.135 -0.151 
  *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.005 0.043 0.024 
  *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.069 0.116 0.093 
  *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.009 0.028 0.019 
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  *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.018 0.009 
  *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + Glu.c 
+ aKetoadi 
0.000 0.009 0.004 
  *AST  OAA + Glu.c <-> Asp + aKG.c  
-
0.108 
-0.075 -0.091 
  *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.017 0.034 0.025 
  *PST 3PG + Glu.c -> Ser + aKG.c  0.024 0.703 0.364 
  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.026 0.706 0.366 
Biomass 
Production 
Biomass 281pg 
0.1326*Asp + 0.1085*Glu.c + 
0.0809*Asn + 0.1239*Ser + 0.0402*His 
+ 0.1849*Gly + 0.1059*Arg + 
0.1686*Ala + 0.0511*Tyr + 0.0407*Cys 
+ 0.1169*Val + 0.0388*Met + 
0.0615*Phe + 0.091*Ile + 0.1585*Leu + 
0.1602*Lys + 0.0905*Gln + 0.0124*Trp 
+ 0.088*Pro + 0.1085*Thr + 
0.0717*MEETHF + 0.0654*CO2 + 
0.6955*AcCoA.c + 0.0342*DHAP + 
0.0654*R5P + 0.0811*G6P -> Biomass 
0.150 0.198 0.174 
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Table 6-A-4. Exchange fluxes of CHOK1SV-GS.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Value 
PPP TK3  X5P + E4P <-> GAP + F6P 0.000 0.884 0.442 
TCA IDH  Cit <-> aKG.m + CO2 1.809 102.196 52.003 
Amino ASNS  Asp <-> Asn 0.000 5.926 2.963 
Acid 
Metabolism 
SHT  Ser <-> Gly + MEETHF 0.065 2.204 1.134 
  *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 6.586 3.293 
  *AST  OAA + Glu.c <-> Asp + aKG.c 1.886 6.246 4.066 
Transport Ser Flux  Ser.e <-> Ser 0.000 1.923 0.961 
  Ala Flux  Ala.e <-> Ala 0.000 1.013 0.507 
  Asp Flux  Asp.e <-> Asp 0.000 2.619 1.309 
  Gln Flux  Gln.e <-> Gln 0.308 1.054 0.681 
  Lac Flux  Lac.e <-> Lac 0.000 0.879 0.439 
  Gly Flux  Gly.e <-> Gly 0.083 1.733 0.908 
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Table 6-A-5. Net fluxes of CHOK1SV-M2.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 0.401 1.103 0.752 
 PFK F6P -> DHAP + GAP 0.822 1.099 0.960 
 TPI  DHAP <-> GAP 0.818 1.095 0.957 
 GADPH  GAP <-> 3PG 1.835 2.191 2.013 
 Eno  3PG <-> PEP 1.378 2.055 1.716 
 PK PEP -> Pyr 1.378 2.055 1.716 
 HK Glc -> G6P 1.002 1.115 1.058 
 LDH  Lac <-> Pyr -0.352 -0.202 -0.277 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.650 0.325 
 R5PE  Ru5P <-> X5P -0.006 0.428 0.211 
 R5PI  Ru5P <-> R5P 0.004 0.221 0.113 
 TK1  X5P + R5P <-> GAP + S7P -0.003 0.214 0.106 
 TK2  S7P + GAP <-> E4P + F6P -0.003 0.214 0.106 
  TK3  X5P + E4P <-> GAP + F6P -0.003 0.214 0.106 
TCA PDH Pyr -> AcCoA + CO2 1.668 2.073 1.870 
 SDH  Suc <-> Fum 2.113 2.546 2.330 
 Fum  Fum <-> Mal 2.113 2.546 2.330 
 MDH  Mal <-> OAA 1.685 2.313 1.999 
 CS OAA + AcCoA -> Cit 1.950 2.358 2.154 
 ADH aKG.m -> Suc + CO2 2.076 2.508 2.292 
 IDH  Cit <-> aKG.m + CO2 1.874 2.285 2.079 
Transport Glc IN Glc.e -> Glc 1.002 1.115 1.058 
 Lys IN Lys.e -> Lys 0.027 0.047 0.037 
 Thr IN Thr.e -> Thr 0.026 0.054 0.040 
 Phe IN Phe.e -> Phe 0.013 0.024 0.019 
 Tyr IN Tyr.e -> Tyr 0.011 0.023 0.017 
 Val IN Val.e -> Val 0.028 0.036 0.032 
 Leu IN Leu.e -> Leu 0.080 0.114 0.097 
 Ile IN Ile.e -> Ile 0.025 0.060 0.042 
 Trp IN Trp.e -> Trp 0.010 0.022 0.016 
 His IN His.e -> His 0.030 0.057 0.043 
 Met IN Met.e -> Met 0.009 0.023 0.016 
 Ser Flux  Ser.e <-> Ser 0.065 0.077 0.071 
 Ala Flux  Ala.e <-> Ala -0.152 -0.121 -0.136 
 Arg Flux  Arg.e <-> Arg 0.032 0.046 0.039 
 Asp Flux  Asp.e <-> Asp 0.032 0.045 0.038 
 Gln Flux  Gln.e <-> Gln -0.041 -0.006 -0.023 
 Pro Flux  Pro.e <-> Pro 0.020 0.024 0.022 
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 Asn Flux  Asn.e <-> Asn -0.007 0.014 0.003 
 Lac Flux  Lac.e <-> Lac -0.352 -0.202 -0.277 
 Gly Flux  Gly.e <-> Gly -0.014 0.000 -0.007 
 Cys Flux  Cys.e <-> Cys 0.001 0.012 0.006 
 Glu Flux  Glu.e <-> Glu.c 0.189 0.241 0.215 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.222 0.285 0.253 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.019 0.009 
Anaplerosis ME Mal -> Pyr + CO2 0.235 0.642 0.438 
 PC Pyr + CO2 -> OAA 0.000 0.377 0.189 
 ACL Cit -> AcCoA.c + Mal 0.060 0.090 0.075 
Amino GLS  Gln <-> Glu.m -0.059 -0.024 -0.042 
Acid ASNS  Asp <-> Asn 0.001 0.022 0.012 
Metabolism SHT  Ser <-> Gly + MEETHF 0.020 0.028 0.024 
 CYST  Ser <-> Cys 0.060 0.678 0.369 
 GS + SHT CO2 + MEETHF -> Gly 0.013 0.020 0.016 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.003 0.017 0.010 
 PheTyr Mtbl Phe -> Tyr 0.000 0.010 0.005 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.029 0.014 
 Histidase His -> FormTHF + Glu.c 0.022 0.049 0.036 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.011 0.045 0.028 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.006 0.017 0.012 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.010 0.030 0.020 
 *GDH  aKG.m  <-> Glu.m -0.247 -0.175 -0.211 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.168 -0.134 -0.151 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.011 0.045 0.028 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.050 0.083 0.066 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.000 0.017 0.008 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.007 0.004 
 *Lys Mtbl 
Lys + aKG.c + aKG.c + -> Glu.c + 
Glu.c + aKetoadi 
0.000 0.017 0.009 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.017 0.008 -0.005 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.015 0.030 0.022 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.062 0.686 0.374 
 *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.067 0.685 0.376 
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Antibody 
Production 
Antibody Flux M2 
503.5*Ala + 290.3*Arg + 386.2*Asp + 
325.7*Asn + 250.2*Cys + 418.4*Gln + 
444.9*Glu.c + 653.1*Gly + 160.6*His + 
205.8*Ile + 658.5*Leu + 539.8*Lys + 
94.27*Met + 345.3*Phe + 617.5*Pro + 
1285*Ser + 683.1*Thr + 143*Trp + 
367.8*Tyr + 853.6*Val -> Antibody 
1.87E-
05 
2.27E-
05 
2.07E-
05 
Biomass 
Production 
Biomass 292pg 
0.1378*Asp + 0.1127*Glu.c + 
0.0841*Asn + 0.1288*Ser + 0.0418*His 
+ 0.1922*Gly + 0.1101*Arg + 
0.1752*Ala + 0.0531*Tyr + 0.0423*Cys 
+ 0.1215*Val + 0.0403*Met + 
0.0639*Phe + 0.0946*Ile + 0.1647*Leu 
+ 0.1664*Lys + 0.094*Gln + 
0.0128*Trp + 0.0914*Pro + 0.1127*Thr 
+ 0.0745*MEETHF + 0.068*CO2 + 
0.7227*AcCoA.c + 0.0355*DHAP + 
0.068*R5P + 0.0842*G6P -> Biomass 
0.082 0.125 0.104 
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Table 6-A-6. Exchange fluxes of CHOK1SV-M2.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
PPP TK2  S7P + GAP <-> E4P + F6P 0.000 4.965 2.482 
 TK3  X5P + E4P <-> GAP + F6P 0.000 0.845 0.423 
Amino   SHT  Ser <-> Gly + MEETHF 0.298 3.516 1.907 
Acid *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 6.711 3.355 
Metabolism *AST  OAA + Glu.c <-> Asp + aKG.c  4.328 30.615 17.471 
Transport Ser Flux  Ser.e <-> Ser 0.000 1.532 0.766 
 Ala Flux  Ala.e <-> Ala 0.026 0.910 0.468 
 Asp Flux  Asp.e <-> Asp 0.000 2.307 1.153 
 Gln Flux  Gln.e <-> Gln 0.296 0.738 0.517 
 Asn Flux  Asn.e <-> Asn 0.000 18.636 9.318 
 Lac Flux  Lac.e <-> Lac 0.000 0.784 0.392 
 Gly Flux  Gly.e <-> Gly 0.090 1.052 0.571 
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Table 6-A-7. Net fluxes of CHOK1SV-M3.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 0.736 1.237 0.986 
 PFK F6P -> DHAP + GAP 0.991 1.233 1.112 
 TPI  DHAP <-> GAP 0.988 1.230 1.109 
 GADPH  GAP <-> 3PG 2.072 2.461 2.266 
 Eno  3PG <-> PEP 1.747 2.216 1.982 
 PK PEP -> Pyr 1.747 2.216 1.982 
 HK Glc -> G6P 1.066 1.244 1.155 
  LDH  Lac <-> Pyr 0.565 0.746 0.656 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.416 0.208 
 R5PE  Ru5P <-> X5P -0.005 0.274 0.134 
 R5PI  Ru5P <-> R5P 0.003 0.143 0.073 
 TK1  X5P + R5P <-> GAP + S7P -0.002 0.137 0.067 
 TK2  S7P + GAP <-> E4P + F6P -0.002 0.137 0.067 
 TK3  X5P + E4P <-> GAP + F6P -0.002 0.137 0.067 
TCA PDH Pyr -> AcCoA + CO2 2.846 3.293 3.069 
 SDH  Suc <-> Fum 3.714 4.200 3.957 
 Fum  Fum <-> Mal 3.714 4.200 3.957 
 MDH  Mal <-> OAA 3.072 3.707 3.390 
 CS OAA + AcCoA -> Cit 3.377 3.837 3.607 
 ADH aKG.m -> Suc + CO2 3.626 4.106 3.866 
  IDH  Cit <-> aKG.m + CO2 3.315 3.776 3.545 
Transport Glc IN Glc.e -> Glc 1.066 1.244 1.155 
 Lys IN Lys.e -> Lys 0.038 0.070 0.054 
 Thr IN Thr.e -> Thr 0.030 0.035 0.033 
 Phe IN Phe.e -> Phe 0.014 0.033 0.023 
 Tyr IN Tyr.e -> Tyr 0.014 0.033 0.023 
 Val IN Val.e -> Val 0.037 0.064 0.050 
 Leu IN Leu.e -> Leu 0.131 0.186 0.159 
 Ile IN Ile.e -> Ile 0.051 0.100 0.075 
 Trp IN Trp.e -> Trp 0.020 0.039 0.030 
 His IN His.e -> His 0.009 0.030 0.020 
 Met IN Met.e -> Met 0.015 0.035 0.025 
 Ser Flux  Ser.e <-> Ser 0.037 0.059 0.048 
 Ala Flux  Ala.e <-> Ala -0.391 -0.322 -0.356 
 Arg Flux  Arg.e <-> Arg 0.038 0.062 0.050 
 Asp Flux  Asp.e <-> Asp 0.073 0.094 0.083 
 Gln Flux  Gln.e <-> Gln -0.028 -0.010 -0.019 
 Pro Flux  Pro.e <-> Pro 0.027 0.032 0.030 
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 Asn Flux  Asn.e <-> Asn 0.063 0.103 0.083 
 Lac Flux  Lac.e <-> Lac 0.565 0.746 0.656 
 Gly Flux  Gly.e <-> Gly -0.059 -0.033 -0.046 
 Cys Flux  Cys.e <-> Cys 0.007 0.028 0.018 
  
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.327 0.403 0.365 
 
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.025 0.013 
 Glu Flux  Glu.e <-> Glu.c 0.309 0.374 0.341 
Anaplerosis ME Mal -> Pyr + CO2 0.501 0.880 0.690 
 PC Pyr + CO2 -> OAA 0.000 0.326 0.163 
  ACL Cit -> AcCoA.c + Mal 0.048 0.077 0.062 
Amino GLS  Gln <-> Glu.m -0.051 -0.033 -0.042 
Acid ASNS  Asp <-> Asn -0.087 -0.046 -0.066 
Metabolism SHT  Ser <-> Gly + MEETHF 0.040 0.052 0.046 
 CYST  Ser <-> Cys 0.066 0.453 0.260 
 GS + SHT CO2 + MEETHF -> Gly 0.034 0.045 0.039 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.009 0.029 0.019 
 PheTyr Mtbl Phe -> Tyr 0.000 0.018 0.009 
 Thr Mtbl Thr -> Pyr + CO2 0.000 0.003 0.002 
 Histidase His -> FormTHF + Glu.c 0.000 0.022 0.011 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.043 0.098 0.071 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.014 0.033 0.023 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.024 0.060 0.042 
 *GDH  aKG.m  <-> Glu.m -0.362 -0.283 -0.323 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.398 -0.324 -0.361 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.034 0.083 0.059 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.096 0.150 0.123 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.001 0.027 0.014 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.027 0.014 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + Glu.c 
+ aKetoadi 
0.003 0.034 0.018 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.148 -0.103 -0.126 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.022 0.047 0.035 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.136 0.523 0.329 
 *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.092 0.479 0.286 
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Biomass 
Production 
Biomass 288pg 
0.1728*Ala + 0.1086*Arg + 
0.1359*Asp + 0.08294*Asn + 
0.04176*Cys + 0.09274*Gln + 
0.1112*Glu.c + 0.1895*Gly + 
0.04118*His + 0.09331*Ile + 
0.1624*Leu + 0.1642*Lys + 
0.03974*Met + 0.06307*Phe + 
0.09014*Pro + 0.127*Ser + 0.1112*Thr 
+ 0.01267*Trp + 0.05242*Tyr + 
0.1198*Val + 0.08309*G6P + 
0.06708*R5P + 0.07344*MEETHF + 
0.03505*DHAP + 0.7128*AcCoA.c + 
0.06708*CO2 -> Biomass 
0.067 0.108 0.087 
Antibody 
Production 
Antibody M3 
484.6*Ala + 196*Arg + 368.9*Asp + 
309.1*Asn + 220.2*Cys + 441*Gln + 
427.2*Glu.c + 647.7*Gly + 145.8*His + 
258.1*Ile + 666.1*Leu + 641.8*Lys + 
79.98*Met + 276.1*Phe + 667*Pro + 
1300*Ser + 689.9*Thr + 154.4*Trp + 
403.3*Tyr + 844.5*Val -> Antibody 
2.99E-
05 
3.60E-
05 
3.29E-
05 
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Table 6-A-8. Exchange fluxes of CHOK1SV-M3.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis LDH  Lac <-> Pyr 6.459 4236.200 2121.329 
PPP TK3  X5P + E4P <-> GAP + F6P 0.000 0.535 0.268 
Amino ASNS  Asp <-> Asn 0.857 4.224 2.541 
Acid SHT  Ser <-> Gly + MEETHF 0.326 1.349 0.838 
Metabolism CYST  Ser <-> Cys 0.000 0.224 0.112 
  *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 4.031 2.015 
Transport Ser Flux  Ser.e <-> Ser 0.000 0.802 0.401 
 Ala Flux  Ala.e <-> Ala 0.015 0.636 0.326 
 Asp Flux  Asp.e <-> Asp 0.000 1.432 0.716 
 Gln Flux  Gln.e <-> Gln 0.000 0.271 0.135 
 Asn Flux  Asn.e <-> Asn 0.000 9.755 4.877 
 Lac Flux  Lac.e <-> Lac 0.000 0.538 0.269 
 Gly Flux  Gly.e <-> Gly 0.207 0.756 0.482 
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Table 6-A-9. Net fluxes of CHOK1SV-M4.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 0.514 0.870 0.692 
 PFK F6P -> DHAP + GAP 0.682 0.866 0.774 
 TPI  DHAP <-> GAP 0.678 0.862 0.770 
 GADPH  GAP <-> 3PG 1.416 1.726 1.571 
 Eno  3PG <-> PEP 1.109 1.610 1.360 
 PK PEP -> Pyr 1.109 1.610 1.360 
 HK Glc -> G6P 0.739 0.877 0.808 
  LDH  Lac <-> Pyr -0.208 -0.084 -0.146 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.290 0.145 
 R5PE  Ru5P <-> X5P -0.006 0.189 0.092 
 R5PI  Ru5P <-> R5P 0.003 0.101 0.052 
 TK1  X5P + R5P <-> GAP + S7P -0.003 0.094 0.046 
 TK2  S7P + GAP <-> E4P + F6P -0.003 0.094 0.046 
 TK3  X5P + E4P <-> GAP + F6P -0.003 0.094 0.046 
TCA PDH Pyr -> AcCoA + CO2 1.528 1.902 1.715 
 SDH  Suc <-> Fum 1.808 2.285 2.046 
 Fum  Fum <-> Mal 1.808 2.285 2.046 
 MDH  Mal <-> OAA 1.407 1.902 1.654 
 CS OAA + AcCoA -> Cit 1.693 2.123 1.908 
 ADH aKG.m -> Suc + CO2 1.699 2.163 1.931 
  IDH  Cit <-> aKG.m + CO2 1.617 2.065 1.841 
Transport Glc IN Glc.e -> Glc 0.739 0.877 0.808 
 Lys IN Lys.e -> Lys 0.034 0.069 0.052 
 Thr IN Thr.e -> Thr 0.035 0.051 0.043 
 Phe IN Phe.e -> Phe 0.016 0.030 0.023 
 Tyr IN Tyr.e -> Tyr 0.028 0.044 0.036 
 Val IN Val.e -> Val 0.056 0.088 0.072 
 Leu IN Leu.e -> Leu 0.022 0.050 0.036 
 Ile IN Ile.e -> Ile 0.044 0.097 0.071 
 Trp IN Trp.e -> Trp 0.003 0.011 0.007 
 His IN His.e -> His 0.021 0.036 0.028 
 Met IN Met.e -> Met 0.005 0.015 0.010 
 Ser Flux  Ser.e <-> Ser 0.050 0.076 0.063 
 Ala Flux  Ala.e <-> Ala -0.173 -0.141 -0.157 
 Arg Flux  Arg.e <-> Arg 0.011 0.022 0.016 
 Asp Flux  Asp.e <-> Asp 0.037 0.059 0.048 
 Gln Flux  Gln.e <-> Gln -0.066 -0.055 -0.060 
 Pro Flux  Pro.e <-> Pro 0.016 0.022 0.019 
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 Asn Flux  Asn.e <-> Asn 0.167 0.216 0.192 
 Lac Flux  Lac.e <-> Lac -0.208 -0.084 -0.146 
 Gly Flux  Gly.e <-> Gly -0.038 -0.023 -0.030 
 Cys Flux  Cys.e <-> Cys 0.015 0.029 0.022 
 Glu Flux  Glu.e <-> Glu.c 0.138 0.186 0.162 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.319 0.483 0.401 
 
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.159 0.310 0.234 
Anaplerosis ME Mal -> Pyr + CO2 0.388 0.670 0.529 
 PC Pyr + CO2 -> OAA 0.000 0.218 0.109 
  ACL Cit -> AcCoA.c + Mal 0.046 0.088 0.067 
Amino GLS  Gln <-> Glu.m -0.083 -0.071 -0.077 
Acid ASNS  Asp <-> Asn -0.203 -0.154 -0.179 
Metabolism SHT  Ser <-> Gly + MEETHF 0.028 0.039 0.033 
 CYST  Ser <-> Cys 0.043 0.442 0.242 
 GS + SHT CO2 + MEETHF -> Gly 0.022 0.031 0.026 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.010 0.005 
 PheTyr Mtbl Phe -> Tyr 0.005 0.020 0.012 
 Thr Mtbl Thr -> Pyr + CO2 0.012 0.029 0.021 
 Histidase His -> FormTHF + Glu.c 0.015 0.030 0.022 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.074 0.138 0.106 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.000 0.008 0.004 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.008 0.046 0.027 
 *GDH  aKG.m  <-> Glu.m -0.407 -0.240 -0.324 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.198 -0.163 -0.181 
 *Ile Mtbl 
Ile + aKG.c -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.032 0.085 0.059 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.000 0.024 0.012 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.025 0.047 0.036 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.031 0.064 0.047 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + Glu.c 
+ aKetoadi 
0.008 0.044 0.026 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.236 -0.180 -0.208 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.000 0.008 0.004 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.051 0.449 0.250 
 *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.060 0.458 0.259 
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Biomass 
Production 
Biomass 191pg 
0.0901*Asp + 0.0737*Glu.c + 
0.055*Asn + 0.0842*Ser + 0.0273*His 
+ 0.1257*Gly + 0.072*Arg + 
0.1146*Ala + 0.0348*Tyr + 0.0277*Cys 
+ 0.0795*Val + 0.0264*Met + 
0.0418*Phe + 0.0619*Ile + 0.1077*Leu 
+ 0.1089*Lys + 0.0615*Gln + 
0.0084*Trp + 0.0598*Pro + 0.0737*Thr 
+ 0.0487*MEETHF + 0.0445*CO2 + 
0.4727*AcCoA.c + 0.0232*DHAP + 
0.0445*R5P + 0.0551*G6P -> Biomass 
0.098 0.186 0.142 
Antibody 
Production 
Antibody Flux M4 
504*Ala + 210.9*Arg + 372.5*Asp + 
298.8*Asn + 222.4*Cys + 485.7*Gln + 
458.1*Glu.c + 684.9*Gly + 120.4*His + 
206*Ile + 658.4*Leu + 593.8*Lys + 
107.8*Met + 305.2*Phe + 617.7*Pro + 
1299*Ser + 710.6*Thr + 155.9*Trp + 
406.9*Tyr + 797*Val -> Antibody 
1.50E-
05 
1.85E-
05 
1.68E-
05 
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Table 6-A-10. Exchange fluxes of CHOK1SV-M4.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
PPP TK3  X5P + E4P <-> GAP + F6P 0.000 0.525 0.263 
Amino ASNS  Asp <-> Asn 0.000 2.403 1.202 
Acid SHT  Ser <-> Gly + MEETHF 0.189 1.967 1.078 
Metabolism *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 2.961 1.480 
  *AST  OAA + Glu.c <-> Asp + aKG.c  1.570 14.170 7.870 
Transport Ser Flux  Ser.e <-> Ser 0.000 1.398 0.699 
 Ala Flux  Ala.e <-> Ala 0.130 0.735 0.432 
 Asp Flux  Asp.e <-> Asp 0.000 2.403 1.202 
 Gln Flux  Gln.e <-> Gln 0.388 1.256 0.822 
 Lac Flux  Lac.e <-> Lac 0.000 0.566 0.283 
 Gly Flux  Gly.e <-> Gly 0.109 0.938 0.524 
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Table 6-A-11. Net fluxes of Bcl-2Δ.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB 
Averag
e 
Glycolysis PGI  G6P <-> F6P 
0.55
7 
1.05
6 
0.807 
 PFK F6P -> DHAP + GAP 
0.83
4 
1.05
0 
0.942 
 TPI  DHAP <-> GAP 
0.82
9 
1.04
5 
0.937 
 GADPH  GAP <-> 3PG 
1.77
6 
2.09
3 
1.934 
 Eno  3PG <-> PEP 
1.43
7 
2.02
3 
1.730 
 PK PEP -> Pyr 
1.43
7 
2.02
3 
1.730 
 HK Glc -> G6P 
0.94
2 
1.06
8 
1.005 
 LDH  Lac <-> Pyr 
-
0.52
8 
-
0.30
6 
-0.417 
PPP 6PGDH G6P -> Ru5P + CO2 
0.00
0 
0.44
0 
0.220 
 R5PE  Ru5P <-> X5P 
-
0.00
7 
0.28
7 
0.140 
 R5PI  Ru5P <-> R5P 
0.00
5 
0.15
3 
0.079 
 TK1  X5P + R5P <-> GAP + S7P 
-
0.00
4 
0.14
4 
0.070 
 TK2  S7P + GAP <-> E4P + F6P 
-
0.00
4 
0.14
4 
0.070 
  TK3  X5P + E4P <-> GAP + F6P 
-
0.00
4 
0.14
4 
0.070 
TCA PDH Pyr -> AcCoA + CO2 
1.61
8 
2.06
8 
1.843 
 SDH  Suc <-> Fum 
1.99
6 
2.64
5 
2.321 
 Fum  Fum <-> Mal 
1.99
6 
2.64
5 
2.321 
 MDH  Mal <-> OAA 
1.62
6 
2.24
4 
1.935 
 CS OAA + AcCoA -> Cit 
1.87
0 
2.44
5 
2.157 
 ADH aKG.m -> Suc + CO2 
1.90
8 
2.53
0 
2.219 
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 IDH  Cit <-> aKG.m + CO2 
1.77
0 
2.35
1 
2.060 
Transport Glc IN Glc.e -> Glc 
0.94
2 
1.06
8 
1.005 
 Lys IN Lys.e -> Lys 
0.05
8 
0.10
3 
0.081 
 Thr IN Thr.e -> Thr 
0.03
7 
0.05
8 
0.047 
 Phe IN Phe.e -> Phe 
0.01
2 
0.03
2 
0.022 
 Tyr IN Tyr.e -> Tyr 
0.02
9 
0.05
1 
0.040 
 Val IN Val.e -> Val 
0.04
3 
0.08
8 
0.066 
 Leu IN Leu.e -> Leu 
0.01
9 
0.08
3 
0.051 
 Ile IN Ile.e -> Ile 
0.03
1 
0.09
3 
0.062 
 Trp IN Trp.e -> Trp 
0.00
2 
0.02
8 
0.015 
 His IN His.e -> His 
0.03
1 
0.05
2 
0.041 
 Met IN Met.e -> Met 
0.00
5 
0.02
0 
0.012 
 Ser Flux  Ser.e <-> Ser 
0.04
5 
0.09
0 
0.067 
 Ala Flux  Ala.e <-> Ala 
-
0.24
0 
-
0.19
1 
-0.215 
 Arg Flux  Arg.e <-> Arg 
0.01
3 
0.02
6 
0.020 
 Asp Flux  Asp.e <-> Asp 
0.02
6 
0.06
1 
0.044 
 Gln Flux  Gln.e <-> Gln 
0.03
6 
0.08
0 
0.058 
 Pro Flux  Pro.e <-> Pro 
0.01
1 
0.01
4 
0.012 
 Asn Flux  Asn.e <-> Asn 
0.16
4 
0.19
4 
0.179 
 Lac Flux  Lac.e <-> Lac 
-
0.52
8 
-
0.30
6 
-0.417 
 Gly Flux  Gly.e <-> Gly 
-
0.06
2 
-
0.04
1 
-0.052 
 Cys Flux  Cys.e <-> Cys 
0.01
3 
0.03
3 
0.023 
 Glu Flux  Glu.e <-> Glu.c 
0.04
4 
0.14
6 
0.095 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 
0.26
7 
0.48
1 
0.374 
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Mal/aKG 
Antiporter 
aKG.m -> aKG.c 
0.16
8 
0.35
2 
0.260 
Anaplerosi
s 
ME Mal -> Pyr + CO2 
0.42
8 
0.72
2 
0.575 
 PC Pyr + CO2 -> OAA 
0.00
0 
0.20
7 
0.103 
 ACL Cit -> AcCoA.c + Mal 
0.08
3 
0.11
1 
0.097 
Amino GLS  Gln <-> Glu.m 
0.02
3 
0.06
8 
0.045 
Acid ASNS  Asp <-> Asn 
-
0.18
3 
-
0.15
3 
-0.168 
Metabolis
m 
SHT  Ser <-> Gly + MEETHF 
0.03
8 
0.04
9 
0.044 
 CYST  Ser <-> Cys 
0.01
2 
0.49
6 
0.254 
 GS + SHT CO2 + MEETHF -> Gly 
0.02
8 
0.03
9 
0.034 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 
0.00
0 
0.01
4 
0.007 
 PheTyr Mtbl Phe -> Tyr 
0.00
3 
0.02
3 
0.013 
 Thr Mtbl Thr -> Pyr + CO2 
0.02
2 
0.04
3 
0.032 
 Histidase His -> FormTHF + Glu.c 
0.02
5 
0.04
6 
0.036 
 CBXase + Mutase ProCoA + CO2 -> Suc 
0.06
0 
0.13
7 
0.098 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 
0.00
0 
0.02
6 
0.013 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.03
8 
0.09
5 
0.067 
 *GDH  aKG.m  <-> Glu.m 
-
0.52
9 
-
0.31
0 
-0.419 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 
-
0.26
1 
-
0.20
0 
-0.230 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.01
8 
0.08
0 
0.049 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.00
0 
0.06
1 
0.031 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA 
+ AcCoA + Glu.c 
0.03
1 
0.06
1 
0.046 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.02
7 
0.07
2 
0.049 
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 *Lys Mtbl 
Lys + aKG.c + aKG.c   -> Glu.c + 
Glu.c + aKetoadi 
0.03
6 
0.08
1 
0.058 
 *AST  OAA + Glu.c <-> Asp + aKG.c  
-
0.21
7 
-
0.17
0 
-0.193 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 
0.00
0 
0.01
2 
0.006 
 *PST 3PG + Glu.c -> Ser + aKG.c  
0.01
6 
0.49
4 
0.255 
  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 
0.03
3 
0.51
6 
0.275 
Biomass 
Production 
Biomass 206pg 
0.0972*Asp + 0.0795*Glu.c + 
0.0593*Asn + 0.0908*Ser + 
0.0295*His + 0.1356*Gly + 
0.0777*Arg + 0.1236*Ala + 
0.0375*Tyr + 0.0299*Cys + 
0.0857*Val + 0.0284*Met + 
0.0451*Phe + 0.0667*Ile + 0.1162*Leu 
+ 0.1174*Lys + 0.0663*Gln + 
0.0091*Trp + 0.0645*Pro + 
0.0795*Thr + 0.0525*MEETHF + 
0.048*CO2 + 0.5098*AcCoA.c + 
0.0251*DHAP + 0.048*R5P + 
0.0594*G6P -> Biomass 
0.16
3 
0.21
7 
0.190 
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Table 6-A-12. Exchange fluxes of Bcl-2Δ.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB 
Averag
e 
Glycolysis LDH  Lac <-> Pyr 
0.00
0 
4.30
4 
2.152 
PPP TK3  X5P + E4P <-> GAP + F6P 
0.02
6 
1.05
1 
0.538 
Amino GLS  Gln <-> Glu.m 
0.45
0 
3.24
9 
1.850 
Acid ASNS  Asp <-> Asn 
0.00
0 
2.08
3 
1.042 
Metabolis
m 
SHT  Ser <-> Gly + MEETHF 
0.09
1 
4.69
2 
2.391 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 
0.00
0 
1.68
9 
0.844 
  *AST  OAA + Glu.c <-> Asp + aKG.c  
0.21
5 
5.11
6 
2.666 
Transport Ser Flux  Ser.e <-> Ser 
0.00
0 
6.09
5 
3.048 
 Ala Flux  Ala.e <-> Ala 
0.12
6 
1.21
2 
0.669 
 Asp Flux  Asp.e <-> Asp 
0.00
0 
1.98
6 
0.993 
 Lac Flux  Lac.e <-> Lac 
0.06
9 
0.85
8 
0.464 
 Gly Flux  Gly.e <-> Gly 
0.00
0 
1.71
2 
0.856 
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Table 6-A-13. Net fluxes of Bcl-2Δ–M2.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 1.259 1.513 1.386 
 PFK F6P -> DHAP + GAP 1.267 1.499 1.383 
 TPI  DHAP <-> GAP 1.256 1.488 1.372 
 GADPH  GAP <-> 3PG 2.516 2.981 2.748 
 Eno  3PG <-> PEP 2.460 2.925 2.693 
 PK PEP -> Pyr 2.460 2.925 2.693 
 HK Glc -> G6P 1.311 1.539 1.425 
  LDH  Lac <-> Pyr 0.343 0.441 0.392 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.121 0.060 
 R5PE  Ru5P <-> X5P -0.018 0.066 0.024 
 R5PI  Ru5P <-> R5P 0.011 0.055 0.033 
 TK1  X5P + R5P <-> GAP + S7P -0.009 0.033 0.012 
 TK2  S7P + GAP <-> E4P + F6P -0.009 0.033 0.012 
 TK3  X5P + E4P <-> GAP + F6P -0.009 0.033 0.012 
TCA PDH Pyr -> AcCoA + CO2 2.947 3.558 3.252 
 SDH  Suc <-> Fum 3.450 4.375 3.912 
 Fum  Fum <-> Mal 3.450 4.375 3.912 
 MDH  Mal <-> OAA 3.387 4.207 3.797 
 CS OAA + AcCoA -> Cit 3.504 4.281 3.892 
 ADH aKG.m -> Suc + CO2 3.403 4.301 3.852 
  IDH  Cit <-> aKG.m + CO2 3.244 4.079 3.662 
Transport Glc IN Glc.e -> Glc 1.311 1.539 1.425 
 Lys IN Lys.e -> Lys 0.098 0.144 0.121 
 Thr IN Thr.e -> Thr 0.060 0.092 0.076 
 Phe IN Phe.e -> Phe 0.026 0.054 0.040 
 Tyr IN Tyr.e -> Tyr 0.022 0.050 0.036 
 Val IN Val.e -> Val 0.043 0.070 0.056 
 Leu IN Leu.e -> Leu 0.109 0.200 0.155 
 Ile IN Ile.e -> Ile 0.036 0.112 0.074 
 Trp IN Trp.e -> Trp 0.064 0.093 0.079 
 His IN His.e -> His 0.020 0.048 0.034 
 Met IN Met.e -> Met 0.014 0.053 0.033 
 Ser Flux  Ser.e <-> Ser 0.112 0.143 0.127 
 Ala Flux  Ala.e <-> Ala -0.300 -0.214 -0.257 
 Arg Flux  Arg.e <-> Arg 0.052 0.089 0.070 
 Asp Flux  Asp.e <-> Asp 0.089 0.120 0.105 
 Gln Flux  Gln.e <-> Gln -0.204 -0.104 -0.154 
 Pro Flux  Pro.e <-> Pro 0.032 0.045 0.038 
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 Asn Flux  Asn.e <-> Asn -0.017 0.034 0.009 
 Lac Flux  Lac.e <-> Lac 0.343 0.441 0.392 
 Gly Flux  Gly.e <-> Gly -0.011 0.030 0.010 
 Cys Flux  Cys.e <-> Cys -0.002 0.029 0.013 
 Glu Flux  Glu.e <-> Glu.c 0.331 0.416 0.373 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.344 0.658 0.501 
 
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.000 0.257 0.128 
Anaplerosis ME Mal -> Pyr + CO2 0.222 0.597 0.409 
 PC Pyr + CO2 -> OAA 0.000 0.264 0.132 
  ACL Cit -> AcCoA.c + Mal 0.180 0.281 0.230 
Amino GLS  Gln <-> Glu.m -0.240 -0.140 -0.190 
Acid ASNS  Asp <-> Asn -0.003 0.049 0.023 
Metabolism SHT  Ser <-> Gly + MEETHF 0.029 0.056 0.043 
 CYST  Ser <-> Cys 0.022 0.163 0.092 
 GS + SHT CO2 + MEETHF -> Gly 0.008 0.030 0.019 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.039 0.019 
 PheTyr Mtbl Phe -> Tyr 0.000 0.029 0.015 
 Thr Mtbl Thr -> Pyr + CO2 0.013 0.048 0.030 
 Histidase His -> FormTHF + Glu.c 0.004 0.033 0.018 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.003 0.082 0.042 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.058 0.087 0.072 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.103 0.162 0.133 
 *GDH  aKG.m  <-> Glu.m -0.477 -0.142 -0.309 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.295 -0.201 -0.248 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.003 0.079 0.041 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.047 0.138 0.092 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.007 0.049 0.028 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.019 0.010 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + Glu.c 
+ aKetoadi 
0.035 0.086 0.060 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.066 0.001 -0.032 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.011 0.051 0.031 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.041 0.157 0.099 
 *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.036 0.177 0.107 
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Antibody 
Production 
Antibody Flux M2 
503.5*Ala + 290.3*Arg + 386.2*Asp + 
325.7*Asn + 250.2*Cys + 418.4*Gln + 
444.9*Glu.c + 653.1*Gly + 160.6*His + 
205.8*Ile + 658.5*Leu + 539.8*Lys + 
94.27*Met + 345.3*Phe + 617.5*Pro + 
1285*Ser + 683.1*Thr + 143*Trp + 
367.8*Tyr + 853.6*Val -> Antibody 
1.19E-
05 
1.76E-
05 
1.47E-
05 
Biomass 
Production 
Biomass 382pg 
0.1802*Asp + 0.1475*Glu.c + 0.11*Asn 
+ 0.1685*Ser + 0.0546*His + 
0.2514*Gly + 0.144*Arg + 0.2292*Ala 
+ 0.0695*Tyr + 0.0554*Cys + 
0.1589*Val + 0.0527*Met + 
0.0837*Phe + 0.1238*Ile + 0.2154*Leu 
+ 0.2177*Lys + 0.123*Gln + 
0.0168*Trp + 0.1196*Pro + 0.1475*Thr 
+ 0.0974*MEETHF + 0.089*CO2 + 
0.9454*AcCoA.c + 0.0465*DHAP + 
0.089*R5P + 0.1102*G6P -> Biomass 
0.190 0.297 0.244 
  
255 
Table 6-A-14. Exchange fluxes of Bcl-2Δ–M2.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis LDH  Lac <-> Pyr 2.994 12.470 7.732 
PPP TK3  X5P + E4P <-> GAP + F6P 0.000 0.202 0.101 
Amino GLS  Gln <-> Glu.m 0.593 1.205 0.899 
Acid ASNS  Asp <-> Asn 0.000 0.587 0.294 
Metabolism SHT  Ser <-> Gly + MEETHF 0.267 1.250 0.758 
  *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 0.298 0.149 
Transport Ser Flux  Ser.e <-> Ser 0.000 0.264 0.132 
 Ala Flux  Ala.e <-> Ala 0.000 0.131 0.066 
 Asp Flux  Asp.e <-> Asp 0.000 0.284 0.142 
 Asn Flux  Asn.e <-> Asn 0.000 0.793 0.397 
 Lac Flux  Lac.e <-> Lac 0.000 0.084 0.042 
 Gly Flux  Gly.e <-> Gly 0.014 0.241 0.127 
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Table 6-A-15. Net fluxes of Bcl-2Δ–M3.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 1.335 1.571 1.453 
 PFK F6P -> DHAP + GAP 1.326 1.562 1.444 
 TPI  DHAP <-> GAP 1.318 1.555 1.436 
 GADPH  GAP <-> 3PG 2.639 3.112 2.875 
 Eno  3PG <-> PEP 2.596 3.068 2.832 
 PK PEP -> Pyr 2.596 3.068 2.832 
 HK Glc -> G6P 1.352 1.588 1.470 
  LDH  Lac <-> Pyr 0.468 0.592 0.530 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.067 0.034 
 R5PE  Ru5P <-> X5P -0.011 0.036 0.012 
 R5PI  Ru5P <-> R5P 0.008 0.032 0.020 
 TK1  X5P + R5P <-> GAP + S7P -0.006 0.018 0.006 
 TK2  S7P + GAP <-> E4P + F6P -0.006 0.018 0.006 
 TK3  X5P + E4P <-> GAP + F6P -0.006 0.018 0.006 
TCA PDH Pyr -> AcCoA + CO2 3.272 3.853 3.562 
 SDH  Suc <-> Fum 4.013 4.849 4.431 
 Fum  Fum <-> Mal 4.013 4.849 4.431 
 MDH  Mal <-> OAA 3.930 4.661 4.296 
 CS OAA + AcCoA -> Cit 3.926 4.668 4.297 
 ADH aKG.m -> Suc + CO2 3.913 4.719 4.316 
  IDH  Cit <-> aKG.m + CO2 3.768 4.530 4.149 
Transport Glc IN Glc.e -> Glc 1.352 1.588 1.470 
 Lys IN Lys.e -> Lys 0.114 0.172 0.143 
 Thr IN Thr.e -> Thr 0.072 0.106 0.089 
 Phe IN Phe.e -> Phe 0.032 0.059 0.046 
 Tyr IN Tyr.e -> Tyr 0.037 0.067 0.052 
 Val IN Val.e -> Val 0.071 0.091 0.081 
 Leu IN Leu.e -> Leu 0.156 0.266 0.211 
 Ile IN Ile.e -> Ile 0.092 0.174 0.133 
 Trp IN Trp.e -> Trp 0.012 0.047 0.029 
 His IN His.e -> His 0.030 0.060 0.045 
 Met IN Met.e -> Met 0.013 0.050 0.031 
 Ser Flux  Ser.e <-> Ser 0.145 0.183 0.164 
 Ala Flux  Ala.e <-> Ala -0.208 -0.123 -0.165 
 Arg Flux  Arg.e <-> Arg 0.052 0.091 0.071 
 Asp Flux  Asp.e <-> Asp 0.066 0.103 0.085 
 Gln Flux  Gln.e <-> Gln -0.023 0.014 -0.004 
 Pro Flux  Pro.e <-> Pro 0.055 0.066 0.061 
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 Asn Flux  Asn.e <-> Asn -0.020 0.029 0.005 
 Lac Flux  Lac.e <-> Lac 0.468 0.592 0.530 
 Gly Flux  Gly.e <-> Gly 0.052 0.071 0.062 
 Cys Flux  Cys.e <-> Cys 0.004 0.035 0.020 
 Glu Flux  Glu.e <-> Glu.c 0.152 0.258 0.205 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 0.332 0.627 0.479 
 
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.133 0.388 0.261 
Anaplerosis ME Mal -> Pyr + CO2 0.224 0.409 0.316 
 PC Pyr + CO2 -> OAA 0.000 0.061 0.031 
  ACL Cit -> AcCoA.c + Mal 0.119 0.177 0.148 
Amino GLS  Gln <-> Glu.m -0.070 -0.033 -0.051 
Acid ASNS  Asp <-> Asn 0.007 0.057 0.032 
Metabolism SHT  Ser <-> Gly + MEETHF 0.012 0.022 0.017 
 CYST  Ser <-> Cys 0.034 0.119 0.076 
 GS + SHT CO2 + MEETHF -> Gly 0.000 0.006 0.003 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.000 0.037 0.019 
 PheTyr Mtbl Phe -> Tyr 0.001 0.029 0.015 
 Thr Mtbl Thr -> Pyr + CO2 0.005 0.041 0.023 
 Histidase His -> FormTHF + Glu.c 0.012 0.043 0.027 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.057 0.138 0.097 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.000 0.034 0.017 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.050 0.120 0.085 
 *GDH  aKG.m  <-> Glu.m -0.579 -0.277 -0.428 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.263 -0.169 -0.216 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.057 0.138 0.097 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.080 0.191 0.136 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.010 0.052 0.031 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.012 0.006 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + Glu.c 
+ aKetoadi 
0.039 0.098 0.069 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.033 0.031 -0.001 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.017 0.056 0.036 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.035 0.089 0.062 
 *Cys Mtbl Cys + aKG.c +  -> Pyr + Glu.c 0.050 0.133 0.091 
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Antibody 
Production 
Antibody M3 
484.6*Ala + 196*Arg + 368.9*Asp + 
309.1*Asn + 220.2*Cys + 441*Gln + 
427.2*Glu.c + 647.7*Gly + 145.8*His + 
258.1*Ile + 666.1*Leu + 641.8*Lys + 
79.98*Met + 276.1*Phe + 667*Pro + 
1300*Ser + 689.9*Thr + 154.4*Trp + 
403.3*Tyr + 844.5*Val -> Antibody 
5.64E-
05 
6.89E-
05 
6.27E-
05 
Biomass 
Production 
Biomass 273pg 
0.1288*Asp + 0.1054*Glu.c + 
0.0786*Asn + 0.1204*Ser + 0.039*His 
+ 0.1797*Gly + 0.1029*Arg + 
0.1638*Ala + 0.0497*Tyr + 0.0396*Cys 
+ 0.1136*Val + 0.0377*Met + 
0.0598*Phe + 0.0885*Ile + 0.154*Leu + 
0.1556*Lys + 0.0879*Gln + 0.012*Trp 
+ 0.0854*Pro + 0.1054*Thr + 
0.0696*MEETHF + 0.0636*CO2 + 
0.6757*AcCoA.c + 0.0332*DHAP + 
0.0636*R5P + 0.0788*G6P -> Biomass 
0.177 0.262 0.219 
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Table 6-A-16. Exchange fluxes of Bcl-2Δ-M3.  Associated with Figure 6-4 and 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis LDH  Lac <-> Pyr 1.157 1.963 1.560 
PPP TK3  X5P + E4P <-> GAP + F6P 0.000 0.272 0.136 
Amino GLS  Gln <-> Glu.m 1.169 5.660 3.415 
Acid ASNS  Asp <-> Asn 0.000 8.379 4.190 
Metabolism SHT  Ser <-> Gly + MEETHF 0.081 0.290 0.185 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 0.129 0.065 
  *AST  OAA + Glu.c <-> Asp + aKG.c  0.118 18.178 9.148 
Transport Ser Flux  Ser.e <-> Ser 0.000 0.151 0.075 
 Ala Flux  Ala.e <-> Ala 0.055 0.163 0.109 
 Asp Flux  Asp.e <-> Asp 0.000 3.256 1.628 
 Asn Flux  Asn.e <-> Asn 0.000 7.565 3.783 
 Lac Flux  Lac.e <-> Lac 0.000 0.058 0.029 
 Gly Flux  Gly.e <-> Gly 0.000 0.289 0.145 
 
  
260 
Table 6-A-17. Net fluxes of Bcl-2Δ-M4.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis PGI  G6P <-> F6P 1.392 1.736 1.564 
 PFK F6P -> DHAP + GAP 1.429 1.728 1.578 
 TPI  DHAP <-> GAP 1.422 1.721 1.572 
 GADPH  GAP <-> 3PG 2.846 3.445 3.146 
 Eno  3PG <-> PEP 2.780 3.382 3.081 
 PK PEP -> Pyr 2.780 3.382 3.081 
 HK Glc -> G6P 1.452 1.751 1.602 
 LDH  Lac <-> Pyr -0.321 0.000 -0.161 
PPP 6PGDH G6P -> Ru5P + CO2 0.000 0.183 0.091 
 R5PE  Ru5P <-> X5P -0.010 0.114 0.052 
 R5PI  Ru5P <-> R5P 0.006 0.069 0.038 
 TK1  X5P + R5P <-> GAP + S7P -0.005 0.057 0.026 
 TK2  S7P + GAP <-> E4P + F6P -0.005 0.057 0.026 
  TK3  X5P + E4P <-> GAP + F6P -0.005 0.057 0.026 
TCA PDH Pyr -> AcCoA + CO2 3.193 3.997 3.595 
 SDH  Suc <-> Fum 4.906 6.017 5.461 
 Fum  Fum <-> Mal 4.906 6.017 5.461 
 MDH  Mal <-> OAA 4.558 5.554 5.056 
 CS OAA + AcCoA -> Cit 4.629 5.635 5.132 
 ADH aKG.m -> Suc + CO2 4.732 5.810 5.271 
 IDH  Cit <-> aKG.m + CO2 4.490 5.512 5.001 
Transport Glc IN Glc.e -> Glc 1.452 1.751 1.602 
 Lys IN Lys.e -> Lys 0.147 0.218 0.182 
 Thr IN Thr.e -> Thr 0.079 0.118 0.098 
 Phe IN Phe.e -> Phe 0.041 0.077 0.059 
 Tyr IN Tyr.e -> Tyr 0.030 0.067 0.049 
 Val IN Val.e -> Val 0.048 0.075 0.061 
 Leu IN Leu.e -> Leu 0.290 0.438 0.364 
 Ile IN Ile.e -> Ile 0.133 0.238 0.186 
 Trp IN Trp.e -> Trp 0.027 0.084 0.055 
 His IN His.e -> His 0.038 0.072 0.055 
 Met IN Met.e -> Met 0.020 0.066 0.043 
 Ser Flux  Ser.e <-> Ser 0.263 0.313 0.288 
 Ala Flux  Ala.e <-> Ala -0.294 -0.199 -0.247 
 Arg Flux  Arg.e <-> Arg 0.077 0.124 0.100 
 Asp Flux  Asp.e <-> Asp 0.083 0.123 0.103 
 Gln Flux  Gln.e <-> Gln -0.021 0.018 -0.002 
 Pro Flux  Pro.e <-> Pro 0.036 0.049 0.043 
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 Asn Flux  Asn.e <-> Asn 0.010 0.075 0.042 
 Lac Flux  Lac.e <-> Lac -0.321 0.000 -0.161 
 Gly Flux  Gly.e <-> Gly 0.029 0.058 0.043 
 Cys Flux  Cys.e <-> Cys 0.005 0.043 0.024 
 Glu Flux  Glu.e <-> Glu.c 0.162 0.313 0.237 
 
Glu/Asp 
Antiporter 
Glu.c -> Glu.m 1.006 1.360 1.183 
  
Mal/aKG 
Antiporter 
aKG.m -> aKG.c 0.716 1.028 0.872 
Anaplerosis ME Mal -> Pyr + CO2 0.486 0.741 0.614 
 PC Pyr + CO2 -> OAA 0.000 0.146 0.073 
 ACL Cit -> AcCoA.c + Mal 0.102 0.160 0.131 
Amino GLS  Gln <-> Glu.m -0.061 -0.019 -0.040 
Acid ASNS  Asp <-> Asn -0.047 0.019 -0.014 
Metabolism SHT  Ser <-> Gly + MEETHF 0.011 0.024 0.017 
 CYST  Ser <-> Cys 0.186 0.350 0.268 
 GS + SHT CO2 + MEETHF -> Gly 0.000 0.011 0.005 
 Met Mtbl Met + Ser -> Methyl + Cys + Suc 0.007 0.054 0.030 
 PheTyr Mtbl Phe -> Tyr 0.016 0.053 0.034 
 Thr Mtbl Thr -> Pyr + CO2 0.026 0.069 0.047 
 Histidase His -> FormTHF + Glu.c 0.024 0.059 0.042 
 CBXase + Mutase ProCoA + CO2 -> Suc 0.107 0.213 0.160 
 Trp Mtbl Trp -> CO2 + CO2 + Ala + aKetoadi 0.018 0.075 0.046 
 Trp2 Mtbl 
aKetoadi -> CO2 + CO2 + AcCoA + 
AcCoA 
0.127 0.220 0.173 
 *GDH  aKG.m  <-> Glu.m -1.322 -0.963 -1.143 
 *ALT  Ala + aKG.c  <-> Pyr + Glu.c -0.308 -0.198 -0.253 
 *Ile Mtbl 
Ile + aKG.c  -> AcCoA + CO2 + 
ProCoA + Glu.c 
0.107 0.213 0.160 
 *Leu Mtbl 
Leu + aKG.c + CO2  -> CO2 + AcCoA 
+ AcCoA + AcCoA + Glu.c 
0.232 0.380 0.306 
 *Tyr Mtbl 
Tyr + aKG.c  -> CO2 + Mal + AcCoA + 
AcCoA + Glu.c 
0.030 0.083 0.056 
 *Val Mtbl 
Val + aKG.c  -> Glu.c + CO2 + CO2 + 
ProCoA 
0.000 0.019 0.010 
 *Lys Mtbl 
Lys + aKG.c + aKG.c  -> Glu.c + Glu.c 
+ aKetoadi 
0.091 0.164 0.127 
 *AST  OAA + Glu.c <-> Asp + aKG.c  -0.116 -0.038 -0.077 
 *Arg Mtbl Arg + aKG.c  -> Glu.c + Urea + Glu.c 0.046 0.095 0.071 
 *PST 3PG + Glu.c -> Ser + aKG.c  0.051 0.182 0.117 
  *Cys Mtbl Cys + aKG.c  -> Pyr + Glu.c 0.225 0.385 0.305 
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Antibody 
Production 
Antibody Flux M4 
504*Ala + 210.9*Arg + 372.5*Asp + 
298.8*Asn + 222.4*Cys + 485.7*Gln + 
458.1*Glu.c + 684.9*Gly + 120.4*His + 
206*Ile + 658.4*Leu + 593.8*Lys + 
107.8*Met + 305.2*Phe + 617.7*Pro + 
1299*Ser + 710.6*Thr + 155.9*Trp + 
406.9*Tyr + 797*Val -> Antibody 
3.38E-
05 
5.08E-
05 
4.23E-
05 
Biomass 
Production 
Biomass 257pg 
0.1213*Asp + 0.0992*Glu.c + 
0.074*Asn + 0.1133*Ser + 0.0368*His 
+ 0.1691*Gly + 0.0969*Arg + 
0.1542*Ala + 0.0468*Tyr + 0.0373*Cys 
+ 0.1069*Val + 0.0355*Met + 
0.0563*Phe + 0.0833*Ile + 0.1449*Leu 
+ 0.1465*Lys + 0.0828*Gln + 
0.0113*Trp + 0.0804*Pro + 0.0992*Thr 
+ 0.0655*MEETHF + 0.0599*CO2 + 
0.6361*AcCoA.c + 0.0313*DHAP + 
0.0599*R5P + 0.0741*G6P -> Biomass 
0.160 0.252 0.206 
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Table 6-A-18. Exchange fluxes of Bcl-2Δ-M4.  Associated with Figure 6-5. 
 
Pathway Enzyme Rxn LB UB Average 
Glycolysis LDH  Lac <-> Pyr 0.000 0.302 0.151 
PPP TK3  X5P + E4P <-> GAP + F6P 0.000 0.881 0.440 
Amino GLS  Gln <-> Glu.m 3.400 17.810 10.605 
Acid SHT  Ser <-> Gly + MEETHF 0.039 0.346 0.192 
Metabolism *ALT  Ala + aKG.c  <-> Pyr + Glu.c 0.000 0.200 0.100 
Transport Ser Flux  Ser.e <-> Ser 0.000 0.527 0.264 
 Ala Flux  Ala.e <-> Ala 0.249 0.701 0.475 
 Asp Flux  Asp.e <-> Asp 0.000 25.761 12.880 
 Lac Flux  Lac.e <-> Lac 0.000 0.328 0.164 
 Gly Flux  Gly.e <-> Gly 0.000 0.449 0.224 
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VII: CONCLUSIONS 
 
Fundamentally, this dissertation accomplishes two goals: 
First, the metabolic phenotypes associated with increasing antibody production in a fed-
batch process were identified.  Oxidative metabolism was consistently found to be correlated 
with increased antibody production, both in DHFR-CHO and GS-CHO lines.  This was found to 
be true not only in terms of increased TCA cycling but also reduced lactate production.  
Increased net NADH and CO2 production accompanied this finding.  Similarly, as net NADPH 
production increased, specific antibody productivity followed suit.   
The time dependency of fed-batch culture was elucidated, and the metabolism associated 
with peak exponential growth was markedly different from peak production phase.  It is realistic 
that genetic manipulation to increase desirable metabolic traits of the production phase could be 
used to increase productivity, but this could have detrimental effects during the exponential 
growth phase.  As a result, it may be important to implement metabolic engineering strategies 
using inducible genetic systems in order to regulate host cell metabolism in a time-dependent 
manner.  Critically, all the aforementioned relationships were identified using industrially 
relevant CHO cell lines, all capable of achieving industrially relevant final antibody titers.  This 
was possible due to the unique collaborative nature of this dissertation with multiple industry 
partners, including Amgen and Janssen. 
Second, various approaches for enhancing the conditions associated with high product 
titers were implemented and evaluated.  In one case, a genetic manipulation was employed to 
express Bcl-2Δ.  Here, increased apoptotic resistance was incorporated into CHO cells with the 
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goal of augmenting IVCD.  In addition to the expected increase in IVCD, we found that pyruvate 
metabolism was significantly rewired.  Bcl-2Δ caused an increased percentage of pyruvate to 
enter the mitochondria to engage in oxidative metabolism while less was fermented to lactate.  
Furthermore, increased enzymatic activity was recorded in both TCA cycle and oxidative 
phosphorylation enzymes.  In another case, a media optimization was implemented.  When 
glutamine was limited in culture, specific growth rate was increased and lactate production 
reduced.  If growth rate can be increased, higher IVCDs can be achieved in less time. 
 
Practical applications to the biopharmaceutical industry 
 Efforts to increase flux to the mitochondria are expected to pay dividends in terms of 
antibody production.  Nearly all the reactions of the TCA cycle were found to be upregulated in 
antibody-producing lines.  Not only was this true when comparing the producer to the control, 
but as specific productivity increased, so did the given TCA cycle flux.  Overexpressing pyruvate 
dehydrogenase (PDH) may be the most logical genetic manipulation to make, as it directly 
increases the total amount of carbon allocated to the mitochondria.  Unfortunately, it is an 
enzyme complex, making expression difficult.  However, overexpression of isocitrate 
dehydrogenase (IDH) also holds promise, as it too has been identified as a rate limiting enzyme 
[1].  IDH is not an enzyme complex, but three known NAD+ isoforms exist [2].  To determine 
the correct IDH isoform to overexpress, RNA interference studies may assist in determining 
which isoform is most critical.   
 NADPH production likewise appears to be essential to high specific productivity.  This 
relationship held true in both GS and DHFR CHO cell lines.  However, while strong linear 
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relationships exist amongst individual TCA cycle reactions and productivity, the same cannot be 
said for individual reactions traditionally known for producing NADPH.  Yet when NADPH 
producing fluxes malic enzyme (ME) and glucose-6-phosphate dehydrogenase (G6PDH) are 
summed together, a key correlation emerges.  Thus, when both enzymes are overexpressed, 
further benefits can potentially be realized in terms of specific productivity. 
 Enhancing apoptotic resistance encourages increased mitochondrial activity, fostering 
conditions favorable for increased productivity.  Perhaps not surprisingly, specific productivity 
in apoptotic resistant lines was generally higher than in control lines.  While expressing Bcl-2Δ 
was associated with a decrease in specific growth rate, it led to a 40% gain in IVCD. 
 
Future Work 
 As mentioned prior, time plays a major role in antibody production.  Constitutive 
expression of a metabolic complex/enzyme to promote antibody production may be detrimental 
to the initial growth phase, which is frequently characterized by substantial lactate production.  
Therefore, it is imperative that an appropriate expression system is determined.  Efforts to induce 
gene expression at reduced temperature [3] as well as tethering expression to a promoter 
naturally activated during peak productivity [4] both show promise.   
Additionally, efforts to overexpress mitochondrial redox transporters, such as the Asp/ 
Glu transporter, may benefit the culture during both exponential growth and peak production 
(stationary-like) phase [5].  As described in the background, a lack of redox transport from the 
cytosol to the mitochondria may force the cell to generate lactate to maintain redox balance.  
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Expression of various isozymes of Asp/Glu transporters [6] gets at the root cause of lactate 
production, and deserves the special attention of MFA. 
The relationship of NADPH production with antibody production merits further research.  
The relationship holds strongly in GS-CHO (CHOK1SV) clones, but not in the Bcl-2Δ variants.  
Oxidative metabolism is associated with the generation of reactive oxygen species (ROS), 
generated as byproduct of incomplete electron transfer.  The fact that the correlation is weak in 
Bcl-2Δ clones compared to the sister GS-CHO clones may hypothetically be related to Bcl-2Δ’s 
capacity to prevent mitochondrial permeabilization.  An experiment measuring ROS production 
in all the GS-CHO lines, including the Bcl-2Δ clones, would be a first step to test this 
hypothesis.  If there is a positive correlation between oxidative stress and NADPH production, 
genetic intervention would be warranted.  Based primarily upon the DHFR-CHO findings, 
efforts to induce overexpression of G6PDH may have the greatest chance of improving titers.  Be 
aware, however, that the pentose phosphate pathway fluxes have large confidence intervals, 
much larger than TCA cycle fluxes.  This lessens the probability of the observed trend actually 
holding true. 
 Most of this work explored carbon metabolism.  However, increased NH3 consumption 
was associated with increased specific antibody production.  After performing a mass balance on 
total nitrogen consumed or produced by the cell, a substantial portion of nitrogen (in one 
instance, more than half) was not accounted for by free amino acid production, antibody, or 
biomass (i.e. there are additional nitrogen sinks) (Figure 7-A-1).  There is a realistic chance that 
a significant portion of this nitrogen may be demanded by other proteins (host cell protein) 
excreted extracellularly by the CHO cell.  If host cell protein (HCP) were to account for all the 
unaccounted nitrogen, HCP would need to be 94% (± 45% s.d.) the summed rate of antibody and 
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biomass (based upon all GS-CHO lines tested).  This corresponds with roughly 10%-30% of the 
total carbon consumed (Figure 7-A-2).  This assumes that for each unaccounted nitrogen, 
stoichiometrically there are 4.1 carbons [7].  It is unlikely that HCP accounts for all the 
unaccounted nitrogen, but realistic that it accounts for a non-negligible portion.  If there is any 
truth to this, a non-negligible amount of carbon would be demanded by HCP, carbon not 
currently accounted for.  CO2 production emanating from the TCA cycle may be overestimated 
in literature as well as our own metabolic models.  A simple Bradford assay to determine the 
changing protein concentration extracellularly offers a reasonable starting point to test this 
hypothesis. 
 
Contribution 
The in-depth quantification of intracellular metabolism of both the GS and DHFR 
expression systems in multiple high-producing CHO cell lines during multiple phases of fed-
batch culture is perhaps this work’s most valuable contribution to the scientific community.  All 
told, this body of work provides a step in the direction of using systems biology, not empirical 
analysis, to increase productivity in mammalian cell culture.  This was primarily achieved by 
successful generation of 13C-aided metabolic models and subsequent analysis to determine the 
biological significance of the results.   
 
In an exercise of humility, the late mathematician/statistician George E.P. Box 
pragmatically stated: 
Essentially, all models are wrong, but some are useful [8]. 
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It is our hope and genuine belief that this body of work will prove to be useful. 
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Appendix 
 
 
Figure 7-A-1.  Unaccounted nitrogen associated with mass balance.  Mass balance includes 
nitrogen associated with biomass and antibody generation, as well as amino acid production.  
Nitrogen balance does not account for host cell protein, or urea production. 
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Figure 7-A-2.  Unaccounted protein in the carbon mass balance.  Calculation assumes 4.1 
C/N and that all the unaccounted nitrogen is converted into protein.   
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